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ABSTRACT 
 
 
Diabetes prevalence is increasing in our ageing and increasingly obese society. 
Diabetes is a heterogeneous condition, and challenges remain in all aspects of 
its management - from diagnosis through to optimising treatment, to managing 
complications. Increasing age brings altered physiological responses to 
disease, treatments and complications - and there may be more wide-ranging 
considerations such as dietary, mobility, dependency or cognition, to name just 
a few. Hypoglycaemia is one of the most important potential side-effects of 
insulin-therapy, and elderly adults are at particular risk from its consequences. 
 
Insulin-treated patients may have long-standing Type 1 diabetes, or have Type 
2 diabetes which has progressed to requiring insulin treatment, due to 
progressive beta cell deficiency. Even within this group of patients, there is 
heterogeneity, and assessment of risks can be challenging.  
 
Endogenous insulin levels can be assessed by measuring C-peptide. Recent 
advances in this has meant this is much more practical, enabling assessment of  
endogenous levels in large numbers of patients more feasible, and hence 
allowing important questions to be addressed. In the context of older patients, 
particularly interesting questions are whether patients with long-standing Type 2 
diabetes can develop severe insulin deficiency, and whether absolute/severe 
endogenous insulin levels have an impact on treatment or complications of 
diabetes within insulin-treated cohorts – such as hypoglycaemia. This may 
thence raise the question of whether C-peptide measurement could potentially 
be used as an extra clinical tool for risk assessment in a patient population 
which can be tricky to manage at times.  
 
The aim of this thesis is thus to explore some of the issues around management 
of diabetes in the elderly: in particular hypoglycaemia, and use of C-peptide to 
more fully assess patients and consider a possible role for it in routine clinical 
care of some patients.  
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Chapter 1 puts the thesis in context, firstly reviewing hypoglycaemia in the 
elderly in general, and then considering aspects of endogenous insulin levels 
and C-peptide measurement.  
 
Chapter 2 addresses the problem of recognition of hypoglycaemia in an elderly 
population, using primary care records and documented symptoms at 
consultations. Are we missing hypoglycaemia in this population? 
 
Accurate diagnosis of diabetes is crucial for getting people on the right 
treatment guidelines, and can be challenging. Chapter 3 uses a spot urine 
measure of C-peptide to test for the first time the accuracy of the UK Practical 
Classification Guidelines (published by the Royal College of General 
Practitioners and NHS Diabetes). 
 
Progressive insulin deficiency in Type 2 diabetes is the main reason people with 
long-standing Type 2 diabetes may eventually require insulin treatment. 
Chapter 4 uses the spot urine measure of C-peptide as a screening tool to 
assess if insulin-treated people with a clinical diagnosis of Type 2 diabetes may 
develop  absolute insulin deficiency.  
 
Even more practical than a spot urine test to measure C-peptide, could be a 
random non-fasting blood measure of C-peptide, which could thus be measured 
when patients have their routine blood tests done in the community or 
outpatient appointments. Chapter 5 looks at how such a measure correlates 
with the gold-standard mixed meal tolerance test C-peptide measure.  
 
Severe insulin deficiency in Type 1 diabetes has been correlated with increased 
complications including hypoglycaemia, but the impact of endogenous insulin 
levels has not been assessed greatly in Type 2 diabetes. Chapter 6 reports a 
study looking into this possible relationship, using hypoglycaemia questionnaire 
responses from a large number of community-dwelling insulin-treated adults (of 
both diagnoses), in the context of their clinical diabetes diagnosis and their 
random non-fasted blood C-peptide levels. 
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Chapter 7 assesses in more detail the rates of hypoglycaemia in a small group 
of insulin-treated patients with a clinical diagnosis of Type 2 diabetes, selected 
on the basis of their endogenous C-peptide levels. As well as subjective 
assessment of their hypoglycaemia experience using questionnaires, 
continuous glucose monitoring was used to objectively assess their rates of 
hypoglycaemia and glucose variability.  
 
Chapter 8 pulls all the above chapters together, summarising them in the 
context of other research, discussing their limitations and possible areas for 
future research, and  their implications for now for clinical practice. 
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CHAPTER 1 – INTRODUCTION 
 
Structure 
 
This chapter is divided into 3 sections.  
Part 1 states the structure and aims of this thesis.  
Part 2 sets the scene with an overall review of clinical aspects of 
hypoglycaemia in older people with diabetes; this was published as 
the Feature Article in the 2013 June edition of the online journal 
Diabetic Hypoglycemia.  
Part 3 introduces the other key concepts used in the thesis, namely 
the clinical implications of endogenous insulin levels altering over 
time in those with diabetes - particularly in terms of hypoglycaemia 
risk, and C-peptide as a useful measure of endogenous insulin 
levels.  
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Part 1:  
Structure and aims of the thesis 
 
This thesis aims to explore some of the diverse aspects of the challenging field 
of management of diabetes in the elderly, and in particular hypoglycaemia.  
A novel theme developed through the thesis is that of the use of C-peptide 
measurement to more fully assess patients with diabetes, and a possible role 
for this in the routine clinical care of some older patients with diabetes is 
considered.  
 
Chapter 1 - Introduction 
This is in two parts. Firstly an overview of hypoglycaemia in the elderly, with 
exploration of some of the key issues facing those with or looking after elderly 
patients with insulin-treated diabetes. The second part discusses the relevance 
of endogenous insulin levels in diabetes, and introduces C-peptide as a useful 
measure of endogenous insulin levels.  
The first part (hypoglycaemia in the elderly review) is a published article in the 
online journal, Diabetic Hypoglycaemia. 
Chapter 2 – Recognising hypoglycaemia 
This chapter attempts to assess in real clinical practice, the notion raised in 
Chapter 1 that hypoglycaemia is an under-recognised phenomenon in the older 
population, partly by virtue of the non-specific nature of symptoms associated 
with it. A systematic approach was used to go through primary care consultation 
records looking for consultations with non-specific symptoms which may have 
represented hypoglycaemia. This short report has been submitted to the 
primary care journal, Family Practice. 
 
24 
 
Chapter 3 – Accurate diagnosis of diabetes type 
Treatment guidelines/pathways in diabetes rely on having a correct starting 
diagnosis, and thus accurate diagnosis is crucial. Being on the right 
management pathway will affect treatment and education, as well as recognition 
by healthcare professionals of factors of relevance for a particular individual, 
such as their risk of hypoglycaemia. However accurate diabetes diagnosis is 
surprisingly challenging, and in the past there has been a dearth of diagnosis 
guidelines. In response to this gap the UK Practical Classification Guidelines 
were published in 2010, and this chapter systematically assesses the accuracy 
of them, against a “gold-standard” definition which incorporates a measure of 
endogenous insulin levels, urinary C-peptide creatinine ratio (UCPCR). This 
paper has been accepted for publication by the British Journal of General 
Practice. 
Chapter 4 – Insulin deficiency in Type 2 diabetes 
Progressive insulin deficiency in Type 2 diabetes results in people with long-
standing Type 2 diabetes often requiring insulin treatment. Chapter 4 uses 
UCPCR as a screening tool to identify people with a clinical diagnosis of Type 2 
diabetes who may have developed absolute insulin deficiency. Stimulated blood 
C-peptide measured in a mixed meal tolerance test (gold-standard C-peptide 
measure) was then used to confirm findings. This chapter is composed of an 
article published in Diabetic Medicine.  
Chapter 5 – Random non-fasting blood C-peptide 
Even more practical than a spot urine test to measure C-peptide, could be a 
random non-fasting blood measure of C-peptide, which could thus be measured 
when patients have a routine blood test. The aim of Chapter 5 was to look at 
how such a measure might correlate with the aforementioned gold-standard 
mixed meal tolerance test measure of C-peptide. This has been accepted for 
publication as a Short Report by Diabetic Medicine. 
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Chapter 6 – Endogenous insulin levels and hypoglycaemia risk  
Chapter 6 makes use of this random non-fasting blood C-peptide measure in 
further evaluating risk of hypoglycaemia in insulin-treated patients. Lower 
endogenous insulin levels are well-known to be associated with increased 
frequency of hypoglycaemia – and hypoglycaemia unawareness – in patients 
with Type 1 diabetes, but there has been limited research on this in Type 2 
diabetes. This study thus evaluated self-reported hypoglycaemia frequency and 
awareness in almost 500 patients with Type 1 or insulin-treated Type 2 diabetes 
using standard hypoglycaemia questionnaires, and evaluated results according 
to their random non-fasting C-peptide levels. An earlier analysis of these results 
was presented as a poster at the Diabetes UK Annual Professional Conference 
in 2015, and the full paper is to be submitted shortly. 
Chapter 7 – Endogenous insulin levels and hypoglycaemia risk  
Chapter 7 addresses whether stratifying insulin-treated patients with Type 2 
diabetes, matched by their clinical characteristics and differing only by C-
peptide level, results in different objective and subjective levels of 
hypoglycaemia. Seventeen patients with insulin-treated Type 2 diabetes and 
very low C-peptide levels were matched by gender and HbA1c 1:1 with 
seventeen patients with higher C-peptide levels. Hypoglycaemia frequency was 
compared using data from continuous glucose monitoring and hypoglycaemia 
questionnaires. These results were presented as an oral presentation at the 
Diabetes UK Annual Professional Conference 2016, and the full paper is to be 
submitted shortly. 
Chapter 8 - Discussion 
The studies presented in the above chapters are summarised and discussed 
especially in terms of their strengths and limitations, their possible implications 
for clinical practice, and possible areas for future research. 
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Part 2:  Overview of 
hypoglycaemia in the elderly 
 
2.1 Introduction 
In an ageing population where the prevalence of diabetes is increasing, a vast 
increase in the number of elderly people with diabetes is expected. Landmark 
diabetes trials have suggested glycaemic control is one of the keys to 
preventing long-term complications from diabetes, and monitoring of HbA1c as 
the usual clinical measure of glycaemic control, is used as a marker of success, 
and deterioration in HbA1c levels often used as the sign to increase intensity of 
treatment.  
Type 1 diabetes is recognised as a disease of absolute insulin deficiency, 
whereas Type 2 diabetes is a more heterogeneous condition, comprising 
people with mainly insulin resistance, to those with more severe insulin 
deficiency. Over time insulin deficiency becomes more important, and people 
with long-standing Type 2 diabetes often need insulin treatment eventually, in 
order to control blood glucose levels. 
The most serious (and feared) complication of insulin treatment, is 
hypoglycaemia. All patients on insulin have the potential to experience 
hypoglycaemia, though it appears some suffer more than others. Those with 
Type 1 diabetes have higher recognised rates than those with Type 2 diabetes. 
Recognition of hypoglycaemia however cannot always be straightforward, and 
particularly in the elderly population, where symptoms can be non-specific and 
interpreted as other conditions. 
The following review introduces hypoglycaemia in the elderly in more detail, and 
some of the key issues surrounding it. 
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Hypoglycaemia in the elderly 
Suzy V Hope and W David Strain 
 
 
2.2 Abstract 
 
Hypoglycemia is a common, under-recognized complication of the management 
of type 2 diabetes. Elderly individuals have a higher burden of co-morbidities, 
cognitive impairment, physical dysfunction and frailty, which makes them more 
vulnerable to complications of hypoglycemia, such as falls, fractures, cognitive 
impairment and cardiovascular events, than younger patients. Furthermore, with 
ageing comes impairment of autoregulatory responses, which means the 
symptoms of hypoglycemia are often less specific, and are therefore either 
missed or incorrectly diagnosed as transient ischemic attacks or other 
cerebrovascular events. Older adults with diabetes have a greater risk of 
hypoglycemia associated with the physiological decline of ageing, and the 
extended duration of diabetes and insulin treatment. The elderly are also more 
prone to the effects of hypoglycemia such as the increased risk of accidents, 
falls and fractures, hospitalizations, in-hospital mortality, and long-term 
impairment of cognition. Using individualized treatment targets to base 
treatment strategies around individual circumstances may reduce the risk of 
hypoglycemia. 
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2.3 Introduction 
Type 2 diabetes is one of the most common chronic conditions in older adults, 
and the number of elderly individuals with diabetes is growing worldwide. For 
example, of the 2.6 million people in the UK with diabetes, at least half are over 
65 years old (1). The prevalence of diabetes in the elderly is more than 10% 
compared with 4.1% in the general adult population (2), and approaches 25% in 
care home residents (1). The management of elderly patients presents unique 
challenges. Episodes of hypoglycemia are a major complication of the treatment 
of diabetes with insulin and some oral medications. The consequences of 
hypoglycemia may be much greater in the frail older population than in younger 
adults. 
This older population with diabetes represents a heterogeneous group, ranging 
from those who have been diagnosed recently (mainly with type 2 diabetes) to 
those with longstanding type 2 diabetes or type 1 diabetes, and from fit and 
active people to frail institutionalized individuals. Treatment of elderly patients 
also varies considerably. Once diabetes is established, the principal aims of 
‘good diabetes care’ comprise blood glucose lowering, managing cardiovascular 
risk and identifying and treating long-term complications (3). As glycemic control 
tends to deteriorate with disease progression, stepwise intensification of 
treatment is usual. This often includes prescription of sulfonylureas (SUs) and 
insulin, the agents most likely to precipitate hypoglycemia. 
The utilization of these agents in order to achieve strict glycemic control is 
facing increasing scrutiny. The Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) study (4) demonstrated increased mortality with intensive 
treatment using strategies based around the use of SUs and insulin. Other 
studies have not shown this increased mortality with stricter glycemic control, 
but they have also failed to show any improvement in all-cause mortality (5-7). 
Meta-analysis of five relevant randomized controlled trials (4-6, 8, 9) that 
examined the effect of intensive glycemic control on major outcomes in type 2 
diabetes, has demonstrated that stricter glycemic control (an average of 0.9% 
reduction in HbA1c maintained over 5 years from a mean baseline of 7.8%) can 
lead to a 17% reduction in events of non-fatal myocardial infarction, and a 15% 
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reduction in events of coronary heart disease (7). In the Action in Diabetes and 
Vascular disease: preterAx and diamicroN MR Controlled Evaluation 
(ADVANCE) study (5), severe hypoglycemia was associated with increased risk 
of macrovascular events, microvascular events, and death from both 
cardiovascular and non-cardiovascular causes (10), although not in a clear 
exposure-outcome or dose-response manner. The link between hypoglycemia 
and other conditions, which is also relevant to quality of life in older patients, 
such as diminishing cognitive function, necessitates a better understanding of 
the precipitants of hypoglycemia and its avoidance in older people with 
diabetes. 
This review examines how hypoglycemia can affect an older population, and 
highlights the need for increased attention to avoid hypoglycemia completely in 
elderly people. 
2.4 Prevalence 
The true prevalence of hypoglycemia in the elderly is unknown. Most studies 
that have tried to address this question rely on recall of hypoglycemic episodes 
by participants. Accurate recall of hypoglycemia is notoriously difficult in any 
age group, and none more so than in an elderly population. For epidemiological 
purposes ‘severe’ hypoglycemia is usually defined as that requiring external 
assistance for treatment. This is easier to measure in terms of prevalence as it 
is usually more dramatic and accuracy of recall is more robust for up to a year 
in type 1 and type 2 diabetes (11, 12). Episodes of severe hypoglycemia can 
also be corroborated with documentary evidence from the medical emergency 
services.  
The difficulties in accurate patient recall of episodes of hypoglycemia was 
addressed by a carefully designed prospective observational study over 9–12 
months in the UK (13). Participants were required to return a data-collection 
sheet every time they experienced a severe hypoglycemia episode. The annual 
prevalence of SU-associated severe hypoglycemia was 7%, similar to that 
observed in people with type 2 diabetes treated with insulin for <2 years. This 
compared to a prevalence of 25% in patients with type 2 diabetes who had 
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received insulin treatment for >5 years, and 46% in those with long-standing 
type 1 diabetes (>15 years). However, the highest mean age of any of the 
subgroups included in this study was only 62 years and all had good glycemic 
control (HbA1c <8%). In the retrospective assessment of an older population 
over the age of 70 years, taking oral glucose-lowering agents, which relied on 
participant recall, Bramlage et al (14) found that only 1% reported episodes of 
symptomatic hypoglycemia external assistance had been required.  
Different definitions, varying ability to recognize hypoglycemia and varying 
ability to recall preceding episodes all contribute to disparate estimates between 
studies. Mild episodes of hypoglycemia – usually defined as those that can be 
self-treated – are much more difficult to estimate. It has been shown that recall 
of mild episodes is unreliable beyond one week in people with type 1 diabetes 
(15). It may be poorer still in the older population with type 2 diabetes in whom 
cognitive function is often diminished. In the year prior to inclusion in their study, 
Bramlage and colleagues found that 12.8% of the participants aged over 70 
years and on oral treatment reported any episode of hypoglycemia, compared 
with 10.1% aged 60–69 years, and 9% aged under 60 years (14). Over one 
year in the prospective UK Hypoglycaemia Study (13) with its intensive 
concurrent data collection, 39% of those with SU-treated type 2 diabetes 
reported at least one episode of mild (self-treated) hypoglycemia, compared 
with 64% in those with type 2 diabetes who had been treated with insulin for >5 
years, and 85% of those with long-standing type 1 diabetes. Furthermore, this 
represented a middle-aged cohort, so the prevalence might well differ in an 
older population, and it may be lower if clinicians are more pragmatic with 
glycemic targets and choice of treatment. However, in the INdividualised 
Treatment targets for EldeRly patients with type 2 diabetes using Vildagliptin 
Add-on or Lone therapy (INTERVAL) study, where clinicians were encouraged 
to set individualized treatment targets for elderly patients, taking account of age, 
frailty, and co-morbidities, physicians still set HbA1c targets in the region of 
7.0% (55 mmol/mol)(16), making this premise unlikely. Conversely, more 
hypoglycemia might be anticipated in elderly patients who eat less and are not 
confident about altering the dose of their medications. In addition, hypoglycemia 
may be missed in older patients when their non-specific symptoms are 
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attributed to other age-related ailments, or the neurological symptoms are 
misinterpreted as transient ischemic attacks (TIAs) or other cerebrovascular 
events (17). 
Knowledge of symptoms of hypoglycemia in patients of this age group is often 
poor (18, 19). Mild episodes of hypoglycemia are under-recognized by patients, 
relatives or carers, and their healthcare providers. Studies have shown poor 
correlation between recall of hypoglycemia by relatives and patients (20-22), 
with relatives tending to recall more episodes. Furthermore, the recognition of 
mild hypoglycemia is made more difficult as the hypoglycemia symptom profile 
changes with age, as do the glycemic thresholds for symptom generation and 
cognitive impairment (23). Even if hypoglycemia is recognized, patients are 
known to under-report this to their doctors (24). 
2.5 Symptoms, physiology and recognition 
The symptoms of hypoglycemia derive from the physiological response to the 
change in glucose (25). Although symptoms may differ between people, in the 
younger adult these are usually easy to perceive. The Edinburgh 
Hypoglycaemia score was developed from analyzing the most common 
symptoms reported by people experiencing hypoglycaemia (26, 27), and 
comprises autonomic symptoms (such as sweating and pounding heart), 
neuroglycopenic symptoms (such as confusion and light-headedness), and non-
specific symptoms (such as malaise). Considerable variability in symptoms 
occurs between hypoglycemic events, even within the same person (28). In 
older people, the symptoms of hypoglycemia are notably less intense during 
hypoglycemia than in younger adults (17, 29), and there is an overall reduced 
subjective awareness of hypoglycemia with increasing age (30). In younger 
people, autonomic symptoms of hypoglycemia tend to be more prominent than 
neuroglycopenic symptoms, although the latter also occur. These autonomic 
symptoms of hypoglycemia become less prominent with increasing duration of 
diabetes and also in older patients with diabetes (29, 31). It has been postulated 
that this change in symptoms may be related to a reduced end-organ response 
in older people (29). The attenuation of autonomic symptoms, and change in 
glycemic threshold at which they are generated, crucially restricts the ‘protective 
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window’ for action between the recognition of symptoms and the onset of 
cognitive dysfunction (23, 32). This may be particularly dangerous in an elderly 
person, who may therefore progress to severe neuroglycopenia. 
The Edinburgh Hypoglycaemia score can be adapted to include the 
neurological symptoms that are common in older people (studied in those aged 
over 70 years); light-headedness and unsteadiness were found to be 
particularly frequent (17). The non-specific nature of symptoms and their lower 
intensity in the elderly person with diabetes can make self-recognition of 
hypoglycemia difficult; a non-specific episode of confusion can be caused by 
numerous conditions prevalent in older patients, such as infection, early 
cognitive impairment, cerebral hypoperfusion resulting from postural 
hypotension or a TIA. If an episode is not thought to be significant enough to 
‘worry the doctor’ it may not be recorded as a hypoglycemic event or even 
treated, and even if it is mentioned to medical attendants, the chances of it 
being recognized as hypoglycemia are not high, because of conflicting 
differential diagnoses. The treatment of the patient’s diabetes may therefore 
remain unchanged, and unrecognized hypoglycemia may continue to occur. As 
with younger patients with diabetes, repeated episodes of hypoglycemia can 
lead to impaired hypoglycemia awareness (27, 33). In insulin-treated people 
with type 2 diabetes, patients with impaired hypoglycemia awareness had a 17-
fold higher frequency of severe hypoglycemia events than those with normal 
awareness (33). Furthermore, newer methodologies, such as continuous 
glucose monitoring (CGM), have demonstrated that hypoglycemia is more 
common than previously appreciated (34).  
As symptoms of hypoglycemia are varied and non-specific in the older 
population (33), the most pertinent pragmatic question is how to identify those 
at greatest risk? 
2.6 Risk factors – including comorbidities and frailty 
Elderly people have multiple potential risk factors for hypoglycemia. These risk 
factors are similar to those observed in young adults, but in people of advanced 
age these risk factors are cumulative and have a greater impact. 
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In type 1 diabetes, duration of insulin therapy, loss of endogenous insulin 
secretion, and a previous history of severe hypoglycemia are predictors for an 
increased risk of severe hypoglycaemia (17, 35). Other than treatment with 
insulin and SUs (8), the predictors for an increase in incidence of hypoglycemia 
in type 2 diabetes are more varied, consistent with the heterogeneity of type 2 
diabetes, and advanced age increases the potential for serious morbidity. One 
important risk factor is the duration of insulin treatment (8, 22, 27, 36, 37). Other 
observed associations vary between studies, and include older age (38), longer 
duration of diabetes per se (22, 27), increased comorbidities (especially chronic 
kidney disease) (38, 39), impaired hypoglycemia awareness (22, 27, 33), 
intensive therapy and strict glycemic control (27, 40), and behavioural factors, 
such as irregular eating (41), exercise(39, 42), and errors in timing of 
medication (42). 
The observed association between increased frequency of hypoglycemia with 
increased duration of diabetes is linked with increasing age and increasing loss 
of endogenous insulin secretion (43). Certainly in type 1 diabetes, the Diabetes 
Care and Complications Trial (among others) showed that the lower the C-
peptide the higher the rate of severe hypoglycaemia (17, 35, 44). Surprisingly, 
few studies have examined the role of endogenous insulin secretion in type 2 
diabetes, and results have been conflicting: the UK Hypoglycaemia Study 
Group found an association with frequency of hypoglycemia and C-peptide 
levels (13), whereas a Danish study by Akram et al (22) did not. 
There is increasing evidence that people with cognitive impairment may be at 
higher risk of experiencing hypoglycaemia (45-49). Of the 11,140 patients with 
type 2 diabetes in the ADVANCE study (45), 212 were classed as having 
‘severe’ cognitive impairment (scoring <24/30 on the Mini-Mental State 
Examination), and this subgroup had double the risk of severe hypoglycemia 
(hazard ratio [HR] 2.10, 95% CI 1.14–3.87; p=0.018), than those with ‘mild’ or 
no cognitive impairment. Similarly, in 497,900 veterans with diabetes aged 65 
years or over (46), the adjusted odds ratios for experiencing hypoglycemia that 
required medical assistance over the course of 1 year were 1.58 (95% CI 1.53–
1.62) for those with dementia. Over a median 3.25 years of follow-up, post-hoc 
analysis of 2,956 patients with type 2 diabetes aged over 55 years in the 
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ACCORD trial (47), showed that poorer scores on a battery of cognitive tests 
were predictive of a first episode of hypoglycemia requiring medical assistance 
(HR 1.13, 95% CI 1.08–1.18). Yaffe at al (49) have recently demonstrated that 
over 12 years of follow-up, 14.2% of patients with diabetes who developed 
dementia, subsequently experienced an episode of severe hypoglycemia, 
compared with 6.3% of those who did not develop dementia (multivariate-
adjusted HR 3.1, 95% CI 1.5–6.6; p<0.001). 
People with diabetes who live in residential homes, where the estimated 
prevalence of diabetes is 20–25% (1, 50), are perhaps at particular risk. 
Reasons for this include advanced age (38), duration on insulin treatment (8, 
22, 27, 36, 37), comorbidities (38, 39),  reduced ability to manage their food 
consumption (41), reduced cognition (45-49), impaired mobility, limited facilities 
to resolve fluctuations in glucose levels, and progressive impairment of 
hypoglycemia awareness (22, 27, 33). Holstein et al (38) found that 34% of 
German patients with type 2 diabetes who required emergency medical 
services for severe hypoglycemia were nursing home residents or were being 
cared for by home nursing services. The residential home population has not, 
however, been systematically evaluated (33, 51). Education about diabetes 
among care home staff is often patchy or absent (52). 
2.7 Effects of hypoglycemia on quality of life, morbidity 
and mortality 
So why does it matter that older people are exposed to hypoglycemia? 
Hypoglycemia has a major adverse impact on quality of life (53-55), which has 
been under-appreciated by healthcare professionals for many years (56). 
Patients fear hypoglycemia more than the long-term consequences of diabetes 
(57). Hypoglycemia has been linked to poor outcomes pertinent to an older 
population: increased risk of accidents (58), falls and fractures (58-60), 
hospitalizations (58), in-hospital mortality (61), frailty (62), long-term impairment 
of cognition (48, 63) and a two-fold increased risk of developing dementia (49, 
64). It is also associated with electrophysiological changes, particularly 
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prolongation of the QT interval, a known precipitant of cardiac dysrhythmia, 
which may persist for up to 48 hours after the hypoglycemic event (65, 66). 
The risk of accidents resulting in hospital visits among people with type 2 
diabetes on medications excluding insulin, was assessed retrospectively in a 
large US health insurance database (58). Hypoglycemia was associated with 
significantly increased hazards for any accident (HR 1.39, 95% CI 1.21–1.59; 
p<0.001), accidental falls (HR 1.36, 95% CI 1.13–1.65; p<0.001) and motor 
vehicle accidents (HR 1.82, 95% CI 1.18–2.80; p=0.007). Diabetes per se is 
associated with an increased risk of osteoporosis (67) and a large retrospective 
observational study in the USA (60) of more than 360,000 patients with type 2 
diabetes aged over 65 years, found 4.7% who had a documented hypoglycemic 
episode over the course of 1 year (resulting in an outpatient medical claim) had 
a 70% higher chance of having a fall-related fracture (odds ratio 1.7, 95% CI 
1.58–1.83); the odds still remained high even after correcting for potential 
confounders, such as presence of diabetic peripheral neuropathy.  
These far-reaching and still under-estimated consequences of hypoglycemia 
have many financial as well as human costs, which are difficult to quantify. 
Hospital admissions resulting from hypoglycemia in type 2 diabetes are longer 
than those with type 1 diabetes, reflecting older age, more comorbidities and 
polypharmacy (68). 
It has been repeatedly observed that dementia is more common in those 
affected by diabetes (69-72), although the precise mechanism(s) are still not 
established. Acute hypoglycemia impairs many aspects of cognition: immediate 
verbal and visual memory, working memory, delayed memory, visual-motor 
skills, visual-spatial skills, and global cognitive dysfunction (71, 73, 74). It has 
been suggested that this transient impairment is associated with long-term 
cognitive defects. Severe hypoglycemia could result in neuronal cell death, 
which might conceivably accelerate the development of dementia (75). One 
might postulate that an episode of severe hypoglycemia may be more likely to 
have a long-term effect on cognition in an older and more vulnerable brain, or 
that repeated episodes of hypoglycemia (even if apparently less severe) may 
have a deleterious effect.  
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One large scale epidemiological study that suggested severe hypoglycemia 
may lead to dementia, was a longitudinal cohort study in the USA by Whitmer 
and colleagues (64). They found a graded increase in risk of dementia with 
increasing numbers of previous hypoglycemic events requiring hospitalization – 
even after adjustment for age, education, comorbidities, duration of diabetes, 
diabetes treatment, years on insulin, and 7-year mean HbA1c. This was based 
on the electronic hospital records of 16,667 patients with a diagnosis of type 2 
diabetes (mean age 65 years): 8.8% (1,465) had documented at least one 
episode of severe hypoglycemia (requiring hospitalization) between 1980 and 
2002, and 11% (1,822) had a diagnosis of dementia by follow-up. The fully 
adjusted HR for dementia having had one episode of hypoglycemia requiring 
hospitalization was 1.26 (95% CI 1.1–1.49), having had two episodes was 1.8 
(95% CI 1.37–2.36), and for three or more episodes was 1.94 (95% CI 1.42-
2.64). Similar HRs were found when considering emergency department 
admissions for hypoglycemia. This appeared to amount to a 2.3% increase in 
absolute risk of dementia per year of follow-up for patients with a history of 
severe hypoglycemia.  
In a broadly similar study design based on the Taiwanese National Health 
Insurance Research Database, Lin and Sheu (76) found that of over 15,000 
people with type 2 diabetes, mean age of 64.2 years and no documentation of a 
dementia diagnosis at recruitment, 7.2% developed dementia over 7 years of 
follow-up. From coding (hospital or ambulatory episodes), approximately 2% of 
the cohort were found to have an episode of hypoglycemia recorded over a 3-
year period. An episode of hypoglycemia predicted an almost 3-fold increase in 
the risk of dementia (29.9 people developing dementia per 1,000 person-years 
[95% CI 22.1–39.2] versus 11.1 per 1,000 person-years [95% CI 10.3–11.8]), 
giving a crude risk ratio of 2.76 (95% CI 2.06–3.70; p<0.001). After adjustment 
for age and sex the risk ratio for developing dementia after hypoglycemia was 
1.60 (95% CI 1.19–2.14; p=0.002), and this was a graded increase in risk 
according to the number of episodes of hypoglycemia experienced. 
Both of these studies (64, 76) can be criticized for potential selection bias, lack 
of correction for certain potentially significant confounders, and inability to 
accurately assess for cognitive function (77). By only recording the most severe 
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hypoglycemic events (those requiring medical assistance), when most episodes 
of hypoglycemia are self-treated in the community, those patients identified may 
be those least able to look after their own diabetes and potentially may be those 
most at risk of being cognitively impaired (eg, with subclinical cerebrovascular 
disease) at the time of their severe hypoglycemia episode, which could neither 
be measured nor corrected for. Other potentially significant comorbid conditions 
such as a history of alcoholism, epilepsy, psychiatric illness or head injury could 
also not be corrected for (77). Additionally, patients who experience 
hypoglycemia needing hospitalization are often considered to be an atypical 
group of patients; they are often severely ill (eg, with sepsis), which may provide 
other causes precipitating subsequent cognitive decline (77). The authors 
considered that because the sub-analysis of data from emergency department 
attendances was as robust as that from hospital episodes, this made this 
scenario less likely – plus the up-to 15 year lag from hospital episode of 
hypoglycemia to diagnosis of dementia was likely to dispel the effect of any 
other comorbid conditions from the hospital admission (78). While it is 
acknowledged by the authors (78) that no observational study can completely 
eliminate all confounders, the strength of the data raises legitimate concerns 
that hypoglycemia may precipitate the onset of dementia. This calls for some 
circumspection when treating frail elderly to strict glycemic targets – and calls 
for the need for prospective studies in this area.  
The Edinburgh Type 2 Diabetes Study avoided some of the methodological 
concerns of the above study (64) and also supported the suggestion of an 
association between severe hypoglycemia and subsequent development of 
dementia (48). In this study, a cross-sectional methodology was used, with 
1,066 participants aged 60–75 who had type 2 diabetes, being asked to 
complete a validated questionnaire to assess their frequency of severe 
hypoglycemia in the previous year, and over their lifetime. Cognitive function 
was assessed both at the time of the study (using age-sensitive psychological 
tests to derive a ‘late-life cognitive ability factor’), and projected prior cognitive 
ability (using vocabulary tests that are stable during ageing). In those reporting 
at least one severe hypoglycemic event (113 patients, 10.6%), a slightly lower 
mean vocabulary score was observed, but was not statistically significant 
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(p=0.13), ie, there was seemingly no major difference in premorbid cognitive 
ability. However, a clear difference was found in their ‘late-life general cognitive 
ability factor’ (p<0.001), and this difference persisted even after adjustment for 
various potential confounders such as duration of diabetes, smoking, HbA1c 
and vascular disease. Additionally, although those having experienced severe 
hypoglycemia scored higher on the Hospital Anxiety and Depression Scale, the 
cognitive associations remained significant after being corrected for this. The 
temporal relationship between hypoglycemia and cognitive decline cannot be 
determined accurately with this cross-sectional design (48), and it is interesting 
to note that 76% of the patients reporting at least one episode of hypoglycemia 
had experienced an episode in the year preceding recruitment. However, on 
analysis no significant difference was observed in the overall strength of the 
association with cognition when hypoglycemia in the year preceding recruitment 
was used versus lifetime history.  
The Fremantle Diabetes Study in Australia (79) found an association between 
previous severe hypoglycemia and subsequent cognitive impairment and 
dementia, when the cognition of 302 individuals was assessed and their 
previous exposure to severe hypoglycemia estimated retrospectively. However, 
a small prospective arm was included in an attempt to address the question of 
temporal decline. The study was probably underpowered to answer this 
question, and the authors did not find an association between severe 
hypoglycemia and evidence of premature dementia in 205 individuals over 70 
years old without cognitive impairment who were followed over a comparatively 
short period of 4 years.  
A recently published prospective study by Yaffe et al (49) provides more 
convincing evidence and lends weight to the causality of dementia in relation to 
hypoglycemia exposure. The authors found a two-fold increased risk of 
developing dementia in people who had experienced an episode of severe 
hypoglycemia requiring hospitalization. A total of 783 older adults (mean age 74 
years) with diabetes but no evidence of cognitive impairment at recruitment 
(determined by a baseline Modified Mini-State Examination), were followed for 
12 years. During this time, 7.8% (61 patients) had a severe hypoglycemic event 
requiring hospitalization, and 18.9% (148 patients) developed dementia 
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(determined by a dementia-related hospital event or prescription of a dementia 
medication, and confirmed by cognitive assessment). Of those who had 
experienced a hypoglycemic event, 34.4% developed dementia, compared with 
17.6% who did not (p<0.001), with a multivariate-adjusted HR of 2.1 (95% CI 
1.0–4.4). A bidirectional association was observed; those who developed 
dementia had a greater risk of subsequently experiencing hypoglycemia 
(14.2%) compared with those who did not develop dementia (6.3%, 
multivariate-adjusted HR 3.1, 95% CI 1.5–6.6; p<0.001).  
Overall, an increasing body of evidence could support a putative association 
between hypoglycemia and dementia – in bidirectional fashion – and given the 
increasing prevalence and burden both of dementia and of diabetes in the older 
population, this is an area that deserves much more attention. Causes of 
dementia are still poorly understood; if reducing hypoglycemic events in the 
older population can help to reduce the likelihood of the development of 
dementia, physicians should tangibly address this possibility.  
2.8 HbA1c targets  
Strict glycemic control and intensive therapy are associated with an increased 
incidence of severe hypoglycaemia (5, 6, 80). A meta-analysis of randomized 
controlled trials (81) – which included over 28,600 patients with type 2 diabetes 
– found the relative risk of severe hypoglycemia was increased by 30% in the 
groups undergoing strict glycemic control. The frequency of mild hypoglycemia 
is also likely to be increased, as are acute daily glucose fluctuations, which are 
increasingly recognized as being associated with poor outcomes, such as 
effects on cognition (63). A retrospective cohort study using data from nearly 
28,000 patients over the age of 50 years and with type 2 diabetes sourced from 
the UK General Practice Research Database, found a U-shaped association 
between HbA1c and all-cause mortality and cardiac events (82), with the lowest 
risk at an HbA1c of 7.5%.  
Targets for glycemic control in elderly patients have become more controversial 
and pragmatic (83). Guidelines are starting to reflect a need for more 
individualized treatment, but the evidence base is very limited. To date only one 
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clinical study has even attempted to utilize individualized treatment targets (16), 
and no study has used clinically meaningful outcomes for elderly patients, such 
as falls, progression of frailty and quality of life. Disappointingly, in the 
INTERVAL study, despite being asked to individualize glycemic targets around 
patients’ age, frailty and co-morbidities, the participating physicians only 
considered baseline HbA1c and gender, and they set a HbA1c target of 7.0%. 
Individualizing the treatment target was associated with lower than anticipated 
side effects, including hypoglycemia, and good tolerability of the strategy. 
Indeed, 27% of the population achieved their targets with nothing more than 
lifestyle change and increased contact with the care-providers. The American 
Diabetes Association (ADA) and the European Association for the Study of 
Diabetes have issued a joint position statement suggesting a more patient-
centered approach for the treatment of type 2 diabetes (84). For older adults, 
they have relaxed the HbA1c target to <7.5% or even 8% if stricter targets are 
more difficult to achieve. In 2012, the ADA and American Geriatrics Society also 
issued a consensus report on diabetes in older adults (85), which suggested 
more pragmatic glycemic targets for older adults than those previously 
published (Table 1).  
However, more relaxed HbA1c targets do not eradicate hypoglycemia. Munshi 
et al (86) used CGM to estimate the frequency of hypoglycemia in an older 
population (>69 years) with a ‘more relaxed’ glycemic target of HbA1c of >8%, 
and found that 65% experienced at least one episode of hypoglycemia (glucose 
<70mg/dl; 3.9 mmol/l) during the 72 hours of monitoring. They concluded that 
relaxing glycemic control to >8% was not necessarily sufficient to prevent 
hypoglycemia in this population. They did not compare the frequency of 
hypoglycemia events in this population with the frequency of events in patients 
with stricter glycemic targets; the frequency of hypoglycemia in patients with 
strict glycemic targets would be expected to be even higher.  
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Table 1. The ADA/American Geriatrics Society consensus guidelines for setting 
HbA1c targets based on patient baseline characteristic  (85) 
 
 
In practice, inadequate recognition of hypoglycemia may not alert patients or 
clinicians to the need to re-evaluate individual treatment targets. With the 
increased recognition of the adverse effects of hypoglycemia and glucose 
variability, an increasing number of older people on insulin, and continued strict 
glycemic targets, hypoglycemia will become increasingly important. A stronger 
evidence base for individualized treatment is needed.  
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Part 3: Endogenous insulin,  
C-peptide and hypos 
 
3.1 Introduction 
In our ageing population, diabetes – and long-standing diabetes - is becoming 
ever more prevalent, and the numbers of people who are insulin-treated ever 
more. As described previously, hypoglycaemia in the older person is important, 
and can be difficult to recognise.  
3.2 Physiology of hypoglycaemia 
Those with Type 1 diabetes are known to have higher rates of hypoglycaemia 
than those with insulin-treated Type 2 diabetes (1); the key difference 
contributing to this being endogenous insulin levels. Homeostasis of blood 
glucose levels is complex, but in summary, when blood glucose levels fall, the 
usual first-line of defence (where possible, ie in those without diabetes, or those 
with diabetes but with retained endogenous insulin levels), is to reduce 
endogenous insulin secretion (Figures 1 & 2). With ongoing reduction in blood 
glucose levels other defence mechanisms come into play: glucagon is released 
from the alpha-cells in the pancreas, which in turn stimulates glucose release 
from stores particularly in the liver; and gluconeogenesis is also stimulated. 
Nervous system sensing that blood glucose levels are falling also results in 
adrenaline release, which as well as stimulating the liver, gives rise to the 
characteristic autonomic symptoms prominent particularly in younger people 
experiencing hypoglycaemia – which alerts the person to eat food or treat 
themselves. 
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Figure 1: Glycaemic thresholds for secretion of counter-regulatory hormones 
and onset of physiological, symptomatic, and cognitive changes in response to 
hypoglycaemia in the non-diabetic human (2) 
 
 
 
 
Figure 2: Symptoms and defence mechanisms in relation to glucose levels in 
the subnormal range (3) 
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In Type 1 diabetes, and “advanced” Type 2 diabetes, these defence 
mechanisms falter. Firstly, with absent or minimal endogenous insulin levels, 
there is limited capacity to reduce any effect of endogenous insulin by stopping 
its secretion. Secondly, being on insulin treatment, exogenous insulin will be “in 
the system”, and unless on an insulin pump, there is no possibility of stopping 
its ongoing action. Thirdly, it has been shown that glucagon release is 
diminished, and thus there is limited capacity for its stimulating action on other 
organs (4-6). These patients are thus heavily dependent on adrenaline 
secretion for their defence against hypoglycaemia – for the symptoms resulting 
in behavioural response, and for the effect of adrenaline on stimulating 
glycogenolysis and gluconeogenesis (6).  
However over time in patients with Type 1 and advanced Type 2 diabetes, 
adrenaline response to falling blood glucose levels has been shown to diminish, 
and this seems to be associated particularly with repeated episodes of 
hypoglycaemia, the so-called “hypoglycaemia-associated autonomic failure” (6, 
7). This is associated with a reduction in symptoms, giving the clinically 
recognised phenomenon of “hypoglycaemia unawareness”. Hypoglycaemia 
unawareness (and partly the reduced adrenaline component of defective 
glucose counter-regulation - but not the absent glucagon component) can be 
reversed by as little as two weeks of strict avoidance of hypoglycaemia (7-9) – 
but this relies on recognition that frequent hypoglycaemia is occurring. Regular 
night-time hypoglycaemia may be even less likely to be picked up on. 
 
3.3 Recognition of symptoms in the elderly 
An additional, potentially increasingly significant, problem of reliance on the 
adrenaline response to hypoglycaemia, is that elderly people even without 
diabetes have reduced autonomic symptoms compared to younger people (10-
12), and those with diabetes have even more pronounced changes (13). Thus 
the characteristic warning symptoms of hypoglycaemia are reduced, those that 
are present are less “intense” – and given their non-specific nature, can easily 
be attributed to other conditions of older age. This may be especially so in those 
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with Type 2 diabetes who may not have had much education on or experience 
of hypoglycaemia. Additionally this reduction in “warning” symptoms means 
there is a smaller window of opportunity to effect behavioural change (eat), 
before more severe symptoms resulting from direct neuroglycopenic effects on 
the brain, such as confusion, drowsiness and eventually coma, may occur.  
In general, symptoms of hypoglycaemia are pretty consistent, both in terms of 
those reported by patients in clinic, and in physiological studies. As alluded to 
above, analyses of symptoms in patients with Type 1 diabetes have found them 
to fall into the general categories of autonomic (eg sweating, palpitations, 
shaking and hunger), general malaise (eg headache and nausea), and 
neuroglycopenic (eg confusion, odd behaviour, speech difficulty and 
drowsiness) (14). This spectrum of symptoms, developed into the Edinburgh 
Hypoglycaemia Questionnaire, has been found to be similar in those with Type 
2 diabetes treated with insulin (15). Jaap et al (16) looked at symptoms 
experienced during daytime episodes of hypoglycaemia by elderly people with 
insulin-treated Type 2 diabetes, and found the frequency and classification of 
symptoms to be different from those seen in younger patients treated with 
insulin. Neurological symptoms were more common, particularly impairment of 
co-ordination and articulation, and light-headedness and dizziness – symptoms 
which may easily be misinterpreted as being due to cerebrovascular or 
cardiovascular causes. 
In view of the non-specific nature of symptoms of hypoglycaemia especially in 
the elderly, a pilot study was done in a Devon GP practice in 2008. This 
comprised a retrospective review of primary care consultations over the 
previous year in all patients on insulin or sulphonylurea treatment, with tight 
glycaemic control (HbA1c <7.5%, 58.5mmol/mol) (Hope, Taylor & Hattersley, 
unpublished). This amounted to 106 patients in total. Any consultation where 
one of the classic hypoglycaemic symptoms (a “hypo clue”) was reported was 
logged, and Figure 3 shows the proportion in each HbA1c group with at least 
one “hypo clue” consultation. Of note, none of these consultations had 
documented hypoglycaemia as having been considered as a possible 
explanation, and thus no changes made to medications had been made. 
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Figure 3: Proportion of patients in each HbA1c group with at least one “hypo 
clue” consultation (Hope, Taylor & Hattersley, unpublished) 
 
 
Subsequently, a general international appreciation that tight glycaemic control 
may bring more risks than benefits in the more frail and elderly population has 
brought about changes in international and national guidelines, with more 
“relaxed” – or individualised - HbA1c targets in those who are deemed “frail”, or 
with multiple co-morbidities (17-21). There is little guidance however on how to 
do this however, with just one study to date specifically attempting to set 
individualised treatment targets (22), and finding clinicians reluctant to deviate 
from traditional glycaemic targets even in the frail elderly.  
Recognition of those most at risk of hypoglycaemia is obviously a good starting 
point, and given it is well-recognised that those with Type 1 diabetes are much 
more at risk of having hypos than those with Type 2, accurate diagnosis is key. 
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3.4 Diagnosis of Type 1 or Type 2 diabetes 
The key difference in terms of clinically managing Type 1 or Type 2 diabetes, is 
a difference in endogenous insulin levels. Type 1 diabetes is generally accepted 
as a condition of absolute insulin deficiency, due to an autoimmune process 
which ultimately leads to loss of pancreatic beta-cell function. The time taken to 
develop absolute insulin deficiency varies between individuals with Type 1 
diabetes, but ultimately all those affected need treatment with exogenous insulin 
for survival.  
Type 2 diabetes is a more heterogeneous condition, and perhaps reflecting this, 
has somewhat imprecise definitions, all on a variation of the theme: a “form of 
diabetes, which accounts for ~90-95% of those with diabetes, previously 
referred to as non-insulin-dependent diabetes… individuals who have insulin 
resistance and usually have relative (rather than absolute) insulin deficiency. … 
There are probably many different causes of this form of diabetes. Although the 
specific etiologies are not known, autoimmune destruction of B-cells does not 
occur, and patients do not have any of the other causes of diabetes listed…”. 
(23). 
Getting the right diagnosis is crucial, as all treatment guidelines depend on 
having selected a diagnosis, and differ in terms of education, monitoring and 
treatment. However it has only been recently that some practical diagnosis 
guidelines from the Royal College of General Practitioners and NHS Diabetes 
have been published (24). 
 
3.5 Endogenous insulin levels in Type 2 diabetes 
Early in the natural history of Type 2 diabetes, endogenous insulin secretion 
increases (Figure 4). Individuals differ in the amount of contribution from insulin 
resistance and (relative) insulin deficiency in the loss of their glucose control. In 
this phase, weight loss (and thus reduction in insulin resistance) can help, some 
people will respond well to “insulin sensitisers” (metformin), and later to “insulin 
secretagogues” (sulphonylureas). But over time, response to these diminishes, 
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and insulin deficiency becomes more prominent – eventually resulting in a need 
for insulin treatment in order to maintain glycaemic control. The physiological 
reason for this decline of endogenous insulin levels is poorly understood, and 
the rapidity of decline varies hugely. Thus even amongst patients with Type 2 
diabetes on insulin, there is clearly a wide spectrum of residual levels of insulin. 
Some of those with a clinical diagnosis of Type 2 diabetes, and a more rapid 
decline in endogenous insulin levels, have some features in common with those 
with Type 1 diabetes, namely pancreatic autoantibodies. When tested, 
approximately 10% of patients with “Type 2 diabetes” are shown to have islet 
autoantibodies, and lower C-peptide levels than most people with T2D. These 
people are sometimes described as having “latent autoimmune diabetes in 
adults”, or “LADA” (25, 26).  A definition of LADA has been proposed: 
development of diabetes >35 years of age, not initially (within the first 12 
months of diagnosis) insulin requiring, but developing the need to start insulin 
treatment relatively soon (usually within 3-5 years), and autoantibody positive 
(26).  
Borg et al (27) performed a prospective 12 year study looking at pancreatic 
autoantibody status and subsequent course of beta-cell failure (defined as 
fasting serum C-peptide <0.1nmol/L) in newly presenting adults (>20 years old) 
with diabetes in Sweden. ICA, IA2 and GAD autoantibodies were assessed at 
diagnosis, 3 years, 5 years and 12 years, and 107 subjects completed the 12 
year follow-up. They found only patients with significant titres of islet antibodies 
developed beta-cell failure over the 12 years: almost all of those with GAD 
and/or ICA at diagnosis, with 91% being on insulin treatment by this point. 
Those with GAD positivity only at diagnosis tended to a slower onset of beta-
cell failure – usually with some preserved function at 5 years, but all reached 
their criteria of beta-cell failure by 12 years. None of the subjects who were 
autoantibody-negative at diagnosis developed complete beta-cell failure by 12 
years, although one third were on insulin-treatment by this point. Interestingly 
their fasting C-peptide levels were not significantly different from their levels at 
diagnosis. The fasting C-peptide levels of those patients with IA2 antibodies 
only at diagnosis were also not significantly changed by 12 years.  
58 
 
However in routine clinical practice, in those thought clinically to have Type 2 
diabetes at presentation, pancreatic autoantibodies are rarely measured, and 
clinical management is based on clinical characteristics and responding to 
deterioration in glycaemic control or side effects of medications. Certainly in the 
UK therefore, the diagnosis of “LADA” is not widely used, and given the 
variation in the rate of loss of endogenous insulin even in those with known 
pancreatic autoantibodies, if a convenient and inexpensive measure of how 
much insulin someone is producing was possible at certain clinical decision-
points, this may prove to be more useful than knowing there is a risk of 
developing severe insulin deficiency at some unknown point in the future. 
 
 
Figure 4. Natural history of insulin resistance and insulin secretion in Type 2 
diabetes (28) 
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3.6 Measuring endogenous insulin levels 
Clinical management of diabetes tends to respond to levels of glycaemia and 
side effects of medications, rather than taking account of the endogenous 
insulin levels directly. Although endogenous insulin levels can be measured 
directly, insulin is rapidly metabolised by the liver, and as such its measurement 
has mainly been limited to research settings, where samples could be collected 
on ice and immediately processed.  
Endogenous insulin levels can also be assessed using C-peptide. This is 
secreted in equimolar quantities to insulin following cleavage of the prohormone 
proinsulin. C-peptide has the distinct advantage that it can also be measured in 
people who are being insulin-treated (29), in contrast to insulin, where assays 
are not always able to distinguish endogenous from exogenous insulin. Fasting, 
glucagon-stimulated, and mixed meal test-stimulated blood C-peptide levels 
have thus all been used in research settings, but again C-peptide was thought 
to be relatively rapidly degraded by serum proteases and thus not practical for 
routine clinical use. However the concept of measuring endogenous insulin 
levels using C-peptide levels has not been lost, with international agreement on 
gold-standard stimulated C-peptide measures being designated as suitable 
outcome measures for intervention studies in Type 1 diabetes (30). 
C-peptide metabolism occurs largely in the kidneys, and the total quantity of C-
peptide excreted in the urine per day represents 5%–10% of pancreatic 
secretion (31). 24 hour urinary C-peptide measurements (31, 32), and spot 
urine measurements for urinary C-peptide creatinine ratio, UCPCR (33), have 
consequently been shown to accurately assess beta-cell secretory capacity. 
They have also been shown to also correlate well with fasting and stimulated 
serum insulin and C-peptide levels (32, 34). The development of the spot urine 
test in 2009 in particular has heralded significant practical advantages for use in 
clinical settings, with it having been shown to be stable in a boric acid container 
for 3 days (33). It subsequently has been demonstrated as a practical outpatient 
tool for differentiating genetic causes of diabetes from Type 1 diabetes (35), and 
for helping in monitoring of success of islet transplants (36). 
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More recent work has demonstrated much greater stability in blood for C-
peptide than was previously appreciated (37), with C-peptide levels found to be 
stable for at least 24 hours at room temperature in both centrifuged and whole 
blood collected in K+ EDTA tubes, and stable after 6 freeze-thaw cycles. This 
has huge potential practical utility for increasing more widespread clinical use of 
C-peptide measurement.  
 
3.7 C-peptide levels as a clinical marker? 
Although Type 1 diabetes is a disease of “absolute insulin deficiency”, the C-
peptide level of 200pmol/L has been considered a threshold associated with an 
increased rate of complications in Type 1 diabetes, in particular hypoglycaemia 
(38-40). The landmark DCCT study found that in those who were intensively 
treated (ie tight glycaemic control, HbA1c<7.5%, 58.5mmol/L), the risk of severe 
hypoglycaemia (seizure or coma) was 17.3 episodes per 100 patient years of 
follow-up in those with a mixed meal tolerance test stimulated serum C-peptide 
(sSCP) level <200pmol/L, compared to 6.6 in those with a sSCP >200pmol/L. 
Steffes et al (30) further analysed the DCCT data, subdividing patients into 
those with a baseline sSCP <30pmol/L as “undetectable”, sSCP 40-200pmol/L 
“minimal”, sSCP >200pmol/L at baseline but <200pmol/L by 1 year follow-up 
“baseline only”, and sSCP >200pmol/L at baseline and at follow-up “sustained”. 
They compared at each level of C-peptide the proportion of patients with at 
least one episode of severe hypoglycaemia in the first 6 months of the study, 
those treated intensively versus conventionally, Figure 5. Intensively-treated 
patients had similar rates of severe hypoglycaemia (~65%) at each level of C-
peptide, apart from those with “sustained” C-peptide who experienced reduced 
rates of ~35%, more similar to the rates in seen in all conventionally-treated 
groups. Of note, the findings in this study remained consistent even when 
adjusted for duration of diabetes, glycaemic control and other factors.  
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Figure 5: Percentages of patients who experienced at least one episode of 
severe hypoglycaemia over the first 6 months of the DCCT (30) 
 
 
 
Modern assays for C-peptide measurement can measure below this range the 
previous “minimal” range (36, 41), and a relationship between hypoglycaemia 
and lower levels of C-peptide has been described (42, 43).  
A recent analysis of the ACCORD study in Type 2 diabetes suggested that 
those participants who suffered from severe hypoglycaemia had significantly 
lower C-peptide levels than those who had similar glycaemic control but who did 
not experience hypoglycaemia (44). This would be consistent with known 
progressive insulin deficiency in Type 2 diabetes and the increase in frequency 
of hypoglycaemia in insulin-treated Type 2 diabetes with increasing duration of 
diabetes (45), and of insulin treatment (2, 15), Figure 6. 
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Figure 6: Proportion of each group experiencing at least one severe self-
reported hypoglycaemic episode during 9–12 months of follow-up.  
Vertical bars, 95% CI (1) 
 
 
 
3.8 Glucose variability  
Intensification of treatment in Type 2 diabetes is due to progressive insulin 
deficiency. As well as endogenous insulin levels declining over time in Type 2 
diabetes, glucose variability increases with increasing treatment intensity 
(Figure 7). Glycaemic variability reflects the fact that blood glucose levels 
fluctuate across the day, and is an important concept, as an equivalent HbA1c 
does not necessarily reflect the same pattern of glycaemic control, see Figure 
8a-c (46, 47). Given the previously described impairments in glucose 
homeostasis particularly in Type 1 diabetes, it is unsurprising that glycaemic 
variability is higher in Type 1 than Type 2 diabetes (48). Increased glycaemic 
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variability has been associated with oxidative stress (49-51), and is proposed to 
be a predictor for the risk of complications of diabetes (52). 
 
Figure 7: Glycaemic variability (as measured by mean amplitude of glycaemic 
excursions) calculated from 72-h continuous glucose monitoring tracings. 
Between-treatment group differences statistically significant, p < 0.001 
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Figures 8a-c: a&b) These represent the same mean glucose (46) 
 
Figure 8c) different glucose profiles with the same average glucose (and thus 
HbA1c) but the person with the paler dotted line is at much higher risk of 
hypoglycaemia (47) 
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Glycaemic variability can be measured using continuous glucose monitoring. 
Appropriate outcome measures have been debated (53-56), and no consensus 
outcome measure agreed upon. The most commonly reported is the 
straightforward standard deviation of glucose measurements (48, 57).  
By uncovering hidden fluctuations (Figure 9), continuous glucose monitoring 
also has the ability to expose asymptomatic hypoglycaemia – which may not 
have previously been revealed eg if blood glucose levels are checked every day 
at the same time(s). It may be particularly valuable to help detect night-time 
hypoglycaemia. However until recently continuous glucose monitoring has been 
prohibitively complex and expensive for widespread use, and as such if there 
was a way to identify those most at risk of high glucose variability and 
hypoglycaemia which was more practical (and cheaper) – such as measuring 
C-peptide - this could be of great clinical utility. 
 
Figure 9: Self-monitoring of blood glucose can miss fluctuations. 
http://www.medtronicdiabetes.co.in/treatment-and-products/i-pro-evaluation 
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3.9 Summary 
Hypoglycaemia recognition in the elderly is tricky. Getting the correct diagnosis 
of type of diabetes is important for subsequent management. People with long-
standing Type 2 diabetes have progressive insulin deficiency, and it is not 
completely clear what clinical consequences this may have when advanced – 
perhaps increased glycaemic variability, and increased risk of hypoglycaemia, 
such as in Type 1 diabetes. Measuring endogenous insulin levels by C-peptide 
measures may have increasing clinical utility, and could have the potential to 
act as a “biomarker” for high risk of hypoglycaemia.  
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Are we missing hypoglycaemia?  
Elderly patients with insulin-treated diabetes present to  
primary care frequently with non-specific symptoms  
associated with hypoglycaemia 
 
Abstract 
 
Introduction 
Hypoglycaemia is a potentially fatal side-effect of diabetes treatment. Its 
recognition is difficult in older patients: as with many clinical presentations in 
this group, the symptoms are non-specific. We explored whether patients at 
high risk for hypoglycaemia were presenting on other occasions with non-
specific symptoms associated with hypoglycaemia, which may represent 
missed hypoglycaemia.  
 
Methods 
Data were collected from the primary care records in a single large practice on 
people aged >65 with and without diabetes. Episodes of hypoglycaemia and 
consultations for non-specific symptoms - “hypo clues” - were identified (eg 
unexplained dizziness, confusion, sweating) between 5/2/12 and 4/2/13. 
Potentially discriminatory symptoms, and their correlation with HbA1c were 
evaluated. 
 
Results 
335 records analysed (79 patients on insulin, 85 on sulphonylureas, 121 on 
metformin only, 50 without diabetes).  
 
27/79 (34%) insulin-treated patients had >1 documented episode of 
hypoglycaemia, compared to 4/85 (5%) sulphonylurea-treated patients, 2/121 
(2%) metformin-only treated patients, and no patients without diabetes, 
p<0.001. 
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Consultations with “hypo clues” were common in all treatment groups: 1.37 
consultations/patient/year in insulin-treated patients, 0.98/patient/year in 
sulphonylurea-treated patients, 0.97/patient/year in metformin only-treated 
patients, and 0.78/patient/year in non-diabetic patients, p=0.34. However of 
insulin-treated patients with a documented episode of hypoglycaemia over the 
year, 20/27 (74%) attended on another occasion with a “hypo clue” symptom, 
compared to 21/52 (40%) of those without hypoglycaemia, p=0.008. There was 
no significant difference in the other treatment groups between the rate of “hypo 
clue” consultations in those with or without hypoglycaemia.  
 
Nausea, falls and unsteadiness were the most potentially discriminatory 
symptoms: 7/33 (21%) patients with hypoglycaemia attended on another 
occasion with nausea compared to 14/302 (5%) without hypoglycaemia, 
p=0.002; 10/33 (30%) vs 36/302 (12%) presented with falls, p=0.007; and 5/33 
(15%) vs 13/302 (4%) presented with unsteadiness, p=0.023. 
 
There was no difference overall in the rate of hypoglycaemia or “hypo clue” 
consultations across the HbA1c range. 
 
Conclusions 
Non-specific symptoms which can represent hypoglycaemia are common in a 
population aged >65. However in insulin-treated patients at risk of 
hypoglycaemia, these “hypo clue” symptoms, in particular nausea, falls and 
unsteadiness, should serve as a reminder to consider hypoglycaemia and 
review medication.  
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INTRODUCTION 
 
Tight glycaemic control in order to prevent long-term complications of diabetes 
(1, 2) has been associated with an increased prevalence of hypoglycaemia in 
Type 1 (3) and Type 2 diabetes (4). The increasing prevalence of diabetes 
coupled with longer life expectancy, and thus longer duration of diabetes, 
means there is an increasing elderly population on potentially hypoglycaemia-
causing medications such as insulin and sulphonylureas (5-7).  
 
Hypoglycaemia is associated with risks such as falls, accidents, hospitalisation, 
impact on driving (8-11), fear and adverse effects on quality of life (12, 13), 
arrhythmias (14), and adverse effects on short and long-term cognition (15-19). 
Recurrent hypoglycaemia can precipitate hypoglycaemia unawareness – 
reduced awareness of symptoms, which leads into a vicious circle (20, 21). 
 
The recognition that elderly people on hypoglycaemia-causing medications may 
be particularly vulnerable has led to alterations of guidelines, incorporating 
more relaxed HbA1c targets for frail elderly, or those with multiple comorbidities 
(22-24).  
 
Hypoglycaemia symptoms in elderly people are less pronounced than in 
younger patients (25-27). Hypoglycaemia is under-reported, and under-
recognised – by patients, carers and healthcare professionals (28-30). 
Symptoms also vary much more between episodes in the same person than is 
often appreciated (31). These factors complicate estimates of the prevalence of 
hypoglycaemia, almost certainly leading to under-estimation.  
 
As blood sugar levels fall, the autonomic symptoms of sweating, palpitations, 
and anxiety first occur; these stimulate food intake, in order to restore blood 
glucose levels (32). However autonomic symptoms become less prominent in 
older age (25, 33), and glucose levels may thus fall into the “neuroglycopenic” 
range before self-correction. Symptoms of insufficient cerebral glucose are non-
specific, including unsteadiness, light-headedness, tiredness and confusion (34, 
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35) – symptoms seen commonly in the general population (36-38), and 
particularly in elderly patients for many other reasons too (39, 40). 
 
The symptoms most associated with hypoglycaemia have been reported (20, 
32, 41, 42), including those particularly seen in the elderly (26). However, their 
non-specific nature, along with multiple alternative explanations, including 
possible co-morbidities, mean that hypoglycaemia may not be recognised. This 
study aimed to establish if patients at risk of hypoglycaemia present more to 
primary care with non-specific symptoms which may represent unrecognised 
episodes of hypoglycaemia. 
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METHOD 
 
We performed a cross-sectional survey in one primary care practice (list size: 
~11,000, ~3300 >65 years old) based in a small market town and with a large 
rural patient population. The practice’s Egton Medical Information Systems 
(EMIS) database was used to identify all patients aged 65 or over who were 
treated with insulin (n=79), sulphonylureas (but not insulin) (n=85), or metformin 
only (n=121), and 50 age-matched non-diabetic patients. 
 
One author (SH: a geriatrician) systematically reviewed patients’ consultation 
notes over a one year period (5/2/12-4/2/13), to identify any episodes of 
hypoglycaemia (defined below), or any “hypo clue consultations” - consultations 
with non-specific symptoms known to be associated with hypoglycaemia (see 
below), where no other obvious explanation or subsequent diagnosis was 
recorded. The records were reviewed sequentially using the practice’s internal 
computer number for each patient (essentially a random number). Review of the 
consultation records was performed independently of patient characteristics 
which were collected on a separate occasion: age, diabetes details, treatment, 
and glycated haemoglobin (HbA1c) blood test results. 
 
Definition of hypoglycaemia 
Hypoglycaemia episodes were defined as episodes having been directly 
confirmed by a doctor or nurse, paramedic or hospital (although the blood 
glucose was not always recorded).  
 
Definition of “hypo clue” consultations 
A “hypo clue consultation” was defined as one or more of the following 
symptoms recorded in the primary care records, without an obvious explanation 
or subsequent diagnosis documented – or documentation that hypoglycaemia 
had been considered. The symptoms (or synonyms) included were shivering, 
shaking, sweating, pounding heart/palpitations, lip tingling, dry mouth, 
apprehension, anxiety, agitation, confusion, odd behaviour, lethargy/fatigue, 
tiredness, drowsiness, weakness, speech difficulty, light-headedness, dizziness, 
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unsteadiness, incoordination, falls, feeling unwell, nausea, hunger, headache, 
double or blurred vision, unexplained waking, depression symptoms, difficulty 
concentrating, and memory complaints (26).  
 
Analysis 
The majority of the data was non-parametric; thus median results and 
interquartile ranges are presented, and chi2/Fisher’s exact tests used for 
comparing frequencies across groups and for the binary analyses of “at least 
one” hypoglycaemia episode or “hypo clue” consultation over the year by 
treatment group.  
 
Frequency of presentation with individual “hypo clue” symptoms was assessed. 
Individual symptom frequencies were compared in patients who had, and those 
who had not had, a recognised episode of hypoglycaemia on another occasion, 
using chi2/Fisher’s exact tests. 
  
The median HbA1c of those with/without at least one hypoglycaemia or “hypo 
clue” consultation per treatment group was compared using the Mann Whitney 
test.  
 
Ethics 
The research project was based on an initial audit within the practice, which did 
not require ethical permission.  
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RESULTS 
 
Frequency of hypoglycaemia 
At least one episode of hypoglycaemia was recorded for 27/79 (34%) insulin-
treated patients, compared to 4/85 (5%) sulphonylurea-treated patients, 2/121 
(2%) metformin-only treated patients, and none in patients without diabetes. 
The total frequency was significantly higher in insulin-treated patients: 51 
episodes (0.65 episodes/patient/year), compared to 5 episodes in the 85 
patients with sulphonylureas (0.06 episodes/patient/year), and 3 in the 121 
(0.02 episodes/patient/year) for the metformin-only treated patients, p<0.001, 
Figure 1. 
 
Frequency of “hypo clue” consultations 
Even patients without diabetes had frequent consultations with at least one non-
specific symptom without other obvious documented explanation (feasibly due 
to hypoglycaemia in an at-risk patient), 0.78 consultations/patient/year (39 
consultations in 50 patients). Rates of hypo-clue consultations were similar for 
all patients with diabetes, regardless of treatment (insulin 1.37, sulphonylureas 
0.98, metformin 0.97 consultations/patient/year; p=0.34), Figure 1.  
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Figure 1: Frequency of documented hypoglycaemia and “hypo clue” 
consultations (per person per year) according to treatment group,  
in patients >65 years. p<0.001 for a difference in rates of hypoglycaemia across 
the groups; p=0.34 for a difference in rates of “hypo clue” consultations. 
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Reported symptoms in “hypo clue” consultations 
The most commonly reported non-specific symptoms overall in this study, in 
decreasing order of frequency, were lethargy/tiredness (47/335, 14%), falls 
(46/335, 13.7%), feeling unwell (37/335, 11%), dizziness/light-headedness 
(35/335, 10.5%), depression symptoms (28/335, 8.4%), nausea (21/335, 6.3%), 
and unsteadiness (18/335, 5.4%).  
 
Consultation with possible “hypo clue” symptoms in those with/without 
documented hypoglycaemia 
In those patients who were insulin-treated and had at least one documented 
episode of documented hypoglycaemia over the year, 20/27 (74%) had 
presented on at least one other occasion with a “hypo clue” symptom, Figure 2. 
This was in comparison to 21/52 (40%) of those insulin-treated patients without 
a documented hypoglycaemia episode, p=0.008. In sulphonylurea and 
metformin treated patients with at least one document episode of 
hypoglycaemia over the year, 2/4 (50%) and 1/2 (50%) respectively had also 
presented at least once with possible “hypo clue” symptoms, with no difference 
in rates between those with or without documented hypoglycaemia, p=1.0.  The 
odds ratio for insulin-treated patients having a hypoglycaemia episode if they 
had consulted on another occasion with a possible “hypo clue” symptom, was 
4.2, compared to 1.1 in sulphonylurea or metformin only-treated patients. 
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Figure 2: Proportion of patients who had at least one documented “hypo clue” 
consultation” over the year, and whether they had also had a documented 
episode of hypoglycaemia over the year 
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Symptoms in “hypo clue” consultations in those with/without documented 
hypoglycaemia 
When the rates were compared overall in those with/without at least one 
episode of documented hypoglycaemia, the symptoms that were significantly 
more common were nausea (7/33, 21.2% vs 14/302, 4.6%, p=0.002), falls 
(10/33, 33.3% vs 36/302, 11.9%, p=0.007), unsteadiness (5/33, 15.2% vs 
13/302, 4.3%, p=0.02), and depression symptoms (6/33, 18.2% vs 22/302, 
7.3%, p=0.044).  
 
The majority of patients (27/33, 81.8%) with at least one documented episode 
of hypoglycaemia were insulin-treated. Of these, 9/27 (33.3%) had presented 
on another occasion with a fall, compared to 4/52 (7.7%) insulin-treated patients 
without a documented episode of hypoglycaemia, p=0.008; and a higher 
proportion had presented with unsteadiness (5/27, 18.5% vs 2/52, 3.9%), 
p=0.043. Presentation with nausea was also more frequent in those insulin-
treated patients with a recognised/reported episode of hypoglycaemia over the 
year: 6/27 (22.2%) vs 1/52 (1.9%), p=0.006. 
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Relationship with HbA1c  
Hypoglycaemia was unrelated to HbA1c (p>0.4), Figure 3. There was also no 
relationship with “hypo clue” consultations and HbA1c, p>0.3 for all. 
 
 
Figure 3: HbA1c in those patients with or without a documented episode of 
“definite” hypoglycaemia  
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DISCUSSION 
 
Non-specific symptoms are a common presentation to primary care in patients 
over 65 with and without diabetes. However we have shown that patients at 
high risk of hypoglycaemia, i.e. patients over the age of 65 who are insulin-
treated and have had a recognised episode of hypoglycaemia, present to 
primary care on other occasions with unexplained non-specific symptoms which 
may represent unrecognised hypoglycaemia. Falls, unsteadiness and nausea 
are particularly worth noting. 
 
Strengths and limitations 
This study examined a difficult question, namely that of whether additional 
episodes of hypoglycaemia might be being missed in the older population. The 
method used was systematic, although reliant on documentation – coding and 
free text - in primary care consultation records, as well as their interpretation 
during analysis. The study was performed in just one primary care practice, 
albeit a reasonably large one. This meant reliance on documentation by a 
limited number of staff; however this may also have offered more internal 
consistency for recording and comparing the vague symptoms between patients 
in this population. The similar rates of “hypo clue” consultations seen in 
sulphonylurea, metformin and non-diabetic patients is reassuring that the 
approach for identification of these consultations was reasonably consistent. 
 
The “hypo clue” consultation definition used was deliberately all-embracing – 
hence high rates were seen in the patients without diabetes. Even so, more 
“hypo clue” consultations were seen in insulin-treated patients who had also 
had a documented episode of hypoglycaemia. Conceivably this rate could be 
artificially elevated as insulin-treated patients may consult more often than the 
other groups. However, we have tried to address this by presenting the results 
comparing those with and without episodes of hypoglycaemia within each 
treatment group. 
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The definition of hypoglycaemia, in contrast, was taken as a strict definition, i.e. 
only those episodes documented as having been confirmed in some way by a 
healthcare professional. This will certainly under-estimate the actual frequency 
of hypoglycaemia, and it may preferentially identify more “severe” episodes. 
This approach combined with the small size of the study may have limited the 
chance of identifying possible associations with those patients experiencing 
hypoglycaemia. In order to corroborate any relationships seen, a prospective 
study of possible “hypo clue” symptoms and hypoglycaemia could be 
undertaken. 
 
Less “severe” episodes of hypoglycaemia (e.g. those which were self-treated 
and not reported to primary care) are also important: they may potentially pose 
a risk for development of reduced hypoglycaemia awareness and a subsequent 
more “severe” event, in addition to as yet under-appreciated possible effects 
e.g. on long-term cognition. These were not captured in the current analysis, 
but a study which also directly asked patients about their experience/frequency 
of hypoglycaemia may prove valuable. This could potentially be combined with 
a more intense but objective assessment of hypoglycaemia, e.g. using 
continuous glucose monitoring. 
  
At the other end of the spectrum, further study in a bigger dataset could be 
revealing: e.g. an “index” event of hypoglycaemia taken and preceding 
consultations analysed to see if “hypo clue” consultations preceded a 
recognised event – and thus potentially expose more robust “red flag” 
symptoms – or corroborate those suggested in the current study. A larger study 
would also allow more sophisticated analyses to be done, in particular 
corrections for factors which may have an impact on risk, such as age (11, 43), 
comorbidities (43, 44), and renal function (11). In addition, insulin-treated 
patients in the current study comprise a heterogeneous group – i.e. some with 
long-standing Type 1 diabetes, and others with Type 2 diabetes and more 
recent initiation of insulin treatment. However although these patients may have 
different rates of presentation with hypoglycaemia or “hypo clues”, the 
underlying type of diabetes in clinical care is not always clearly defined, and 
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thus an all-encompassing “insulin-treated” group was felt to be a more useful 
analysis in the current study.  
 
Finally, HbA1c analysis was limited as it was based on a single HbA1c level 
from the year; and therefore does not reflect potential variation (and possible 
altered risks) over the year. No apparent relationship with hypoglycaemia or 
“hypo clues” was seen in the current study. This particular practice had been 
subject to a similar audit previously, and thus it is possible that the frequency of 
patients with very low HbA1c was lower than average. 
 
Comparison with previous literature 
Consistent with published literature, we found that documented hypoglycaemia 
is more frequent in insulin-treated patients, and the finding that 34% of insulin-
treated patients had a “definite” episode of hypoglycaemia confirmed by a 
healthcare professional over the year is consistent with the 7-46% in insulin-
treated patients of different durations in the UK Hypoglycaemia Study (6): as 
previously mentioned, the insulin-treated patients in the current study comprised 
a heterogeneous group. 5% of sulphonylurea-treated patients having an 
episode of hypoglycaemia is also consistent with the 7% seen in the UK 
Hypoglycaemia Study (6).  
 
18/50 (36%) of patients without diabetes had a “hypo clue” consultation by our 
definition. As previously discussed, this was an all-embracing definition, which 
included many non-specific symptoms frequently presenting to primary care. 
Although not directly comparable, other primary care studies have found 22-
48% patients presenting with symptoms which could not be given a same-day 
diagnosis (36). 
 
Regarding presentation with non-specific symptoms, lethargy/fatigue, feeling 
“generally unwell”, falls, and light-headedness/dizziness were the most 
frequently reported, each in over 10% of these patients aged >65. However falls 
and unsteadiness, along with nausea, were reported significantly more 
frequently in those who had also had (on another occasion) a hypoglycaemia 
episode. Overall 21% of those with at least one episode of documented 
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hypoglycaemia over the year had attended on another occasion with nausea 
without a documented diagnosis, in comparison to 5% of those without an 
episode of hypoglycaemia – and 22% vs 2% in those who were insulin-treated.  
 
It is perhaps not surprising falls were one of the most frequently presenting 
symptoms, as they are one of the most dramatic. However the difference of 
30% vs 12% (or 33% vs 8% of insulin-treated) patients presenting with a fall in 
those who had/had not also had a documented hypoglycaemic episode on a 
different occasion is marked. Kachroo et al (45) identified in a study of over 
21,000 patients with Type 2 diabetes, those who had experienced a 
documented episode of hypoglycaemia over a one-year period, had an 
increased risk of fall-related events compared with an age and gender-matched 
group of patients with Type 2 diabetes without hypoglycaemia. Those >75 had 
an adjusted odds ratio (aOR) for a fall-related event of 1.77 (95% CI 1.48-2.12), 
and those under 75 an aOR of 2.20 (95% CI 1.77-2.12). The greatest risk was 
seen within the first 30 days after a fall (aOR 5.86, 95% CI 4.08-8.43) – and 
increased risk seen in patients with recurrent episodes of hypoglycaemia.  
 
Recognised symptoms associated with hypoglycaemia which could predispose 
to falls include shakiness, anxiety, confusion, lethargy/fatigue, tiredness, 
drowsiness, weakness, light-headedness, dizziness, unsteadiness, 
incoordination, and double or blurred vision (10). The finding that unsteadiness 
was the other most notable discriminatory symptom may be consistent with this: 
15% vs 4% (or 19% vs 4% of insulin-treated) patients with/without 
hypoglycaemia on another occasion presented with unsteadiness. When 
originally reviewing the symptoms associated with hypoglycaemia in the elderly 
in comparison to younger adults, Jaap et al identified that unsteadiness and 
light-headedness were amongst the most frequently occurring and intense (26). 
This study was done by asking 102 insulin-treated patients with Type 2 diabetes 
who had experienced hypoglycaemia in the preceding 2 months their subjective 
experience of the presence of 22 symptoms of hypoglycaemia during a ‘typical’ 
hypoglycaemic episode. Falls were not given as an option in this study, and 
interestingly nausea had a low frequency (6%). 
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In contrast to the current study, a large meta-analysis showed a 30% increase 
in severe hypoglycaemia with tight glycaemic control in people with Type 2 
diabetes (4). The apparent lack of relationship in the current study may reflect 
the low rates of “definite” hypoglycaemia documented, and at the other end of 
the spectrum, the all-embracing definition for “hypo clue” consultations used in 
this relatively small study may have masked results.  
 
Clinical implications 
Patients over the age of 65 and who are insulin-treated are at the highest risk of 
hypoglycaemia, as will be well-recognised and documented by primary care 
practitioners. However, hypoglycaemia in older adults is associated with non-
specific and less intense symptoms than in younger people (25-27). It is known 
to be under-reported to healthcare professionals (30, 46), which can be due to a 
failure to appreciate its significance, or poor recognition (28, 29) perhaps 
particularly in those with Type 2 diabetes, who may not have had education to 
go with the increased risk of hypoglycaemia with insulin (6), or with increasing 
duration of diabetes (20). Symptoms can differ between episodes in the same 
person, which can make recognition especially challenging (31). Additionally 
episodes of hypoglycaemia can be poorly recalled by patients (47, 48), which 
may be exacerbated by cognitive impairment. There may also be a fear of its 
implications such as relating to driving (46). However, as previously discussed, 
it carries a high morbidity (35). This means healthcare professionals need to 
take a more pro-active approach in enquiring about hypoglycaemia.  
 
This study suggests those who have had a recognised episode of 
hypoglycaemia seem more likely to present on another occasion with a non-
specific symptom which could conceivably be due to hypoglycaemia, and 
nausea, falls and unsteadiness seem to be particularly notable. The likelihood 
of this is corroborated by other published data, and as such, insulin-treated 
patients presenting with these symptoms should be reviewed with 
hypoglycaemia in mind.  
 
More recent guidelines for older adults (22-24) favour a more common-sense 
approach in actively addressing glycaemic targets, particularly in a more elderly 
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and frail population, who can ill-afford to be exposed to risk factors for accidents 
(8-10) and cognitive decline (15-17). As previously discussed the current study 
did not show a clear relationship between hypoglycaemia or “hypo clue” 
consultations and HbA1c, but much larger meta-analyses have (49) – and 
additionally increased all-cause mortality has been observed with HbA1c results 
below 7.5% (50). On the other hand, avoidance of hypoglycaemia is not as 
simple as relaxing HbA1c targets – Munshi et al (51) demonstrated using 
continuous glucose monitoring that 65% of a group of (mainly insulin-treated) 
elderly patients with HbA1c >8% experienced at least one episode of 
hypoglycaemia (blood glucose <3.9mmol/L) over 3 days’ monitoring. 
 
At the very least however, clinicians should be alert to the possibility of 
unrecognised hypoglycaemia in their older insulin-treated patients, and review 
them with this in mind. 
 
 
CONCLUSION 
 
 
Non-specific symptoms which can be symptoms of hypoglycaemia are common 
in a population over 65. However in insulin-treated patients at risk of 
hypoglycaemia, these “hypo clue” symptoms, in particular nausea, falls and 
unsteadiness, may represent episodes of hypoglycaemia not recognised by the 
patient. Thus GPs should consider a review, including of diabetes medication, 
when patients report or present with these symptoms.   
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Assessment of Practical Classification Guidelines for 
Diabetes in insulin-treated patients 
 
Abstract 
 
Background 
Differentiating between Type 1(T1D) and Type 2 diabetes (T2D) is fundamental 
for appropriate treatment and management of patients, but can be challenging, 
especially when patients are insulin-treated. UK Practical Classification 
Guidelines (using age at diagnosis and time to insulin treatment) were 
developed, but their accuracy has not been assessed.  
 
Aim  
To assess the diagnostic accuracy of the UK guidelines against “gold-standard” 
definitions of T1D and T2D based on measured C-peptide levels.  
 
Design & Setting 
601 adults with insulin-treated diabetes and diabetes duration >5years were 
recruited in Devon, Northamptonshire & Leicestershire.  
 
Method 
Baseline information and a home urine sample for urinary C-peptide creatinine 
ratio (UCPCR, a measure of endogenous insulin production) were collected. 
“Gold-standard” T1D was defined as continuous insulin treatment within 3 years 
of diagnosis and absolute insulin deficiency (UCPCR<0.2nmol/mmol >5years 
post-diagnosis); all other patients classed as T2D. Diagnostic performance of 
the clinical criteria assessed and other criteria explored using ROC curves. 
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Results 
UK guidelines correctly classified 86% of participants. 
 
Most misclassifications occurred in patients classed as T1D who had significant 
endogenous insulin levels (57/601; 9%); the majority in those diagnosed >35y 
and treated with insulin from diagnosis(37/66;56% misclassified). 
 
Time to insulin and age at diagnosis performed best in predicting long-term 
endogenous insulin production (ROC AUC=0.904 and 0.871); BMI at diagnosis 
was a less strong predictor of diabetes type (AUC=0.824).  
 
Conclusion 
Current UK guidelines provide a pragmatic clinical approach to classification 
that reflects long-term endogenous insulin production; caution is needed in 
older patients commencing insulin from diagnosis, where misclassification rates 
are increased.  
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Introduction 
 
Correctly classifying patients with diabetes with Type 1 or 2 is fundamental to 
ensuring they receive correct management(1-3).  In clinical practice this can be 
challenging, with 7-15% patients misclassified, and large variations in practice 
(4-7). 
 
Historical lack of clear clinical guidelines for diabetes classification is likely to 
have contributed to this variation.  International guidelines from WHO(8) and 
ADA(9) base classification on underlying aetiology, with Type 1 described as a 
destruction of beta cells leading to absolute insulin deficiency. However these 
guidelines do not provide clear criteria or classification pathways for clinical use 
(8, 9).  
 
A pragmatic classification algorithm was thus developed in 2010 by key 
diabetes stakeholders in the UK, and published by the Royal College of General 
Practitioners (RCGP) and NHS Diabetes in their Coding, Classification and 
Diagnosis of Diabetes document(4), Figure 1. This uses age at diagnosis and 
time to commencing insulin treatment from diagnosis as its diagnostic criteria. 
The efficacy of this algorithm has not yet been tested on a large cohort of 
patients with diabetes.  
 
The fundamental difference between Type 1 and Type 2 diabetes is the rapid 
development of absolute insulin deficiency in Type 1, forming the basis of their 
different treatment and management.  Patients with Type 1 require accurate 
insulin dose replacement(10, 11); patients with Type 2 continue to produce 
substantial amounts of their own insulin,  responding to non-insulin therapy, or if 
insulin is needed good control can be achieved with non-physiological insulin 
regimes(12, 13). Measuring endogenous insulin secretion (using C-peptide, a 
component of the insulin pro-hormone secreted in equimolar amounts to insulin) 
in longstanding diabetes may be a useful “gold standard” marker of 
endogenous insulin production, confirming a diagnosis of Type 1 versus Type 2 
diabetes. Development of the spot urine test urinary C-peptide creatinine ratio 
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(UCPCR)(14-17) has enabled practical testing in a community setting. UCPCR 
is well-correlated with mixed meal tolerance test measures(16, 17), and a 
UCPCR cut-off of 0.2nmol/mmol gives a sensitivity and specificity of 100% and 
>95% for detecting severe insulin deficiency(16, 17) as defined by the gold-
standard mixed meal test 90-minute C-peptide level of 200pmol/L(18). 
 
We thus aimed to determine the reliability of the 2010 UK Practical 
Classification Guidelines(4) to correctly classify diabetes in a large cohort of 
insulin-treated participants against “gold-standard” classification based on 
measurement of C-peptide, in those with diabetes of >5 years’ duration.  
Although UCPCR can be used at any stage in diabetes to confirm endogenous 
insulin levels, in the current study we chose >5 years’ duration in order to avoid 
misclassifying people with early Type 1 who may have been still producing their 
own insulin.    
 
 
Figure 1: UK Practical Classification Guidelines for Diabetes (extract showing 
classification guidelines for Type 1 and Type 2 diabetes) 
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Methods 
  
Subjects 
Adults with insulin-treated diabetes in 3 UK centres (Devon, Northamptonshire 
& Leicestershire) were invited to participate when attending for routine diabetes 
appointments (in primary and secondary care). 601 white Caucasian and 30 
Asian patients with a duration of diabetes >5years provided data on age at 
diagnosis, weight at diagnosis, current age, weight and height, treatment, and 
time to insulin from diagnosis. BMI at diagnosis and recruitment were calculated 
where possible; weight at diagnosis for those diagnosed as children converted 
to the adult equivalent using the UK Child Growth Reference Standards(19).  
 
Participants were asked to collect a urine sample for UCPCR(14) two hours 
after their largest meal of a day, and return by post for analysis in the Exeter 
Biochemistry laboratory.   
 
Classification of Diabetes  
Participants were classified as having Type 1 or Type 2 diabetes using the UK 
guidelines(4), Figure 1.  We developed “gold-standard” criteria:  
 
- Type 1 diabetes: continuous insulin treatment within the first 3 years of 
diagnosis and absolute insulin deficiency (UCPCR<0.2 nmol/mmol >5 years 
post-diagnosis)(16) 
- Type 2 diabetes: if Type 1 diabetes criteria were not met 
 
Statistical analysis  
Proportions of patients correctly classified by the UK guidelines according to the 
“gold standard” C-peptide-based definition were calculated, and differences in 
clinical characteristics between those correctly and incorrectly categorised were 
explored using the Mann-Whitney test.  
 
Diagnostic performance of continuous variables (age at diagnosis, time to 
insulin, BMI at diagnosis and recruitment) was assessed using receiver 
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operating characteristic (ROC) curves. Optimal cut-offs for these variables (with 
maximum specificity and sensitivity for discrimination) were calculated, and we 
explored whether use of these optimal cut-offs led to improvements in 
classification over and above the RCGP algorithm using net reclassification 
improvement(20).    
 
Detailed subgroup analysis could not be carried out on the Asian patients due 
to small numbers. 
 
Analysis was carried out on Stata version 13.1 and R version 3.1.2.  
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Results  
 
We compared the UK clinical classification criteria with “gold-standard” C-
peptide-based criteria for defining Type 1 and Type 2 diabetes in this cohort of 
601 patients (Figures 2&3). Table 1 shows participant characteristics. 
 
Table 1: Participant characteristics: median (interquartile range) 
 
 
UK guidelines correctly classify 86% of insulin-treated patients >5 years post-
diagnosis 
514/601 (86%, 95% confidence interval, CI, 83-88%) of patients overall were 
correctly classified by the UK guidelines when compared with our “gold-
standard” criteria: 163/193 (84%, 95% CI 79-89%) with Type 1, and 351/408 
(86%, 95% CI 82-89%) with Type 2 (Figure 2).  In the Asian group the criteria 
(taking note of the age cut-off of 30 years for high risk racial groups) performed 
less well classifying only 21/30 (70%) correctly (p=0.02 for comparison with 
white Caucasians).   
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Figure 2: Classification of type of diabetes according to UK guidelines’ clinical 
criteria compared to “gold-standard” C-peptide-based criteria 
 
 
 
 
Most misclassifications were in patients classified as having Type 1 diabetes 
according the UK guidelines 
Of patients misclassified by the UK guidelines’ clinical criteria in comparison to 
our C-peptide derived “gold-standard” criteria, the majority, 57/87(66%) were 
misclassified as having Type 1 diabetes but were still producing substantial 
endogenous insulin >5 years post-diagnosis.  30/87(34%) were misclassified as 
having Type 2 (but were severely insulin-deficient and had started insulin 
treatment within 3 years of diagnosis). The majority of misclassifications (8/9) in 
the Asian group were also cases where the UK guidelines’ criteria suggested 
Type 1 (NB UK guidelines age cut-off 30) but the patients were still producing 
their own insulin. 
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The majority of misclassified patients with Type 1 diabetes were diagnosed 
aged >35 years, and went immediately onto insulin 
By UK guidelines these 66 patients had Type 1 diabetes, but 37/66(56%) had a 
UCPCR >0.2nmol/mmol, and thus by “gold-standard” criteria had Type 2 
diabetes.  
 
 
Figure 3:  Proportion of patients classified as Type 1 or Type 2 diabetes 
according to the UK guidelines (Figures 1 & 2). Grey bars: proportion whose 
classification is correct according to the C-peptide–derived “gold standard” 
definition; black bars: proportion misclassified. Age diag - age at diagnosis,  
TTI - time to insulin treatment from diagnosis 
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Those misclassified as having Type 1 had clinical characteristics consistent with 
Type 2; those misclassified as having Type 2 had clinical characteristics more 
consistent with Type 1 
Those misclassified as having Type 1 diabetes were older than those correctly 
classified (median age (IQR) 44 (30-59) vs 20 (11-30), p<0.001), and had a 
higher BMI at diagnosis (26.4kg/m2 (23-30.3) vs 21.8(18.9-25.4), p=0.002). 
 
In contrast, those who were insulin deficient but were incorrectly classified by 
the UK guidelines as having Type 2 diabetes, went onto insulin more quickly 
than those correctly classified as having Type 2 (time to insulin from diagnosis 
12 months(2-18) vs 84 months(42-138), p<0.001), had lower BMI (22.5kg/m2 
(21.1-26.3) vs 28.1(25.4-33.3), p<0.001), and were younger at diagnosis 
(44y(35-56) vs 51(43-59), p=0.014).    
 
Assessment of optimal clinical criteria for differentiating Type 1 and Type 2 
diabetes 
We used ROC curves (Figure 4) to examine the discriminative ability of key 
clinical criteria (time to insulin, age at diagnosis, BMI at diagnosis, and BMI at 
recruitment) and to identify the best cut-offs for classification based on the 
“gold-standard” criteria. An area under the curve (AUC) equal to 1 represents 
the perfect discrimination between types of diabetes, and an AUC>0.8 is 
generally deemed clinically useful. 
 
The most discriminatory individual characteristic (Figure 4) was months from 
diagnosis to insulin treatment (AUC 0.904, 95% CI 0.88-0.93), with the optimal 
cut-off at 12 months, classifying 91.5% patients correctly as having Type 1 and 
82.1% correctly as Type 2.  
 
Age at diagnosis was also a useful discriminator between Type 1 and Type 2 
diabetes (AUC 0.871, 95% CI 0.84-0.9), with the optimal cut-off being ≤39y for 
Type 1. This correctly classified 81.9% of patients with Type 1 and 84.3% of 
those with Type 2 diabetes.  
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BMI at diagnosis gave an AUC of 0.824 (95% CI 0.77-0.87; data available in 
359/601(59.7%) patients), with the optimal cut-off being <23.1kg/m2. However, 
although this correctly classified 89.4% of those with Type 2 diabetes, it only 
classified 65.7% patients with Type 1 correctly. BMI at recruitment was less 
discriminatory again, giving an AUC of 0.715(95% CI 0.67-0.76) and an optimal 
cut-off of 28.0kg/m2. This correctly classified just 66.8% people with Type 2 
diabetes, and 61.8% people with Type 1. 
 
 
Figure 4: ROC curve for discriminating between Type 1 and Type 2 diabetes 
based on the gold standard definition. Red: time to insulin from diagnosis 
(AUC=0.904); black: age at diagnosis (AUC=0.871); blue: BMI at diagnosis 
(AUC=0.824); green: BMI at recruitment (AUC=0.715) 
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Modifying the UK guidelines’ clinical criteria only results in marginal 
improvements in accuracy 
The UK guidelines use age at diagnosis and time to insulin as the classification 
criteria for differentiating between Type 1 and 2 diabetes, with 84.5% correctly 
classified with Type 1, and 86% as Type 2, compared to the gold-standard. On 
the basis of the ROC curve data, we incorporated the optimal cut-offs for time to 
insulin (12 months), age at diagnosis (39), BMI at diagnosis (23.1kg/m2) and 
recruitment (28.0kg/m2) into modified criteria in various combinations, to see if 
these improved diagnostic accuracy. Aiming for a sensitivity and specificity of 
>80% (equivalent to an ROC AUC of >0.8), none were superior to the UK 
guidelines, as improvements in sensitivity led to greater decreases in specificity 
and vice versa. The best performing alternative was the combination of age cut-
off of 39 and time to insulin of 12 months; this improved correct classification of 
those with Type 2 diabetes to 94%, but reduced to 78.3% those correctly 
classified with Type 1 diabetes. In general, adding BMI at diagnosis/recruitment 
improved the proportion of those with Type 2 correctly classified, but markedly 
reduced the proportion correctly classified with Type 1 diabetes. 
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Discussion  
 
The UK guidelines are an accurate method of predicting long-term endogenous 
insulin production 
Our results show the UK guidelines perform well in correctly classifying those 
with insulin-treated diabetes based on the development of absolute insulin 
deficiency, with 86% agreeing with a “gold-standard” based on endogenous 
insulin levels and time to insulin from diagnosis.  This supports their use as a 
useful pragmatic way of classifying patients. When all patients with diabetes are 
considered, the performance of the UK guidelines will be even better as the 
vast majority of patients who are not insulin-treated will be correctly classified as 
having Type 2 diabetes.  
 
Patients diagnosed at an older age (>35 years) with insulin treatment 
commenced at diagnosis are at the highest risk of being misclassified when 
using the UK guidelines 
The majority of classification errors occur when using the UK criteria to define 
Type 1 diabetes in participants diagnosed >35 years and on insulin treatment 
from diagnosis. Clinically, where the subtype of diabetes is unclear, giving 
insulin from diagnosis is a rational decision to avoid the potential consequences 
of untreated Type 1 diabetes such as ketoacidosis.  This study demonstrates 
that the majority of these patients are likely to have Type 2 (and therefore may 
potentially not require insulin), so revisiting the diagnosis following an acute 
presentation may be worthwhile. 
 
Time to insulin from diagnosis and age at diagnosis are the best predictors of 
long-term endogenous insulin production  
In clinical practice, emphasis is often placed on BMI to help in differentiating 
between Type 1 and Type 2 diabetes. Our data suggests that amongst insulin-
treated patients, time to insulin and age at diagnosis are better predictors of 
diabetes subtype than BMI, with ROC AUCs of 0.904 and 0.871 respectively, 
and 0.824 for BMI at diagnosis. Median BMI at diagnosis of those with Type 1 
by our “gold-standard” criteria was lower than those with Type 2 diabetes - 
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21.8kg/m2  vs 28.1kg/m2 (p<0.001), but the interquartile ranges overlapped 
(19.8-26.3 and 25.4-32.9kg/m2). By time of recruitment (ie >5 years from 
diagnosis), the difference in BMI between those with Type 1 and 2 was smaller: 
26.5kg/m2 (23.1-29.3) vs 29.7 (26.6-34.5), although still significant (p<0.001), 
and the ROC AUC was low (0.715), highlighting the reduced discriminative 
ability of this as a clinical marker to differentiate between Type 1 and 2 diabetes 
once on insulin.  
 
Strengths and limitations 
These are the only pragmatic clinical guidelines produced by clinical bodies for 
the classification of T1D and T2D, and to our knowledge this is the first 
assessment of them in comparison to a C-peptide based gold-standard, rather 
than coding errors (4, 6, 21, 22). We studied insulin-treated patients with a 
duration of >5 years. If considering all patients with diabetes the 
misclassification rate of 14% is likely to be significantly lower: patients tablet or 
diet-treated >5y from diagnosis are likely to have been correctly diagnosed with 
Type 2 diabetes. In patients with a diabetes duration of <5y, a few patients with 
Type 1 may be still producing insulin (the “honeymoon period”) and not yet 
insulin-treated; however it is rare for patients with Type 1 diabetes to treated 
without insulin for prolonged periods. 
 
Due to recruitment locations and difficulty in recruiting Asian patients (23), the 
majority of our recruited patients were white Caucasian, with only 30 Asian 
patients studied. We thus cannot comment on these criteria for high prevalence 
populations and further work is needed in these groups.   
 
We had limited data on BMI at diagnosis (available for 60% participants), which 
could be improved in future prospective study. Age and gender could be 
considered in more detail in any future (larger) classification studies. It would be 
interesting to follow up those identified as misclassified, and those diagnosed 
with Type 2 and still producing insulin beyond 5 years, to find out if some might 
be able to withdraw successfully from insulin. 
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We have concentrated on the two main types of diabetes, but recognise there 
are alternative subgroups such as genetic forms of diabetes (e.g. MODY). 
These are rare but also part of the UK guidelines(4), and have their own criteria 
for diagnosis(24). It is important the clinician takes into account other factors 
that may indicate these. The term latent autoimmune diabetes in adults (LADA) 
is sometimes proposed for adults with islet autoantibodies who eventually (up to 
12 years) become severely insulin-deficient, but do not require insulin for at 
least the first 6 months (25-28). However LADA is not included in international 
guidelines for classification or treatment, and given endogenous insulin status 
determines treatment requirements, we feel it appropriate to classify according 
to UCPCR status as per our “gold-standard” criteria.  
 
Our gold-standard criteria used a UCPCR cut-off of 0.2nmol/mmol, which has a 
sensitivity and specificity of 100% and >95% to detect absolute insulin 
deficiency (16, 29). It is the best “gold-standard” we have in this context, being 
practical for use in large numbers of community-dwelling adults. Insulin 
treatment has the potential to suppress endogenous insulin (30-32), but we 
have shown this rarely affects diabetes classification (32) – and the small 
possibility of an over-diagnosis of Type 1 diabetes is a safer direction of error 
than the opposite.  
 
Comparisons with existing literature  
Previous reports on “misclassification” of diabetes(4, 6, 21, 22) were mainly 
based on contraindications in coding rather than on gold standard definitions of 
insulin deficiency(18, 33, 34).  
 
A recently published systematic review systematically identified diagnostic 
accuracy studies in the literature which compared clinical criteria with C-peptide 
cut-offs(7). Age at diagnosis, time to insulin, and BMI are the clinical 
characteristics most frequently used to classify Type 1 and 2 diabetes, but few 
studies have addressed clearly which are most strongly associated with long-
term C-peptide secretion(7). Where strength of association has been measured, 
time to insulin and age at diagnosis appear stronger than BMI. Combinations of 
the former two improve diagnostic accuracy, with BMI adding little(7).  
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Implications for clinical practice 
Correct classification of Type 1 or Type 2 diabetes is important so the 
appropriate treatment and management guidelines are followed(3, 35), to 
include treatment, education (eg DAFNE for those with Type 1), and monitoring 
of complications – all of which are based on the presence or absence of 
endogenous insulin. 
 
The clinical problem facing GPs and other healthcare professionals is that 
classification can be tricky at diagnosis – and all guidelines, including these UK 
classification guidelines, rely on information available further down the line (eg 
time to insulin). The gold-standard classification using UCPCR at/beyond 5 
years from diagnosis by definition cannot completely solve this conundrum: 
UCPCR>0.2nmol/mol <5 years from diagnosis may represent someone with 
Type 1 diabetes still in the “honeymoon” phase, or someone with Type 2 
diabetes. UCPCR <0.2nmol/mmol within 5 years of diagnosis can diagnose 
Type 1 diabetes however. Studies designed to improve classification at 
diagnosis, eg by using islet antibodies, are needed to address this problem.  
 
We have shown that the UK guidelines based on time to insulin and age at 
diagnosis are accurate and pragmatic for classifying patients with diabetes. 
“Time to insulin” is subject to many influences - physician or patient factors, or 
guidelines for treatment in a particular area/patient population – but the high 
rate of correlation of diagnosis with the gold-standard suggests overall timing of 
insulin initiation may be reasonably consistent. However it is important to revisit 
the diabetes diagnosis particularly in those diagnosed >35 years of age, given 
the high rates of misclassification seen in this category of patients. We suggest 
if there is diagnostic uncertainty, a review of diagnosis is made, specialist 
advice sought and further investigations (eg C-peptide and islet autoantibodies) 
be considered.  
 
We did not find that modification of the criteria used or the cut-offs proposed 
would improve their diagnostic performance.  Our study, like others (7), suggest 
age of diagnosis is a better clinical predictor of Type 1 diabetes than BMI which 
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is often used clinically to determine diabetes subtype in intermediate patients - 
supporting that more emphasis should be placed on age of diagnosis in 
uncertain cases. This is perhaps particularly relevant in a time when the 
average population BMI is ever increasing.  
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Conclusion  
 
Our study demonstrates that the UK Practical Classification Guidelines for 
Diabetes are an accurate means for determining diabetes subtype, with time to 
insulin and age at diagnosis being the most discriminatory clinical 
characteristics. Older patients treated with insulin from diagnosis had the 
highest rate of misclassification (56% classed incorrectly as having Type 1), and 
further investigation should be considered in this subgroup.  
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Urinary C-peptide creatinine ratio detects absolute 
insulin deficiency in Type 2 diabetes 
 
Abstract 
 
Aims 
It is unclear whether progressive beta-cell failure in type 2 diabetes (T2DM) can 
result in absolute insulin deficiency, which would cause increased risk of 
hypoglycaemia and ketoacidosis, as in T1D. We aimed to determine the 
prevalence and clinical characteristics of absolute insulin deficiency in 
longstanding T2DM, using a strategy based on home urinary C-peptide 
creatinine ratio (UCPCR) measurement.  
 
Methods 
2-hour post-home meal UCPCR was assessed in 191 insulin-treated 
participants with T2DM (diagnosis age >45, no insulin in the first year). Where 
initial UCPCR was<0.2nmol/mmol (representing absolute insulin deficiency) it 
was repeated. A standardized mixed-meal tolerance test (MMTT) with 90-
minute stimulated serum C-peptide (sSCP) measurement was performed in 9 
subjects with UCPCR<0.2nmol/mmol (and 9 controls with 
UCPCR>0.2nmol/mmol) to confirm absolute insulin deficiency. 
 
Results  
2.7% of participants had absolute insulin deficiency confirmed by MMTT. They 
were identified initially using UCPCR: 11/191(5.8%) had two consistent 
UCPCRs<0.2nmol/mmol; 9/11 completed a MMTT and had a median sSCP of 
0.18nmol/L. 5/9 had sSCP<0.2nmol/L. 9/9 participants with UCPCR>0.2 had 
confirmed endogenous insulin secretion in MMTT.  
Compared to participants with UCPCR>0.2, those with confirmed absolute 
insulin deficiency had shorter time to insulin (median 2.5v6years,p=0.005) and 
lower BMIs (25.1v29.1kg/m2, p=0.04). 2/5 were GAD autoantibody positive.   
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Conclusions 
Absolute insulin deficiency may occur in long-standing T2DM, and cannot be 
reliably predicted by clinical features or autoantibodies. Its recognition should 
help guide treatment, education and management. UCPCR is a practical non-
invasive method to aid detection of absolute insulin deficiency, with 
UCPCR>0.2nmol/mmol being a reliable indicator of retained endogenous 
insulin secretion.  
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Introduction 
 
Most older patients with diabetes have type 2 diabetes (T2DM), which is 
typically a disease where endogenous insulin persists. Progressive beta-cell 
dysfunction occurs in T2DM(1-4), but it is unclear if this leads to absolute insulin 
deficiency. In contrast, in type 1 diabetes (T1D) absolute insulin deficiency is 
usual outside the initial “honeymoon period” (ie the period soon after diagnosis 
when some residual beta-cell function may persist) (5). 
 
Some patients may present later in life clinically as having T2DM, but have the 
autoimmune destructive process as seen in T1D. These patients can be 
recognised by pancreatic autoantibodies, known as latent autoimmune diabetes 
in adults (LADA)(6). People with LADA may develop absolute insulin deficiency 
(7-10). However in practice, autoantibody levels are rarely measured in patients 
presenting with adult-onset diabetes: a clinical diagnosis of T2DM is usually 
made, and seldom revisited. Hence later subsequent development of absolute 
insulin deficiency is rarely suspected or tested for. 
 
Absolute insulin deficiency in patients with T2DM is likely to carry similar risks to 
those associated with T1D, such as fluctuant blood glucose levels, high 
hypoglycaemia risk and diabetic ketoacidosis(11). The patient with T2DM 
however is unlikely to be offered a similar level of education to deal adequately 
with these, such as the Dose Adjustment For Normal Eating programme 
(DAFNE)(12). Frail older people in particular may be ill-equipped to cope with 
such complications, with less functional reserve both physically and cognitively, 
and in terms of their social support. The development of absolute insulin 
deficiency in T2DM will alter treatment: oral hypoglycaemic agents (especially 
sulphonylureas) will not be effective, the newer agents e.g. GLP-1 receptor 
analogues and DPP4 inhibitors are not suitable, and the most appropriate 
insulin regimen may be for example basal-bolus rather than background long-
acting insulin. With an estimated 870,000 people with insulin-treated T2DM in 
the UK, development of absolute insulin deficiency in even a small proportion 
could have significant impact on both individuals and society.  
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Endogenous insulin levels are rarely measured in routine clinical practice - even 
in secondary care - due to practical limitations including the need for rapid 
laboratory analysis of blood tests. The majority of patients with T2DM are cared 
for in primary care where this is even less practical. Recently a simple urine test 
- Urinary C-Peptide Creatinine Ratio (UCPCR)(13) has been shown both in T1D 
and T2DM, to be excellently correlated with the gold-standard measure of 
endogenous insulin secretion, the formal mixed meal tolerance test (MMTT) - 
and a sensitive and specific test for absolute insulin deficiency(5, 14). The 
UCPCR test has the advantages of being widely available, and stable at room 
temperature for 3 days so offering the potential for widespread non-invasive 
testing which may be particularly useful for a more frail older population. Our 
study aimed to use UCPCR to test for absolute insulin deficiency in older people 
with insulin-treated T2DM.  
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Methods 
 
Subjects  
191 insulin-treated participants with type 2 diabetes (clinical diagnosis of type 2 
diabetes, diagnosis > 45 years of age, no insulin within 1 year of diagnosis) 
were recruited from primary care at the time of their routine retinal screening 
appointment, and written consent obtained for participation in the study. 
Baseline data collected included duration of diabetes, current treatment, BMI 
and most recent HbA1c.  
 
Urine collection and analysis  
Participants were asked to provide an initial urine sample, collected at home, 2 
hours after their largest meal of the day. The urine sample was collected in a 
standard mid-stream urine boric acid-containing specimen pot, and returned by 
post to the routine pathology labs for UCPCR analysis.  UCPCR 
<0.2nmol/mmol is equivalent to a stimulated serum C-peptide of 0.2nmol/L in a 
mixed meal tolerance test (MMTT) (15, 16), representing an absence of 
clinically significant insulin secretion (11). This level is associated with unstable 
glycaemia, increased risk of hypoglycaemia and microvascular complications 
(as well as absolute insulin requirement) in T1D (11, 16). 
 
All patients identified as insulin-deficient were asked to provide a repeat sample 
to confirm their initial result, as were a random group of those with a UCPCR 
>0.2nmol/mmol.  
 
Mixed Meal Tolerance Test  
In those patients with consistent UCPCR results <0.2nmol/mmol, we performed 
a formal mixed meal tolerance test (MMTT) with their insulin excluded, to 
confirm the absolute insulin deficiency(5). A comparison group of age-matched 
participants with UCPCR >0.2nmol/mmol also underwent the standardised 
MMTT(17). In brief, subjects fasted from midnight, and omitted their morning 
medications including insulin. Fasting serum and urine samples were taken 
before participants consumed 6ml/kg Ensure Plus HP (Abbott). A blood sample 
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for stimulated serum C-peptide (sSCP) was taken 90 minutes later, and a urine 
sample for UCPCR at 2 hours. As above, an sSCP of <0.2mmol/L was used to 
represent absolute insulin deficiency (5, 18). 
 
Sample Analysis 
Urine and serum samples were analysed for C-peptide using 
electrochemiluminescence immunoassay (intraassay CV <3.3%; interassay CV 
<4.5%) on a Roche Diagnostics E170 analyzer (Mannheim, Germany) by the 
Biochemistry department at the Royal Devon & Exeter Hospital. Urine creatinine 
was analyzed on the Roche P800 platform using creatinine Jaffé reagent 
(standardized against ID-MS) to obtain a urinary C-peptide creatinineratio 
(nmol/mmol). Blood samples for all patients completing the MMTT were 
analysed for GAD65 and IA2 autoantibodies, using the Biokit automated Elisa 
System (BEST 2000, Biokit, Barcelona) following manufacturers’ instructions. 
Cut-offs used were those based on the 99th centile for 500 non-diabetic 
individuals; for GAD65 the reference positive value was >64 units/ml, for IA-2 
the reference positive value >15 units/ml. 
 
 
Data analysis 
The data were not normally distributed, and so are presented as medians and 
interquartile ranges. Results were analysed primarily in terms of clinical 
characteristics between those with confirmed absolute insulin deficiency on 
MMTT, versus those with endogenous insulin secretion, using Mann-Whitney U 
and chi-squared tests (using Predictive Analytic Software PASW 17.0). The full 
group of 167 participants with initial home UCPCR >0.2nmol/mmol was used to 
represent those with significant insulin secretion, given the consistency of 
repeat UCPCR and MMTT results in subgroups drawn from these (see Results 
and Figure 1). 
 
Ethics approval was obtained from the Southwest Research Ethics Committee. 
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Results 
 
191 participants (median age 73.5 years, interquartile range (IQR) 67-78, 37% 
women) provided an initial urine sample for UCPCR measurement. They had a 
median age at diagnosis of 58 years (IQR 50-65), duration of diabetes of 13.5 
years (9-19), and BMI at recruitment of 29kg/m2 (25.9-33.54). Their median 
time to insulin from diagnosis was 6 years (3.5-11). 
 
UCPCR detected subjects with low endogenous insulin levels 
Figure 1 summarises flow of patients through the study. Of the 191 participants 
screened, 24 (12.5%) had UCPCR<0.2nmol/mmol.  Of these, 21 provided a 
repeat sample, and 11/188 (6% of the whole cohort) had two consistent UCPCR 
results of <0.2nmol/mmol.  
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Figure 1: Flow of participants through the study 
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Table 1: UCPCR and serum C-peptide values in 9 subjects with two home UCPCRs of 
<0.2nmol/mmol, compared to 9 matched subjects with two home UCPCRs of 
>0.2nmol/mmol. Data shown as median values and interquartile ranges.  
fSCP: fasting serum C-peptide; sSCP: stimulated serum C-peptide; MMTT: mixed meal 
tolerance test. 
 
 
 
UCPCR <0.2 UCPCR >0.2 P value 
UCPCR (home) 
(nmol/mmol) 
<0.02 
(<0.02-0.2) 
1.7 
(0.8-7.1) 
<0.001 
UCPCR (MMTT) 
(nmol/mmol) 
0.07 
(<0.02-0.7) 
2.6 
(1.9-5.6) 
0.001 
fSCP 
(nmol/L) 
0.13 
(0.08-0.35) 
0.59 
(0.45-0.88) 
0.003 
sSCP 
(nmol/L) 
0.18 
(0.08-0.64) 
2.0 
(1.53-2.52) 
0.002 
 
 
Patients with clinically diagnosed T2DM show absolute insulin deficiency with 
mixed meal tolerance testing  
Table 1 summarises the MMTT results of the two groups selected on the basis 
of their UCPCR. These two groups were similar in age, duration of diabetes, 
time to insulin from diagnosis, and BMI. As expected the stimulated serum C-
peptide (sSCP) was lower in those with a low UCPCR compared to those with a 
high UCPCR (median 0.18 nmol/L v 2.0 nmol/L, p= 0.002). 5 of the 9 patients 
with a low UCPCR had a stimulated C-peptide <0.2nmo/L representing absolute 
insulin deficiency(18) in contrast to none with a high UCPCR.  This suggests the 
minimum prevalence of absolute insulin deficiency in insulin-treated T2DM is 
3% (5/186, excluding the 5 who were unable to provide repeat urine samples or 
participate in the MMTT, see Figure 1).  
 
Of note, the UCPCR results obtained in both groups were substantially higher 
after the MMTT than the home meal. For those four patients with two home 
UCPCRs <0.2nmol/mmol but an sSCP>0.2nmol/L, the post-MMTT UCPCR 
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results were also >0.2nmol/mmol. This suggests the MMTT provided more 
beta-cell stimulation than the meals consumed at home. 
 
Patients with absolute insulin deficiency went onto insulin sooner and are 
slimmer 
The 5 patients with confirmed absolute deficiency on MMTT were slimmer (BMI 
25.1 kg/m2 versus 29.1, p=0.04), and commenced insulin more rapidly after 
diagnosis (2.5 years versus 6, p=0.005), although there was substantial overlap 
for both these measures between those with (n=5) and without (n=167) 
absolute insulin deficiency. There was no difference in age of diagnosis, 
duration of diabetes, glycaemic control or insulin dose (Table 2).   
 
Two of the five participants with absolute insulin deficiency were GAD-positive 
(titre in both >2000 units/ml); one of these was also IA-2 positive (titre 74.9 
units/ml). In addition, one patient who had two low UCPCR measurements from 
home but a stimulated C-peptide of 0.37nmol/L,was GAD-positive (titre >2000 
units/ml). None of the 9 participants from the comparison MMTT group, ie with 
home UCPCR demonstrating residual endogenous insulin secretion and 
confirmed on MMTT, were positive for GAD or IA-2 antibodies. 
 
Of note only 2 of the 5 participants with absolute insulin deficiency were on a 
basal-bolus regimen, and two were treated with oral agents in combination with 
insulin. 
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Table 2: Clinical characteristics of those with absolute insulin deficiency as 
confirmed by MMTT, versus those with endogenous insulin secretion (UCPCR 
>0.2nmol/mmol). Data shown as medians (interquartile range).  *OHA: oral 
hypoglycaemic agent(s); **Basal bolus regime: 4 or 5 injections of insulin a day. 
$Chi-square tests; all others Mann-Whitney U 
 
 
 
Absolute 
insulin 
deficiency 
Endogenous 
insulin 
secretion 
P 
N 5 167  
Age at diagnosis  
(years) 
63  
(54-72) 
58  
(50-66) 
0.28 
Duration of diabetes 
(years) 
12  
(9.5-19.5) 
13  
(9-17) 
0.87 
BMI (kg/m2) 
25.1  
(22.8-28.8) 
29.1  
(26.3-33.6) 
0.04 
HbA1c  (mmol/mol) 
HbA1c (%) 
72 (57-85) 
8.7 (7.4-9.9) 
62 (55-69) 
7.8 (7.2-8.5) 
0.24 
Time to insulin  (years) 
2.5  
(1.5-3) 
6  
(3-10.75) 
0.005 
Insulin/kg/24hrs 
(units/kg/24h) 
0.72  
(0.54-0.88) 
0.51  
(0.31-0.84) 
0.26 
On OHA (in addn to 
insulin)*$ 
2/5  
(40%) 
115/167  
(69%) 
0.17 
On basal bolus regime**$ 
2/5  
(40%) 
19/167  
(11%) 
0.05 
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Discussion 
 
2.7% of insulin-treated patients with a clinical diagnosis of T2DM in this study 
have been shown to have absolute insulin deficiency. Patients who may have 
had absolute insulin deficiency were detected using the simple non-invasive 
testing method, Urinary C-Peptide Creatinine Ratio (UCPCR), and the MMTT 
was used to confirm findings. These patients cannot be solely identified on the 
basis of clinical characteristics, or by testing of GAD antibodies.  
 
Prevalence & aetiology of absolute insulin deficiency in T2DM 
Our prevalence of absolute insulin deficiency of 2.7% (5/186) in an insulin-
treated group of patients with a clinical diagnosis of T2DM is similar to the 2.3% 
(3/133) found at 10 years from diagnosis in an observational study by Niskanen 
et al (7). This looked at adult patients over the age of 45 with new-onset non-
insulin-dependent diabetes, and measured sSCP and GAD titres at 0, 5 and 10 
years. By including only insulin-treated patients in our study, one might have 
expected a more insulin-deficient group and hence a comparatively higher 
proportion of patients with absolute insulin deficiency than in Niskanen’s study. 
The aim for tighter glycaemic control (and hence earlier initiation of insulin) in 
the post-DCCT/UKPDS era may provide explanation for why this was not seen. 
Additionally, the 2.7% prevalence in our study population is a minimum: there 
were 5 additional participants with initial UCPCR suggestive of absolute insulin 
deficiency who were either uncontactable or unable to undergo a MMTT (Figure 
1), if all these had confirmed sSCP<0.2nmol/L the prevalence would have risen 
to 5.2% (10/191). 
 
In patients with high titres of GAD antibodies, reasonably long duration (10-12 
years) prospective longitudinal studies have shown many (but not all)develop 
absolute insulin deficiency (7, 9). When combined with the clinical features of 
adult-onset diabetes not immediately requiring insulin treatment, the presence 
of pancreatic autoantibodies has been called “latent autoimmune diabetes in 
adults” (LADA) (7, 9, 10). Two of the 5 participants with absolute insulin 
deficiency in our study fit these criteria, having high GAD-titres (>2000units/ml, 
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reference value >64units/ml).  However, with 3 participants with confirmed 
absolute insulin deficiency not exhibiting GAD antibodies, it suggests that the 
presence of these antibodies is not a sensitive test for detecting the 
development of absolute insulin deficiency in those with longstanding diabetes.  
 
Our study has hence identified 3 people with apparent non-autoimmune T2DM 
and confirmed absolute insulin deficiency. Of the three patients developing 
absolute insulin deficiency in Niskanen et al’s study [7], one was GAD-antibody 
negative. This was the only other case we found in the literature of absolute 
insulin deficiency confirmed using stimulated serum c-peptide, in non-
autoimmune T2DM(7). It is possible that the cross-sectional measurement of 
pancreatic autoantibodies in our study may have missed some patients who 
were antibody-positive at an earlier stage but lost this positivity over time. 
However numerous studies have found high GAD-titres persist (7, 9, 19, 
20).The cross-sectional design of this study meant we were able to look a wide 
range of durations of diabetes, longer than that looked at before in T2DM, and 
this may help explain why we have detected absolute insulin deficiency where 
others have not. No previous studies we have found were designed to look for 
absolute insulin deficiency in T2DM; the majority have looked at the significance 
of GAD antibodies on the deterioration in beta-cell function over time.  
 
UCPCR testing 
UCPCR was used in this study as a practical test in a large number of 
individuals, and was able to detect patients at risk of absolute insulin deficiency. 
The gold-standard MMTT was used to confirm findings. Those with evidence of 
endogenous insulin secretion on an initial UCPCR test had consistent results 
both on repeat UCPCR and MMTT. As would be expected by regression to the 
mean when selecting a low cut-off, those with initial low UCPCR suggesting 
absolute insulin deficiency had a tendency to higher results upon repeat testing, 
taking them above the designated 0.2nmol/mmol threshold. In addition, some 
practical issues were identified which may have led to erroneously low UCPCR 
results upon initial testing: these included patients tipping out the boric acid 
preservative from the sample pots, and postal delays. Additionally in those with 
low endogenous insulin levels, variation in meal stimulus may have contributed 
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to a low UCPCR on one occasion versus a UCPCR over the 0.2nmol/mmol 
threshold on another occasion. This is supported by the finding that in four 
patients, despite two home UCPCR results suggestive of absolute insulin 
deficiency, a higher UCPCR and measurable sSCP (though low) levels were 
seen under controlled MMTT conditions. This suggests the MMTT was more 
stimulating than the home meals of these patients and they were still able to 
mount an insulin response when maximally stimulated. However insulin 
secretion with their normal diet may be clinically more relevant.  
 
The screening method did identify individuals with genuine absolute insulin 
deficiency. With clear instructions on how to optimally take a sample for UCPCR 
testing, and advice to repeat a low UCPCR in the first instance, it is a very easy 
and practical test which has the advantage of being widely available, avoids the 
need for venepuncture, and can be done at home and posted in. Since the 
completion of this study, it has been shown that the previously widely perceived 
practical limitations in measurement of c-peptide in blood may be to some 
extent overcome by using EDTA sample tubes: these can improve the stability 
of C-peptide concentrations to over 24 hours at room temperature(21). This 
would also make measurement of C-peptide in blood a viable test in the 
outpatient/primary care setting. 
 
In the increasingly complex climate of diabetes management options, 
confirmation (or not) of insulin deficiency should help guide treatment, 
education and management decisions, which will be valuable in optimising care 
for any patient, but perhaps particularly the more frail older patient. We would 
suggest a measure of c-peptide, such as UCPCR, may have an important role 
when clinical features like marked variation in blood glucose values suggest 
absolute insulin deficiency. 
 
Clinical characteristics 
Those with confirmed absolute insulin deficiency had started insulin sooner after 
diagnosis than those with retained endogenous insulin (2.5 years versus 6), and 
had lower BMIs (25 versus 29). In terms of other easily available and 
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measurable baseline patient characteristics, there was little else to distinguish 
them.  
 
Although 2 of the 5 patients with confirmed absolute insulin deficiency were on 
basal bolus regimens, the three others, and several of those with low 
endogenous insulin levels, were on unusual regimens more suited to patients 
with endogenous insulin secretion. 2 of the 5 were still on oral hypoglycaemic 
agents, and none had had any training such as DAFNE(12) to help them 
understand and manage their diabetes better. 
 
Theoretically despite a clinical diagnosis of T2D, the patients with absolute 
insulin deficiency may be at risk of complications as seen in T1D. This was 
reflected in all of the patients with absolute insulin deficiency – and those with 
low endogenous insulin levels - reporting difficulty in managing their blood 
glucose levels due to seemingly unpredictable fluctuations in blood glucose 
levels, and one patient having had an episode of diabetic ketoacidosis (DKA). 
 
Implications for clinical practice 
Identification of absolute insulin deficiency in patients with a clinical diagnosis of 
T2DM may enable optimisation of their treatment  such as basal bolus 
regimens, management and education such as DAFNE(12) courses, and 
recognition of potential complications such as higher risks of hypoglycaemia or 
DKA. All these have not been traditional considerations in many patients with 
T2DM, and recognition should help improve the quality of life of these 
individuals.  
 
UCPCR is a practical and useful test to detect absolute insulin deficiency in 
T2DM and should be used in “T2DM” individuals developing DKA, severe 
hypoglycaemia or having large fluctuation in blood glucose values, to help 
inform optimal diagnosis and/or management. A UCPCR suggestive of 
endogenous insulin production is reliable, and in this clinical context may 
suggest other explanations for the clinical features (such as compliance). A low 
UCPCR suggestive of insulin deficiency should be repeated in the first instance, 
but may help guide management and education as described above. 
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Conclusion 
 
We have shown that absolute insulin deficiency is present in 3% of insulin-
treated patients with T2DM and may be detected using Urinary C-peptide 
creatinine ratio, UCPCR. Clinical features such as GAD antibodies, starting 
insulin sooner after diagnosis, and having a lower BMI are pointers to help 
recognise those at risk, but are not diagnostic. Those with absolute insulin 
deficiency are at risk of more fluctuant blood glucose levels, hypoglycaemia and 
diabetic ketoacidosis, which may adversely affect quality of life as well as 
potentially having more severe consequences especially in the older population. 
Recognition of absolute insulin deficiency is thus important as it will aid optimal 
management of these individuals, and UCPCR is a useful test that can be used 
in general practice or outpatients to confirm a clinical suspicion of insulin 
deficiency. 
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Random non-fasting C-peptide:  
bringing robust assessment of endogenous insulin 
secretion to the clinic 
 
Abstract 
 
Background 
Measuring endogenous insulin secretion using C-peptide can assist diabetes 
management, but standard stimulation tests are impractical for clinical use. 
Random non-fasting C-peptide assessment would allow testing when a patient 
is seen in clinic. 
 
Methods 
We compared C-peptide at 90 minutes in the mixed meal tolerance test (sCP) 
with random non-fasting blood C-peptide (rCP) and random non-fasting urine C-
peptide creatinine ratio (rUCPCR) in 41 participants with insulin-treated 
diabetes.  We assessed sensitivity and specificity for previously reported 
optimal mixed meal test thresholds for insulin deficiency (<200pmol/L) and Type 
1 diabetes/inability to withdraw insulin (<600pmol/L), and assessed impact of 
concurrent glucose.  
 
Results 
rCP and sCP levels were similar (median 546pmol/L and 487pmol/L, p=0.92). 
rCP was highly correlated with sCP,  r=0.91, p<0.0001, improving to r=0.96 
when excluding samples with concurrent glucose <8mmol/L. 
An rCP cut-off of 200pmol/L gave sensitivity of 100% and specificity of 93% for 
detecting severe insulin deficiency (sCP<200pmol/L), with area under the ROC 
curve 0.99. An rCP <600pmol/L gave sensitivity of 87% and specificity of 83% 
to detect sCP<600pmol/L, with specificity improving to 100% when excluding 
samples with concurrent glucose <8mmol/L. 
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rUCPCR (0.52nmol/mmol) was also well-correlated with sCP, r=0.82, p<0.0001. 
An rUCPCR cut-off of <0.2nmol/mmol gave sensitivity and specificity of 83% 
and 93% to detect severe insulin deficiency, with ROC AUC 0.98.  
 
Conclusions  
Random non-fasting C-peptide measures are strongly correlated with mixed 
meal C-peptide, and have high sensitivity and specificity for identifying clinically 
relevant thresholds. These tests allow assessment of C-peptide at the point 
patients are seen for clinical care. 
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INTRODUCTION 
 
Assessment of endogenous insulin secretion using C-peptide is useful in clinical 
practice to assist classification and treatment of diabetes (1). Assessment of a 
stimulated blood C-peptide level following a standardised stimulus such as a 
mixed meal (mixed meal tolerance test, MMTT) provides a gold-standard 
measure of endogenous insulin secretion, but is impractical for clinical use (2).  
Other C-peptide measures such as fasting blood C-peptide (3), or a post-home 
meal urinary C-peptide creatinine ratio (UCPCR)(4-6), give a reasonable 
approximation to the gold-standard, and high sensitivity and specificity in 
classifying diabetes (7-10). However, for routine clinical care, the most practical 
test would be a spot “random” non-fasting sample, sent when a patient is seen 
in an outpatient or primary care clinic. 
 
Random non-fasting blood C-peptide (rCP) has been shown to have superior 
performance to both post-glucagon and fasting blood C-peptide assessment in 
differentiating clinically well-defined Type 1 and Type 2 diabetes (7, 8), and to 
have clinical utility in detecting MODY (11, 12). However rCP has never been 
formally validated against a gold-standard MMTT C-peptide assessment. While 
UCPCR changes little from 2 to 4 hours post-meal in those with Type 2 diabetes 
(McDonald, unpublished), utility of a random non-fasting UCPCR sample has 
never been assessed. 
 
We aimed to compare non-fasting random blood C-peptide and UCPCR with 
‘gold-standard’ blood C-peptide assessment at 90 minutes in the MMTT. 
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METHODS 
 
Subjects 
41 participants with insulin-treated diabetes were recruited to the GREAT study 
(https://clinicaltrials.gov, NCT02506296). To ensure a range of C-peptide 
values, participants were selected on the basis of prior C-peptide assessment to 
include participants with and without severe insulin deficiency (under/over 
200pmol/L post-MMTT blood C-peptide or equivalent (1)). All participants had a 
clinical diagnosis of Type 2 diabetes, and an estimated glomerular filtration rate 
(eGFR) >30ml/min/1.73m2. Ethical approval was obtained from the NRES 
Committee South West, and all participants gave written informed consent. 
 
Mixed meal tolerance test 
Participants fasted from 10pm, then attended the following day prior to 11am 
having not taken their morning medication prior to arrival. Baseline bloods for 
glucose and C-peptide were taken, morning insulin given (13), and 160ml of 
Fortisip Compact (Nutricia, Trowbridge, UK) drunk within 10 minutes 
(content/100ml: carbohydrate 29.7g, protein 9.6g, fat 9.3g). Bloods for C-
peptide and glucose analysis were repeated every 30 minutes, up to and 
including 180 minutes post-mixed meal. Samples were immediately centrifuged 
after collection and stored at -800C, for later batched analysis. 
 
Non-fasting tests 
On a separate occasion (within 8 days of the MMTT), blood was taken between 
9am and 5pm, within 5 hours of a meal, and without restriction on snacks or 
other intake. Whole blood samples collected in potassium-EDTA (C-peptide) 
and fluoride oxalate (concurrent glucose) tubes were sent at room temperature 
to be processed routinely at the Royal Devon & Exeter Hospital Blood Sciences 
department. Participants were also asked to provide a spot urine sample. This 
was frozen at -800C before later batch analysis. 
 
 
151 
 
Sample analysis 
C-peptide was analysed using the automated Roche diagnostics (Manheim, 
Germany) E170 immuno-analyser (limit of detection 3.3pmol/L, inter- and intra-
assay coefficients of variations <4.5% and <3.3% respectively). Urinary 
creatinine was analysed on the Roche P800 platform to obtain a urine C-
peptide creatinine ratio (UCPCR, nmol/mmol). 
 
Analysis 
We compared the median random non-fasting blood C-peptide (rCP) with the 
median blood C-peptide at 90 minutes in the mixed meal tolerance test (sCP) 
using Wilcoxon’s signed rank test, and correlation coefficient between both rCP 
and random non-fasting UCPCR (rUCPCR) with sCP using Spearman’s rank 
correlation.  
 
We then assessed the utility of rCP and rUCPCR in correctly classifying 
participants in relation to previously described clinically relevant MMTT C-
peptide thresholds using receiver operating characteristic (ROC) curves, with 
corresponding specificities and sensitivities: 
1. MMTT sCP <200pmol/L: absolute insulin deficiency (1, 14)  
2. MMTT sCP  <600pmol/L: Type 1 diabetes/inability to withdraw insulin (1)  
 
Finally, we assessed the influence of concurrent glucose repeating the above 
analyses excluding hypoglycemia (concurrent glucose <4mmol/L), and a 
previously suggested cut-off of <8mmol/L (1, 8, 15).  
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RESULTS 
 
Participant characteristics  
28/41 (68%) of participants were men. Participants had a median age of 73 
(interquartile range, IQR 68-78), diabetes duration 21 (14-31) years, BMI 26.8 
(25-29.9) kg/m2, and HbA1c 68 (58-75) mmol/mol/8.4% (7.5-9.0%).  
12/41 (29%) participants had severe insulin deficiency (sCP<200pmol/L). C-
peptide was detectable (>2.9pmol/L) at all time-points - fasting and stimulated - 
in 40/41 participants. 
 
C-peptide was stable 1-3 hours after meal stimulation 
There was little change in the C-peptide from 60 mins to 3 hours post-MMTT: 
median C-peptide ranged from 487 to 622pmol/L across these five time points, 
Figure 1a. Mean individual coefficient of variation over the 1-3 hour-post MMTT 
period was 14.3%. 
 
Random non-fasting blood C-peptide level is strongly correlated with the gold-
standard 90-minute mixed meal test C-peptide  
Median rCP of 546 pmol/L (IQR 76-943) was similar to sCP at 90 minutes, 487 
pmol/L(75-985), p=0.92, Figure 1a.  
 
rCP was strongly correlated with sCP: Spearman’s rho correlation 
coefficient=0.913, p<0.0001, Figure 1b. When only participants who had a 
concurrent lab glucose value of >8mmol/L were included (66% participants), the 
correlation coefficient increased to 0.96.  
 
To be expected, results showed more variation in the higher C-peptide range, 
Figure 2.  
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Figure 1 (a) Blood C-peptide levels on random sampling and in the mixed meal 
test. rCP: random non-fasting; time points reflect minutes post mixed meal 
ingestion, 0m: fasting sample. 
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Figure 1 (b) Random non-fasting C-peptide versus 90 minute C-peptide in the 
mixed meal tolerance test. Blue diamonds: concurrent blood glucose >8mmol/L; 
green circles: concurrent blood glucose >4 to 8mmol/L; red triangles: concurrent 
blood glucose <4mmol/L.  
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Figure 2: Bland-Altman plot showing the difference between 90-minute C-
peptide (sCP) and random non-fasting C-peptide (rCP). Level of blood glucose 
measured concurrently with rCP shown by blue diamonds >8mmol/L; green 
circles >4 to 8 mmol/L; red triangles: <4 mmol/L 
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Random non-fasting blood C-peptide is a highly sensitive and specific test for 
severe insulin deficiency  
rCP was a highly sensitive and specific test for severe insulin deficiency 
(sCP<200pmol/L), with area under the ROC curve (AUC ROC) of 0.99 (Table 
1). An rCP cut-off of <200pmol/L gave a sensitivity of 100% and specificity of 
93% for severe insulin deficiency, with 95% of participants correctly classified. 
This did not alter significantly with concurrent glucose (Table 1). 
 
rCP was also able to identify participants with sCP <600pmol/L (Type 1 
diabetes/inability to withdraw insulin): AUC ROC 0.94 (95% CI 0.84-0.99). An 
rCP value <600pmol/L gave a sensitivity of 87% and specificity of 83% to detect 
sCP<600pmol/L - with 85% correctly classified. Excluding concurrent glucose 
values <8mmol/L improved specificity to 100% without altering sensitivity, Table 
1.  
 
Random non-fasting UCPCR is also strongly correlated with the gold-standard 
blood C-peptide measure and a sensitive and specific test for severe insulin 
deficiency 
rUCPCR (median 0.52nmol/mmol (IQR 0.095-1.57nmol/mmol), was well-
correlated with sCP, r=0.82, p<0.0001 (n=40). rUCPCR was also a sensitive 
and specific test for detecting the clinically relevant thresholds of sCP 
<200pmol/L and <600pmol/L: ROC AUC 0.98 and 0.90 respectively, Table 1. 
For identifying severe insulin deficiency (sCP<200pmol/L), an rUCPCR cut-off 
of <0.2nmol/mmol gave a sensitivity and specificity of 83% and 93%, with 90% 
participants being correctly classified. An rUCPCR cut-off of <0.6nmol/mmol 
had a sensitivity and specificity of 82% and 83% for detecting sCP<600pmol/L.  
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Table 1: Ability of random non-fasting blood C-peptide (rCP) and UCPCR 
(rUCPCR) to define absolute insulin deficiency (90-minute mixed meal tolerance 
test C-peptide (sCP) <200pmol/L) and type 1 diabetes/insulin dependence (sCP 
<600pmol/L) using equivalent thresholds, with and without exclusion based on 
concurrent glucose (blood C-peptide only). Sensitivity, specificity and % correct 
classification are given for numerically equivalent thresholds (rCP 200 and 
600pmol/L, UCPCR 0.2 and 0.6nmol/mol) as these were close to optimal on 
ROC analysis. 
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DISCUSSION 
 
Our results show that random non-fasting blood C-peptide and UCPCR 
measurements taken when a patient attends clinic are highly correlated with the 
gold-standard mixed meal test assessment of endogenous insulin secretion, 
and are sensitive and specific tests for clinically relevant thresholds. These 
tests, combined with the demonstration of stability at room temperature of blood 
C-peptide for >24 hours (in EDTA (16))  and UCPCR for >72 hours (in boric 
acid (17)), offer a practical way of assessing endogenous insulin excretion when 
contact is made for clinical care.  
 
Our findings are consistent with previous research demonstrating that a random 
non-fasting blood C-peptide offers similar performance to C-peptide in a formal 
glucagon stimulation test when classifying clinically well-defined Type 1 and 2 
diabetes (8), is superior to fasting C-peptide when identifying autoimmune 
diabetes (7) and has high clinical utility for detecting patients with undiagnosed 
monogenic diabetes (11). This is the first study to formally evaluate use of a 
random non-fasting C-peptide sample against a gold-standard in a mixed meal 
test. The use of a random non-fasting UCPCR has not been previously 
assessed. 
 
Limitations of our study include that our modest sample size limits our ability to 
assess the impact of concurrent glucose on rCP testing. In addition our 
population may not be representative of the patients where C-peptide testing 
has most utility (difficult to classify diabetes) in that they are elderly and have 
been selected on the basis of a clinical diagnosis of Type 2 diabetes with or 
without discordant C-peptide.  
 
Our results suggest that a random non-fasting blood C-peptide or UCPCR could 
be used to assess endogenous insulin secretion in clinical practice. This would 
have major practical advantages in that the test can be conducted when a 
patient is seen for clinical care. While our sample size is too small to robustly 
assess the impact of concurrent glucose our results suggest this has only 
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modest impact. While a high value in the presence of any glucose is likely to be 
robust it may be prudent to treat rCP values below a clinical threshold where 
concurrent glucose is <8mmol/L with caution, and consider a repeat sample.  
 
 
  
160 
 
CONCLUSION 
 
We have shown that random non-fasting blood and urine C-peptide measures 
are strongly correlated with the gold-standard C-peptide test and have high 
sensitivity and specificity in identifying clinically relevant C-peptide thresholds. 
These tests allow assessment of C-peptide at the point patients are seen for 
clinical care. 
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A clinically collected random non-fasting C-peptide 
sample may be used as a risk assessment tool for 
hypoglycaemia frequency and awareness in insulin-
treated patients 
 
Abstract 
 
Background and aims 
There is considerable variation in the degree of endogenous insulin secretion in 
insulin-treated diabetes. Recently we have shown that C-peptide is stable >6 
hours at room temperature. We aimed to assess whether random non-fasting 
C-peptide (rCP) correlates well with the gold-standard C-peptide measure (90 
minute stimulated sample (sCP) in mixed meal test (MMTT), and whether rCP 
analysis could be done on routinely collected diabetes blood samples from 
primary care, in order to provide a model for integration with research and 
clinical care. 
 
We then aimed to assess the relationship between rCP and hypoglycaemia 
frequency and hypoglycaemia awareness in insulin-treated patients (Type 1 or 
2 diabetes). 
 
Methods 
50 participants underwent a standardised MMTT for comparison of rCP and 
sCP. 480 insulin-treated patients, median age 66 (IQR 54-74), diabetes 
duration 19 (13-29) years, and HbA1c 65mmol/mol (57-74) provided rCP 
samples and completed Clarke’s Hypoglycaemia questionnaire. Results were 
analysed across C-peptide deciles, and non-parametric analysis performed.  
 
Results 
rCP was strongly correlated with sCP: rho correlation coefficient=0.93, 
p<0.0001. Median rCP was 415pmol/L (IQR 19-789) compared to sCP, 
368pmol/L (28-954), p=0.67. 
166 
 
 
Increased frequency of recognised hypoglycaemia episodes with blood glucose 
<3.5mmol/L was associated with lower C-peptide deciles, p=0.0001, regardless 
of the clinical diagnosis of Type 1 or Type 2. HbA1c levels were similar across 
all C-peptide deciles, p=0.44. 
 
37/429 (8.6%) patients had impaired hypoglycaemia awareness. Median C-
peptide was lower than in those with awareness: 12pmol/L (2.9-977) vs 370(12-
910), p=0.044. Other than duration of diabetes (31(16-43) vs 18(13-27)years, 
p=0.0015), clinical characteristics were similar including age, gender, BMI, 
HbA1c, and type of diabetes. 
 
Conclusion 
We have demonstrated a clear link between patient-reported hypoglycaemia 
frequency and awareness, and C-peptide level in all insulin-treated patients, 
regardless of clinical diagnosis. We propose measuring rCP could be a useful 
clinical tool in assessment and management of insulin-treated patients and their 
risks of hypoglycaemia. 
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INTRODUCTION 
 
C-peptide and hypoglycaemia risk 
C-peptide is used for assessing endogenous insulin secretion in diabetes, for 
assisting in classification and treatment (1-7), and as a marker for intervention 
(8) - eg success of islet transplantation (9). Patients with Type 1 diabetes have 
a higher risk of hypoglycaemia than those with Type 2 diabetes (10). The DCCT 
demonstrated that there was a correlation between C-peptide levels (in its 
broadly stratified groups of stimulated C-peptide level in people with Type 1 
diabetes) and risk of hypoglycaemia (11, 12), with lower levels correlated with 
increasing risk.  
 
With increasing sensitivity of C-peptide assays in recent years, it has been 
demonstrated that the vast majority of people with Type 1 diabetes continue to 
produce small amounts of endogenous insulin – termed “microsecretors” (13-
15), and even at these very low levels of endogenous insulin, there appears to 
be a continuous correlation with diabetes complications, including 
hypoglycaemia (16, 17).  
 
Frequency of hypoglycaemia in insulin-treated Type 2 diabetes is correlated 
with duration of diabetes (18), and of insulin treatment (19, 20). A recent 
analysis of ACCORD suggested that those participants (with Type 2 diabetes) 
who suffered from severe hypoglycaemia had significantly lower C-peptide 
levels than those who had similar glycaemic control but who did not experience 
hypoglycaemia (21).  
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Measuring C-peptide 
C-peptide is secreted in equimolar amounts with endogenous insulin following 
cleavage of proinsulin, and has the advantage (over measuring insulin) that it 
can be used to measure endogenous insulin levels in those receiving 
subcutaneous insulin treatment (8, 22).  
 
Previously perceived instability of C-peptide in blood samples and need to 
collect on ice, centrifuge and get to the laboratory rapidly, has limited its use to 
mainly research. However it has now been shown that C-peptide is stable for at 
least 24 hours in EDTA tubes at room temperature (23) – thus markedly 
increasing its potential use. 
 
Historically fasting levels of C-peptide, glucagon-stimulated levels, or those 
stimulated in a standardised mixed meal tolerance test, have most often been 
used. Fasting levels can under-represent insulin secretory capacity. Stimulated 
levels in formal glucagon or mixed meal tolerance tests are not practical for 
routine clinical use – especially where the majority of patients are looked after in 
outpatients or primary care. 
 
There have been increasing calls recently for more routine use of C-peptide in 
clinical care (24). The practical feasability of this has been increased by the 
demonstration of stability of C-peptide in routine blood tubes (23), and if a 
random non-fasting measure of C-peptide could be shown to correlate well with 
the gold-standard 90 minute stimulated C-peptide in a mixed meal tolerance 
test (25)), it could mean a spot “random” non-fasting sample could be sent 
when a patient is seen in an outpatient or primary care clinic. 
 
More widespread C-peptide analysis in the population with diabetes may enable 
further assessment of its relationship with complications such as hypoglycaemia 
– and raises the possibility of random non-fasting C-peptide as part of a risk 
assessment tool for hypoglycaemia. 
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Linking routine C-peptide analysis with clinical evaluation of hypoglycaemia 
We thus aimed to establish a method by which random non-fasting C-peptide 
analysis could be done on routinely collected diabetes blood samples from 
primary care, to provide a model for integration with research and clinical care. 
We aimed to assess the relationship between C-peptide and hypoglycaemia 
frequency and hypoglycaemia awareness in insulin-treated patients (with a 
clinical diagnosis of Type 1 or Type 2 diabetes), by integrating random non-
fasting C-peptide results with results from the standardised Clarke & Gold 
Hypoglycaemia questionnaire (26).  
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METHODS 
 
Participants 
All insulin-treated patients on the Diabetes Alliance for Research England 
(DARE) database in Exeter (27) were invited to participate. DARE is a national 
UK study aiming to explore environmental and genetic influences in diabetes 
and its associated complications, by acquiring information from as many 
patients with diabetes as possible. 
 
Establishing reflex testing for C-peptide  
Potential participants were asked for permission to test C-peptide on residual 
blood from their routine HbA1c tests sent in from primary care. Ethical approval 
was obtained from the NRES Committee South West. Consenting participants 
were flagged on the Blood Sciences database at the Royal Devon & Exeter 
Hospital, and any HbA1c sample received for these patients automatically also 
got tested for C-peptide. Results from 1.6.14 to 30.10.15 were included. These 
results were reported back to primary care physicians along with HbA1c results, 
and generic guidelines developed for reference. 
 
C-peptide was analysed using the automated Roche diagnostics (Manheim, 
Germany) E170 immuno-analyser (limit of detection 3.3pmol/L, inter- and intra-
assay coefficients of variations <4.5% and <3.3% respectively).  
 
Demonstration of random non-fasting C-peptide as a robust and pragmatic 
measure of beta cell function 
Spearmans’ correlation coefficient between random non-fasting C-peptide 
levels and gold-standard 90 minute C-peptide values were assessed in a 
subgroup of 50 participants who had undergone a standardised mixed meal 
tolerance test (MMTT). 
 
All participants in this evaluation were insulin-treated; 9/50 had a clinical 
diagnosis of Type 1 diabetes, and 41/50 Type 2 diabetes. To ensure a range of 
C-peptide values, participants were selected on the basis of prior C-peptide 
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assessment to include participants with and without severe insulin deficiency 
(under/over 200pmol/L post-MMTT blood C-peptide or equivalent (22)), and 
thus 19/50 (38%) had C-peptide <200pmol/L. All had an estimated glomerular 
filtration rate (eGFR) >30ml/min/1.72m2.  
 
In brief, for the 50 patients completing a MMTT, participants attended before 
11am having fasted from 10pm the evening before, without taking morning 
medication prior to arrival. Baseline bloods for glucose and C-peptide were 
taken, morning insulin given (28), and 160ml of Fortisip Compact (Nutricia, 
Trowbridge, UK) drunk within 10 minutes (content/100ml: carbohydrate 29.7g, 
protein 9.6g, fat 9.3g). Bloods for C-peptide were taken at 90 minutes, 
immediately centrifuged and stored at -800C, for later batched analysis. 
 
Hypoglycaemia questionnaires 
All insulin-treated patients in DARE were posted the Clarke & Gold 
hypoglycaemia questionnaire in May/June 2014 (26), and provided with a 
stamped addressed envelope for returning it. New DARE recruits were asked to 
complete the questionnaire on recruitment throughout the study time period. 
 
Hypoglycaemia frequency and awareness were evaluated from the 
questionnaire, including calculation of the Clarke score (26). 
 
Statistical analysis 
The majority of clinical characteristics reported on were distributed in non-
parametric fashion, so medians and interquartile ranges are reported 
throughout. C-peptide results were also non-parametric, not corrected by 
logging results. As such, the random non-fasting C-peptide results were split 
into deciles for the purpose of analysis.  
 
Hypoglycaemia frequency was assessed by the Clarke Hypoglycaemia 
questions 3-6, asking respectively about frequency of experience of “moderate” 
or “severe” hypoglycaemia, and episodes where blood glucose was <3.5mmol/L 
with/without symptoms. Questions 5 and 6 categorise frequency of episodes 
into groups, thus for statistical analysis we assigned an estimated frequency per 
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answer for an approximation of numbers of episodes in the last month:  1-3 
times became 2, 1 time/week became 1x4=4, 2-3 times/week became 
2.5x4=10, 4-5 times/week became 4.5x4=18, and almost daily was estimated at 
25 episodes. We evaluated the frequency of episodes with symptoms (Q5) and 
without symptoms (Q6) both added together for a total estimate of the number 
of episodes of blood glucose <3.5mmol/L in the last month, and separately. 
 
Hypoglycaemia awareness was assessed by calculating the Clarke score (26): 
questions are allocated a score of “aware” (scoring 0) or “reduced awareness” 
(scoring 1), and added together. A score of 4 or more is classed as “reduced 
awareness”, and a score of 2 or fewer “aware”. 
 
Non-parametric analysis was used for assessing the frequency of 
hypoglycaemia episodes and hypoglycaemia awareness in relation to C-peptide 
deciles and clinical diagnosis. Chi2 or Fisher’s exact tests were used for 
comparing proportions.  
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RESULTS 
 
Participant characteristics 
480 participants had both a random non-fasting C-peptide blood sample 
processed in the study period and had completed the hypoglycaemia 
questionnaire. Random non-fasting C-peptide levels reported here thus were 
measured a maximum of 1 year after questionnaire completion. 
 
Clinical characteristics are summarised in Table 1. Participants were classified 
as having Type 1 or Type 2 diabetes by the RCGP classification guidelines (29): 
40.3% had Type 1 diabetes, and 59.7% Type 2 diabetes.  
 
 
Table 1: Clinical characteristics (overall, Type 1 and Type 2 by RCGP 
guidelines). Median and interquartile range shown. 
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Median random non-fasting C-peptide was 291pmol/L (interquartile range 6-
920pmol/L), and was significantly different between those with Type 1 and Type 
2 diabetes: 8 (2.9-125) versus 697pmol/L (250-1180) respectively, p<0.0001. 
Results were analysed by C-peptide deciles for the whole group (approximately 
48 participants in each group). Figure 1 shows the distribution (proportion) of 
those with Type 1 or Type 2 in each C-peptide decile. 
 
 
Figure 1: Proportion of participants with Type 1 or Type 2 diabetes per  
C-peptide decile 
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Of note, the distribution of HbA1c results across the C-peptide deciles did not 
significantly differ, p=0.44. The median HbA1c was 65mmol/mol (57-74), and 
the distribution across C-peptide deciles shown in Figure 2. 
 
 
Figure 2: Distribution of HbA1c values per C-peptide decile 
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Random non-fasting blood C-peptide is strongly correlated with gold-standard 
90 minute blood C-peptide in mixed meal tolerance test 
Random non-fasting blood C-peptide (rCP) was strongly correlated with the 90 
minute blood stimulated C-peptide (sCP): Spearman’s rho correlation 
coefficient=0.93, p<0.0001, Figure 3. Median rCP of 415 pmol/L (IQR 19-789) 
was similar to sCP at 90 minutes, 368pmol/L (28-954), p=0.67. 
 
 
Figure 3: Correlation between random non-fasting blood C-peptide (rCP) and 
90 minute blood stimulated C-peptide (sCP) in the mixed meal tolerance text for 
50 patients: Spearman’s rho correlation coefficient=0.93, p<0.0001. Reference 
lines at 200pmol/L. 
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Lower C-peptide levels are associated with more frequent hypoglycaemia, 
regardless of clinical diagnosis 
The total number of self-reported estimated episodes of blood glucose 
<3.5mmol/L in the last month (Q5 + Q6 on the Clarke questionnaire (26)), was 
significantly different across the C-peptide deciles, p=0.0001: the more 
episodes the lower the C-peptide decile, Figure 4. The pattern of 
hypoglycaemia frequency with C-peptide remained the same regardless of 
clinical diagnosis: the median number of episodes of blood glucose <3.5mmol/L 
in the last month decreased according to C-peptide decile, Figure 5.   
 
 
Figure 4: Total self-estimated number of episodes of blood glucose <3.5mmol/L 
in the last month, by C-peptide decile 
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Figure 5: Median estimated number of episodes of blood glucose <3.5mmol/L 
in the last month, by C-peptide decile and clinical diabetes diagnosis 
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When looking at the accepted “traditional” level of C-peptide for severe insulin 
deficiency, 200pmol/L (22, 30), both self-reported episodes <3.5mmol/L with 
(Q5) and without (Q6) symptoms separately were significantly higher in those 
with a random non-fasting C-peptide less than 200pmol/L: p<0.0001 and 
p=0.001 respectively, Figure 6. 
 
 
Figure 6: Self-reporting of blood glucose levels <3.5mmol/L in the last month 
with and without symptoms, in those with a random non-fasting C-peptide 
above or below 200pmol/L 
 
 
 
 
More severe episodes of hypoglycaemia – Q3 (“in the past 6 months how often 
have you had moderate hypoglycaemia episodes where you might feel 
confused, disorientated or lethargic and were unable to treat yourself?”), or Q4 
(“in the past year how often have you had severe hypoglycaemic episodes 
where you were unconscious or had a seizure and needed glucagon or 
intravenous glucose?”), were not seen to increase significantly in frequency with 
lower C-peptide deciles (p=0.38 and p=0.53 respectively). The median C-
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peptide seen in the 9.9% of people who reported at least one “severe” episode 
of hypoglycaemia in the past year (Q4), was 52 (IQR 5-785), compared to 319 
(7-916) in those who had not reported an episode of severe hypoglycaemia, 
although this did not reach statistical significance, p=0.06. 
 
Low C-peptide levels are associated with hypoglycaemia unawareness 
Overall, 8.6% of participants had reduced hypoglycaemia awareness by the 
Clarke method, ie a score of >4 out of a possible 7. Those with a random non-
fasting C-peptide below 200pmol/L had a higher rate of reduced awareness 
than those with a C-peptide above 200pmol, 12.8% vs 5.2%, p=0.005, Figure 
7. This was more discriminatory than separating by clinical diagnosis, where 
11.8% of those with Type 1 had reduced awareness compared to 6.6% of those 
with Type 2, p=0.06. 
 
 
Figure 7: Proportion of patients with C-peptide under or over 200pmol/L with 
reduced hypoglycaemia awareness (Clarke method) 
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Comparing those with reduced hypoglycaemia awareness by the Clarke 
method, clinical features were similar in terms of age, gender, BMI, HbA1c, 
whether they were on oral agents in addition to insulin, and even type of 
diabetes, Table 2. Those with reduced awareness did have lower C-peptide 
with median C-peptide of 12 (2.9-977) compared to 370 (12-910), p=0.044, and 
had had diabetes for significantly longer 31 (16-43) vs 18 (13-27) years, 
p=0.0015.  
 
 
Table 2: Clinical characteristics for those with reduced awareness by the Clarke 
method, compared to those without reduced awareness  
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DISCUSSION 
 
Summary 
We have set up a simple automated system whereby random non-fasting C-
peptide blood levels can easily be measured on routine HbA1c samples sent to 
the hospital laboratory, and have demonstrated good correlation between 
random non-fasting C-peptide levels and the gold-standard stimulated measure 
in a mixed meal tolerance test. The ability to monitor C-peptides longitudinally in 
patients is proving an invaluable source of information for further research, and 
will allow prospective studies to be done.  
 
We have demonstrated a clear link between patient-reported hypoglycaemia 
frequency and C-peptide level in all insulin-treated patients, regardless of 
clinical diagnosis and glycaemic control. We have also reported an association 
between C-peptide levels and hypoglycaemia awareness.  
 
Lower C-peptide levels are associated with more frequent hypoglycaemia, 
regardless of clinical diagnosis  
Our findings of a correlation between decreasing C-peptide levels and 
frequency of self-reported hypoglycaemia frequency is consistent with the 
findings of the DCCT (11, 12, 17), and more recent findings at lower levels of C-
peptide (16, 17). Although our C-peptide results cover a range of levels lower 
than that seen in the DCCT, it is interesting that in the current study the 
“traditional” 200pmol/L threshold appears to remain a significant one for 
increased frequency of hypoglycaemia seen. Recent modelling analysis based 
on the DCCT results concluded that there was a continuous relationship 
between C-peptide levels and  the 200pmol/L cut-off may be too simple a 
definition for clinically significant residual insulin secretion (17); future additional 
data and statistical modelling in our expanding cohort may help explore this 
further.  
 
The direct demonstration of a relationship between C-peptide levels and 
hypoglycaemia frequency in those with a clinical diagnosis of Type 2 diabetes is 
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less widely recognised. Certainly it is known that the frequency of 
hypoglycaemia in Type 2 diabetes is correlated with the duration of diabetes 
(18), and those with long-standing insulin-treated Type 2 diabetes can have 
similar rates of hypoglycaemia to those with Type 1 diabetes (10). It has been 
demonstrated that those with a clinical diagnosis of Type 2 diabetes can 
develop levels on insulin deficiency comparable to that of those with Type 1 (31, 
32).  
 
We have concentrated on reporting the results where participants reported 
episodes of blood glucose <3.5 with or without symptoms, as these had a wider 
range of responses. The prevalence of “severe” or “moderate” (requiring help) 
episodes were much lower, and our study is underpowered to detect a 
significant difference in the low rates of severe hypoglycaemia reported 
according to C-peptide levels, although a trend was seen. This is consistent 
with the recent analysis of ACCORD which suggested those participants with 
Type 2 diabetes who were unable to achieve the study’s treatment target of 
<6.0% (42mmol/mol) due to severe hypoglycaemia had significantly lower C-
peptide levels than those who had similar glycaemic control but who did not 
experience hypoglycaemia (21) – with an adjusted odds ratio of 23.2 [95% CI 
9.0, 59.5], p<0.0001. 
 
Overall the finding that there is a clear relationship between C-peptide levels 
and hypoglycaemia frequency in those with a clinical diagnosis of Type 2 
diabetes - is of significance. Combined with the increasing evidence of random 
non-fasting C-peptide as a practical routine test which can be done in routine 
clinical care, it may help support the argument that knowledge of C-peptide 
levels in insulin-treated diabetes patients may  greatly enhance clinical care, 
and perhaps contribute to a risk assessment tool in identifying patients at high 
risk of hypoglycaemia. 
 
Low C-peptide levels are associated with hypoglycaemia unawareness 
We found that those with a C-peptide <200pmol/L had significantly higher rates 
of reduced awareness than those with a C-peptide over 200pmol/L. Clinical 
characteristics between those with reduced awareness and those without 
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reduced awareness did not differ significantly, apart from duration of diabetes, 
and C-peptide. This included clinical diagnosis of type of diabetes, age, and 
HbA1c. Impaired awareness being associated with duration of diabetes is 
consistent with previous findings in Type 1 diabetes (33), though not 
consistently in insulin-treated Type 2 diabetes (34). 
 
The overall rates of hypoglycaemia awareness in the current study (11.8% of 
those with Type 1, and 6.6% with Type 2) were lower than those sometimes 
reported in the literature – eg estimated prevalence of 19-25% in Type 1 (33, 
35), and 8-10% in Type 2 (18, 34). However these studies used the less 
discriminatory Gold score. If applied to the current study, 19.6% of those with 
Type 1 and 22.4% with Type 2 fitted the Gold criteria for having reduced 
hypoglycaemia awareness.  
 
Strengths and weaknesses 
This is a cross-sectional study performed in community-dwelling insulin-treated 
adults with diabetes, which simply required the participants to complete and 
post back in a stamped addressed envelope a standard hypoglycaemia 
questionnaire. The C-peptide samples were analysed on routine blood samples 
sent into the blood sciences laboratory. As such, this study includes a good 
cross-section of participants, including a lot of older adults who are often 
excluded from research studies.  
 
The standardised hypoglycaemia questionnaire is not the most user-friendly, 
and some patients reported difficulty or frustration in completing it. However 
given its wide use in clinical and research settings it seemed appropriate to use.  
The random non-fasting C-peptide measures were taken as close to completion 
of the questionnaires as possible. The possible lag between the two means it is 
conceivable there may have been the occasional participant whose C-peptide 
levels were rapidly falling and as such there may have been a discrepancy 
between their results. However this is unlikely to have been a major problem: 
rapidly changing C-peptide levels are most likely to occur in those with recently 
diagnosed Type 1 diabetes, and during the course of the study new recruits to 
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DARE were completing the questionnaire at recruitment, and C-peptide levels 
would have been taken at the same time. 
 
Random non-fasting C-peptide is well-correlated with the gold-standard 90 
minute C-peptide in a mixed meal tolerance test, although can be suppressed in 
the setting of a low ambient glucose (22). It has the advantage over studies 
done with fasting C-peptide that it is a stimulated sample (16). Endogenous 
insulin levels (and thus C-peptide levels) have the potential to be suppressed by 
exogenous insulin treatment (28, 36, 37). It is possible that those with 
hypoglycaemia as a result of over-treatment with exogenous insulin, may have 
lower C-peptide levels on random non-fasting measurement than they are 
capable of. Taken in a clinical context however, a review of anyone with 
apparent low C-peptide or frequent hypos would be relevant, and thus a low C-
peptide level could serve as an alert for review. 
 
Clinical implications 
Of particular importance in the current study, are the findings that there are a 
high proportion of people with a clinical diagnosis of Type 2 diabetes who have 
a C-peptide less than the traditional threshold of 200pmol/L, and that regardless 
of diagnosis type, lower C-peptide levels are associated with increasing 
frequency of hypoglycaemia.  
 
Given the heterogeneity of the population of those with Type 2 diabetes, which 
is ever-expanding, a clinical tool which can help determine risk of one of the 
most feared (38-40) complications of diabetes, and thus help with choices 
regarding next-line therapy, monitoring and education needed, must be 
beneficial. C-peptide is cheap and practical for widespread outpatient clinical 
use, and could contribute hugely to this field. 
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CONCLUSION 
 
We have demonstrated a clear link between patient-reported hypoglycaemia 
frequency and C-peptide level in all insulin-treated patients, regardless of 
clinical diagnosis. We have also reported an association between C-peptide 
levels and hypoglycaemia awareness. We propose measuring random non-
fasting C-peptide could be a useful clinical tool in assessment and management 
of insulin-treated patients and their risks of hypoglycaemia. 
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Low c-peptide is associated with high glycaemic 
variability and hypoglycaemia in insulin-treated 
patients with type 2 diabetes 
 
Abstract 
 
Aims 
We aimed to determine whether random c-peptide could be used as a 
biomarker for hypoglycaemia risk in insulin-treated Type 2 diabetes. 
 
Methods 
We assessed hypoglycaemia risk using continuous glucose monitoring (CGM, 
mean duration 4.1 days/person) and Clarke’s hypoglycaemia questionnaire, in 
34 insulin-treated participants with type 2 diabetes (diagnosed >35 years old, 
>2 years before starting insulin). 17 participants with severe insulin deficiency 
(random non-fasting serum c-peptide (rCP) <200pmol/L) were matched with 17 
controls with rCP >500pmol/L, for HbA1c and gender.  
 
Results 
Glucose variability was greater in the low c-peptide group: standard deviation of 
glucose measurements 4.15 vs 3.01mmol/L, p=0.0005. This was despite similar 
mean glucose in the low vs high group: 10.2vs9.9mmol/L (p=0.50), HbA1c 72 
vs 72mmol/mol (p=0.88), age 72.8 vs 71.8 (p=0.71), and BMI 26.6 vs 27.9kg/m2 
(p=0.19).  
 
The number of episodes of hypoglycaemia on CGM (>20mins <4mmol/L) was 
higher in the low c-peptide group: median (interquartile range) 5.3(1.7-7.7) vs 
0(0-2.3) episodes/person/week, p=0.003. 
 
Participants in the low c-peptide group reported a median of 4 episodes 
<3.5mmol/L in the last month, compared to a median of 0 in controls with 
preserved c-peptide, p=0.002; the majority were asymptomatic. 
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Summary  
In insulin-treated participants with type 2 diabetes matched for clinical 
characteristics and glycaemia, low endogenous insulin is associated with 
markedly increased hypoglycaemia risk compared to those with preserved 
insulin secretion. Assessment of a non-fasting C-peptide can identify patients 
with insulin-treated type 2 diabetes at high risk of hypoglycaemia. 
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INTRODUCTION 
 
Hypoglycaemia is a serious complication of insulin-treated diabetes, and a 
limiting factor in obtaining good glycaemic control (1, 2). Detecting 
hypoglycaemia is not straightforward, particularly in the older population as 
symptoms are non-specific, and autonomic symptoms are less intense than in 
younger patients (2-5).  
 
In patients with Type 1 diabetes, measured C-peptide has been shown to be 
strongly associated with hypoglycaemia risk (6-8) and high glucose variability 
(9). In the DCCT study intensively treated participants who developed mixed 
meal test stimulated C-peptide <200pmol/L (the vast majority of patients with 
Type 1 diabetes) had 3x as many severe hypos as those with preserved C-
peptide above this level, despite higher HbA1c (7, 8). The threshold of 
200pmol/L is commonly described as identifying absolute insulin deficiency, 
although modern assays can measure below this range (10, 11) and a 
relationship between hypoglycaemia and lower levels of C-peptide has been 
described (12, 13). For this reason clinical guidelines for Type 1 diabetes 
incorporate intensive strategies to minimise hypoglycaemia such as multiple 
daily injections, carbohydrate counting and insulin pumps. 
  
Absolute insulin deficiency can occur in people meeting clinical criteria for long-
standing type 2 diabetes, but the clinical consequences of this have not been 
examined (14). People with Type 2 diabetes and increasing duration of diabetes 
have higher glycaemic variability and higher risk of hypoglycaemia (15-18). A 
recent analysis of the ACCORD study suggested that those participants (with 
Type 2 diabetes) who suffered from severe hypoglycaemia had significantly 
lower C-peptide levels than those who had similar glycaemic control without 
hypoglycaemia (19). It is likely that patients with severe insulin deficiency will 
have high glycaemic variability and high hypoglycaemia risk whatever the 
underlying diabetes aetiology or classification, however the utility of C-peptide 
as a biomarker for glycaemic variability and hypoglycaemia has not been 
investigated outside of type 1 diabetes populations.   
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We aimed to determine whether random c-peptide could be used as a 
biomarker for hypoglycaemia risk in insulin-treated Type 2 diabetes. 
 
 
  
197 
 
METHODS 
 
Participants 
We recruited 34 participants with a clinical diagnosis of Type 2 diabetes 
receiving insulin therapy. All participants were diagnosed with diabetes >35 
years old, started insulin >2 years after diagnosis, and had an estimated 
glomerular filtration rate (eGFR) >30ml/min/1.73m2. Participants were recruited 
based on known C-peptide status (random non-fasted serum sample at 
recruitment visit) and clinical characteristics in the Diabetes Alliance for 
Research in England (DARE) database. 17 participants known to have severe 
insulin deficiency (previous testing demonstrating a non-fasting C-peptide 
<200pmol/L or equivalent (20)), were individually matched on gender and 
HbA1c (+/-10mmol/L) with a control participant who had preserved endogenous 
insulin secretion (previous testing demonstrating a non-fasting C-peptide 
>500pmol/L).  
 
Ethics approval was obtained from the NRES Committee South West. 
 
Baseline visit 
Participants attended non-fasting within 5 hours of a meal. Following informed 
consent, baseline characteristics were collected, and blood taken to confirm C-
peptide status and HbA1c. Clarke’s Hypoglycaemia Questionnaire (21) was 
completed by all participants.  
 
Continuous glucose monitoring  
Following the baseline visit participants commenced at least three consecutive 
days’ continuous glucose monitoring (CGM, iPro2 Professional, Medtronic, 
Watford, UK). For calibration purposes participants were asked to keep a diary 
of 3-4 self-monitoring blood glucose tests per day over the CGMS period, and 
these readings were entered into the iPro2 online software on downloading the 
data (23).  
 
198 
 
The following criteria were required for CGMS data to be included in analysis 
(22): at least three self-monitoring blood glucose (SMBG) calibrations per 24 
hours, no more than 24 hours between SMBG readings, no missing data points, 
correlation between SMBG and iPro2 readings >0.77 in 24 hours, mean 
variation for each 24 hours (MAD%) <28 %; and a minimum of 24 hours 
meeting these criteria.   
 
CGM analysis 
The mean glucose, standard deviation of glucose measurements and mean 
amplitude of glycaemic excursions (MAGE) were analysed for individual 
patients using online software, EasyGV (23, 24). 
 
An episode of hypoglycaemia was defined as >20 minutes at or below the 
interstitial glucose level of 4, 3 or 2.2 (LIG4, LIG3 and LIG2.2 respectively), and 
only complete once readings had been above the threshold for >20 mins. The 
proportion of participants in each group who had at least one episode of 
hypoglycaemia over the period recorded were compared using a chi2 test. 
Results were converted for each person to median number of episodes per 
week and duration of episodes per week, and by day (8am – midnight) and 
night (midnight – 8am).  
 
Clarke’s hypoglycaemia questionnaire  
This is scored out of seven, with four or more suggesting reduced awareness 
(21).  
 
Mixed Meal Tolerance Test 
Approximately one week after the recruitment visit participants who were able 
attended fasted for a standardised mixed meal tolerance test (25), in which a 
stimulated blood C-peptide test was taken 90 minutes following ingestion of 
160ml of Fortisip Compact (Nutricia, Trowbridge, UK). Samples were 
immediately centrifuged after collection and stored at -80C, for later batched 
analysis. 
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Laboratory analysis  
Samples were processed by the Blood Sciences department, Royal Devon & 
Exeter Hospital. C-peptide was analysed using the automated Roche 
diagnostics (Manheim, Germany) E170 immuno-analyser (limit of detection 
3.3pmol/L, inter- and intra-assay coefficients of variations <4.5% and <3.3% 
respectively).  
 
GAD65 and IA2 autoantibodies were assessed using the Biokit automated Elisa 
System (BEST 2000, Biokit, Barcelona) following manufacturers’ instructions. 
Cut-offs used were those based on the 99th centile for 500 non-diabetic 
individuals; for GAD65 the reference positive value was >54 units/ml, for IA-2 
the reference positive value >15 units/ml. 
 
Statistical analysis 
Differences in continuous measures of glucose variability, hypoglycaemia and 
baseline characteristics between low and high C-peptide pairs were assessed 
using paired T tests and where T test assumptions were not met, the Wilcoxon 
signed rank test. Chi2 tests were used for comparing proportions.  
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RESULTS 
 
Participant characteristics and data quality 
Participant characteristics are shown in Table 1. HbA1c, age, duration of 
diabetes and BMI did not differ by C-peptide status, however participants with 
severe insulin deficiency had progressed more rapidly to insulin treatment, 
received higher insulin dose and were more likely to receive basal bolus insulin 
therapy. 
 
Mean duration of CGM recording meeting inclusion criteria for analysis was 4.1 
days (range 1 to 6.2 days), and this was similar between the two groups: 4.3 
(range 1-6.2) days in the low C-peptide group compared to 3.9 (1.3-6) days in 
the high C-peptide group, p=0.34. The mean glucose across the period of CGM 
monitoring in the low vs high group was similar: 10.2 vs 9.9mmol/L, p=0.5.  
 
 
Table 1: Participant characteristics. Median (interquartile range) shown, and  
p value for comparison between groups. 
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Standard deviation of glucose readings on CGM was higher in the low C-
peptide group 
Glucose variability was greater in the low C-peptide group: standard deviation of 
glucose measurements 4.15 vs 3.01mmol/L, p=0.0004, Figure 1. Mean 
amplitude of glycaemic excursions (MAGE) did not differ (7.05 (2) vs 6.03 
(2.39), p=0.1. 
 
 
Figure 1: Mean (and 95% confidence interval) of standard deviation of glucose 
values on continuous glucose monitoring, by C-peptide group. 
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Hypoglycaemia is markedly more frequent in those with low C-peptide 
94% of participants in the low C-peptide group experienced at least one 
episode of hypoglycaemia on CGM (>20mins <4mmol/L), compared to 41% of 
those in the high C-peptide group, p=0.002, Figure 2.  
 
The number of episodes of hypoglycaemia/person/week (>20mins <4mmol/L) 
on CGM was also markedly higher in the low c-peptide group: median 5.3 
(interquartile range (IQR) 1.7-7.7) episodes/person/week compared to 0 (0-2.3), 
p=0.0031. The total duration of hypoglycaemia was also higher in the low c-
peptide group: median 407 (196-988) minutes/person/week, compared to 0 (0-
305), p=0.0027. 
 
 
Figure 2: Proportion of patients by C-peptide category, with at least 1 episode 
of hypoglycaemia during continuous glucose monitoring. Shading denotes level 
of lowest recorded glucose 
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88% of participants in the low C-peptide group experienced at least one 
episode of hypoglycaemia <4mmol/L during the daytime, compared to 24% of 
those in the higher c-peptide group, p<0.001. 71% vs 29% of participants 
experienced at least one episode overnight, p=0.038.  
 
The frequency and total duration of episodes of hypoglycaemia less than 
3mmol/L were also higher in the low C-peptide group (0 (0-3.7) episodes <3 per 
week vs 0 (0-0), p=0.04; 0 (0-386) hours <3 per week vs 0 (0-0), p=0.039). 
However differences in severe hypoglycaemia <2.2 were not significant 
(p=0.25). All hypoglycaemia episodes below 3mmol/L in the high C-peptide 
group occurred at night. 
 
Participants in the low C-peptide group self-reported more hypoglycaemia 
Participants in the low C-peptide group reported more episodes of 
hypoglycaemia (blood glucose level <3.5mmol/L) in the last month than those in 
the high C-peptide group, Figure 3. 47% of participants in the low C-peptide 
group reported at least one episode without symptoms, compared to none in 
the high C-peptide group, p=0.003.  
 
The number of participants reporting severe hypoglycaemia episodes 
(questions 3 & 4 on the Clarke Hypoglycaemia questionnaire (21)) in the last 
year was low and not statistically different between groups.  
 
“Hypoglycaemia awareness” as measured by a formal Clarke score of >4 did 
not differ between the C-peptide groups: 2/17 (12%) versus 0/17 (0%), p=0.49.  
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Figure 3: Self-estimated frequency of episodes of blood glucose <3.5  
with or without symptoms in the past month, by C-peptide group  
(Clarke hypoglycaemia questionnaire questions 5 & 6) 
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DISCUSSION 
 
Our results demonstrate that insulin-treated patients with a clinical diagnosis of 
Type 2 diabetes but low C-peptide levels have markedly higher rates and 
duration of hypoglycaemia in comparison to those patients with preserved 
endogenous insulin secretion. Participants with low C-peptide had a median of 
5 hypoglycaemic episodes on continuous glucose monitoring per week 
compared to 0 in those with preserved C-peptide, and both self-reported 
hypoglycaemic unawareness and more severe daytime hypoglycaemia were 
entirely confined to participants with low C-peptide. These differences occurred 
despite similar glycaemic control, mean glucose, and clinical characteristics in 
those with and without preserved endogenous insulin secretion.   
 
We have also demonstrated higher glucose variability in those in those with low 
C-peptide when assessed by standard deviation of blood glucose measured by 
continuous glucose monitoring, the most commonly used measure of glycaemic 
variability (26-28), and that which has been viewed as the most practical 
measure of quantifying glycaemic variability (18). A second marker of glycaemic 
variability, MAGE, showed a similar pattern but this did not reach statistical 
significance, which may reflect our small sample size and the higher sensitivity 
of standard deviation in detecting isolated swings in glucose.  
 
Strengths & limitations 
This is to our knowledge the first study specifically looking at whether C-peptide 
testing can help identify people with Type 2 diabetes at higher hypoglycaemia 
risk. However our findings are consistent with previous studies showing a strong 
relationship between C-peptide and hypoglycaemia in Type 1 diabetes (7, 8) 
and lower hypoglycaemia in those with preserved C-peptide in a Type 2 
diabetes interventional trial (19). 
 
Strengths of our study include that the two groups were well-matched by clinical 
characteristics, and importantly by HbA1c, and had similar mean glucose 
across the time of CGM. The mean age of participants was high, at 72.3, which 
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represents an age group at high risk of adverse consequences of 
hypoglycaemia where it can be especially difficult to optimise treatment and 
management. 
 
A weakness of our study is that the sample size was small, although power was 
increased by matching of participants. A larger sample size may have been able 
to detect differences in other measures of glucose variability, such as MAGE, or 
episodes of severe hypoglycaemia. With the sample size achieved, at 80% 
power and at a significance level of 0.05, we were powered to detect only a 1.9 
mmol/L mean difference in MAGE between groups therefore negative findings 
from this cohort should be treated with caution. 
 
Random non-fasting C-peptide (rCP) was used as a practical measure in this 
study to categorise participants into the two groups, this is the most easily 
available C-petpide measure in clinical practice as the sample can be taken at 
the point of clinical contact. rCP has been shown to be well-correlated (r=0.91) 
with the gold-standard measure of C-peptide, 90 minute stimulated C-peptide in 
a mixed meal tolerance test (29). Of the 29/34 participants who underwent a 
mixed meal test 27/29 (93%) remained consistently in the same category on 90 
minute post mixed meal C-peptide; the other two had stimulated C-peptide 
levels of 221 and 443 pmol/L respectively. The latter had an (asymptomatic) 
blood glucose of 2mmol/mol when the random non-fasting C-peptide sample 
was taken, confirming the recommendation of avoiding concurrent 
hypoglycaemia for accurate assessment of C-peptide levels (20), Hope et al, 
submitted).   
 
Clinical implications 
We have shown that insulin-treated patients with a clinical diagnosis of Type 2 
diabetes who are similar in their clinical characteristics and HbA1c, but differ in 
their endogenous insulin levels as indicated by a random non-fasting C-peptide 
level, have substantially different rates of glycaemic variability and 
hypoglycaemia risk. This study demonstrates that a random non-fasting C-
peptide sample taken when a patient with Type 2 diabetes is seen in clinic can 
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help identify those patients who - despite a clinical diagnosis of Type 2 
diabetes, may have high glucose variability and hypoglycaemia risk.  
 
Although many participants with low C-peptide in this study had positive islet 
autoantibodies, suggesting autoimmune aetiology, importantly these patients 
could not be identified by their clinical features and autoantibody status are 
rarely measured in patients with these characteristics in clinical care. Clinically it 
is not practical to do continuous glucose monitoring on all patients, and a 
random non-fasting blood C-peptide test could offer a useful additional tool in 
identifying those at most risk of hypoglycaemia and difficult glucose control. 
 
This may be particularly pertinent in an older population where hypoglycaemia 
is often not recognised and consequences more severe. Individualising 
treatment in this population has been advocated (30-34), but there is little 
guidance on how to do this. Just one study to date specifically attempted to set 
individualised treatment targets (35), but found clinicians reluctant to deviate 
from traditional glycaemic targets even in the frail elderly. It is possible that 
random non-fasting C-peptide may offer a tool to give more confidence in 
helping to stratify risk of hypoglycaemia, and decide whether tight glycaemic 
control is appropriate.  
 
An additional area where a robust biomarker for hypoglycaemia risk would be 
clinically useful, is in stratification of hypoglycaemia risk in relation to driving. 
Our results show clearly the markedly increased risk in those with low C-peptide 
and that this is independent of clinical features. In conjunction with the 
extensive evidence in Type 1 populations this data supports use of C-peptide 
testing as a biomarker for hypoglycaemia risk which is additive to knowledge of 
a person’s clinical features and diabetes subtype. 
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CONCLUSION 
 
Random non-fasting C-peptide testing can identify patients with insulin-treated 
type 2 diabetes at markedly higher risk of hypoglycaemia, which may help risk 
stratification, decision making, and management in routine clinical practice. 
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CHAPTER 8: DISCUSSION 
 
 
 
This thesis addresses several facets of managing diabetes in older patients, ranging 
from recognition of symptoms of hypoglycaemia, to accurate diagnosis of diabetes, 
and examining heterogeneity within “Type 2” diabetes – particularly in recognition of 
the fact that severe insulin deficiency can develop, and this may have significant 
impact on the risk of hypoglycaemia. Measurement of endogenous insulin levels 
using random non-fasting C-peptide in routine blood tests is proposed as a useful 
clinical measure, and two studies using this to demonstrate a relationship with the 
risk of hypoglycaemia are presented.  
 
This chapter gives an overview of the main findings of the thesis – each chapter is 
briefly summarised, its implications and limitations discussed, and potential areas for 
further research suggested.   
 
Complexity sums up physiological, psychological and social aspects of older people, 
and the complex and far-reaching implications of diabetes combined with this makes 
for fascinating yet challenging clinical scenarios. This thesis touches the tip of the 
iceberg, but hopefully has presented a potentially useful clinical tool that has been 
shown to be relevant, easy to understand and use, in order to help recognise those 
at high risk of hypoglycaemia, and thus help improve patient care. 
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Chapter 2 
Are we missing hypoglycaemia? 
Elderly patients with insulin-treated diabetes present to primary care 
frequently with non-specific symptoms associated with hypoglycaemia 
 
Summary 
Hypoglycaemia symptoms are non-specific, and in the elderly can be difficult to 
recognise, as may be hard to distinguish from non-specific symptoms caused by 
other factors associated with older age. This chapter looks in patients over the age of 
65 in one general practice, at the frequency of hypoglycaemia, and the frequency of 
consultations with non-specific symptoms known to be associated with 
hypoglycaemia, in patients treated with insulin, sulphonylureas, just metformin, or 
who did not have diabetes.  
 
Insulin-treated patients had a much higher documented rate of hypoglycaemia 
episodes/patient/year (1.1 vs 0.2 and 0.07 in the sulphonylurea-treated and 
metformin only-treated patients respectively), p<0.0001. In insulin-treated patients, 
74% of those with a documented episode of hypoglycaemia over the year attended 
on another occasion with a non-specific “hypo clue” symptom, compared to 40% of 
those without a recorded episode of hypoglycaemia, p=0.008. Nausea, falls and 
unsteadiness were the most potentially discriminatory symptoms: 7/33 (21%) 
patients with hypoglycaemia attended on another occasion with nausea compared to 
14/302 (5%) without hypoglycaemia, p=0.002; 10/33 (30%) vs 36/302 (12%) 
presented with falls, p=0.007; and 5/33 (15%) vs 13/302 (4%) presented with 
unsteadiness, p=0.023. 
 
Limitations 
One should be wary of drawing too many conclusions from this study; it was a small 
observational study done in one GP practice, and by design was attempting to tackle 
some of the most “woolly” corners of primary care consultations – ie the symptoms 
which do not consistently get reported by patients or carers, or asked about or 
documented by healthcare professionals. They are the sorts of symptoms which are 
filtered or “interpreted” at every level – ie by patients/carers, by healthcare 
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professionals - and probably by researchers. The recording is heavily dependent on 
the style of documentation in consultation notes, and hence on the individuals seeing 
the patients. They are also not routinely coded, hence manually going through every 
consultation record for every patient over a one year-period. Due to the likely low 
rate of recording of these symptoms, and the likelihood that if a healthcare 
professional was likely to record one from one patient they might be likely to record 
several, a rather “catch-all” definition of a “hypo clue” consultation was used, ie if one 
or more symptom was mentioned. Inevitably this led to high rates of “hypo clue” 
consultations seen, even amongst those without diabetes (0.76 
episodes/patient/year) – but the rates did seem to differ when looked at in those 
most at risk of hypoglycaemia.  
 
A systematic approach was used, although due to the labour intensity involved in 
looking manually at the free text of every consultation over a one year period for 
every patient, the recording in this study was done by one person. A sample of 
patients was repeated on a separate occasion and found to be consistently 
recorded, but the study could have higher validity if the consultations had been 
reviewed and recorded by another researcher as well.  
 
The rates are presented as episodes per patient per year. For hypoglycaemia this 
was defined this as episodes directly confirmed by a doctor or nurse, paramedic or 
hospital (although the blood glucose was not always recorded). Data on 
hypoglycaemia episodes reported by patients (eg at their annual diabetes review) 
was also available, but it was felt to be more robust to concentrate on the confirmed 
episodes, given the variability in this additional data (being dependent on the 
patient’s awareness of hypoglycaemia and self-monitoring of blood glucose, and on 
the healthcare professional doing the annual review (usually practice nurse) to 
specifically ask and record consistently about the patients’ hypoglycaemia 
experience – ie not just ask those who are known to have had hypoglycaemia 
before, or those assumed to be at high risk). 
 
The data collection here did not include a count of the total number of consultations 
had by each patient, ie it was not possible to calculate a total rate of consultations 
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per patient per year. It seems likely that insulin-treated patients may consult more 
often, and hence despite an apparently higher rate of “hypo clue” consultations, this 
may merely represent a higher rate of consultations per se. Presentation of the data 
as “at least one episode” attempted to minimise the possible effect this may have 
had. Additionally, the difference in falls seen in those with and without 
hypoglycaemia suggests that the findings in this study may be genuine, but would be 
more robust with this additional evidence.   
 
The original pilot audit which led onto this study was done a few years earlier in the 
same practice, and thus the results obtained from this practice conceivably are not 
representative of other primary care practices. A primary care survey done of nearly 
25,000 patients over the age of 70 found that of those who were on insulin or 
sulphonylureas, nearly 30% had an HbA1c of <7% (53mmol/mol), and 12% had an 
HbA1c <6.5% (48mmol/mol) (1). This is compared to 28% under 7% (53mmol/mol) 
and 8.5% under 6.5% (48mmol/mol) in this group of patients over the age of 65. 
 
Future work 
This was a cross-sectional study looking at any episodes of hypoglycaemia or “hypo 
clue” consultations over a year. Acknowledging the limitations of this sort of study, it 
would be of great interest to do a similar study in other practices, for the reasons 
mentioned above. 
 
Despite the limitations in the current study, there do seem to be differences in the 
rates of “hypo clue” symptoms that may be teasing out something more than just an 
increased rate of consultation in those at risk of hypoglycaemia. To explore more 
clearly the possible link, and determine whether presentations of hypoglycaemia as 
non-specific symptoms are being missed, an examination of possible “hypo clue” 
consultations in the run-up to an index event of hypoglycaemia, could be much 
stronger.  
 
The low rates of definite hypoglycaemia seen in one GP practice mean that in order 
to assess this properly, this sort of study could be done in a much larger dataset, eg 
the Clinical Practice Research Datalink (CPRD, previously General Practice 
Research Database, GPRD). The disadvantage of this is that again the non-specific 
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symptoms may be less well-coded. However a review of the possible association of 
more specific symptoms, eg of falls in those insulin-treated patients with 
hypoglycaemia versus not, could be examined. 
 
As mentioned previously, knowing the rates of all consultations would help in 
determining whether the apparent increased rates of consultations with non-specific 
symptoms in those insulin-treated patients with a documented episode of 
hypoglycaemia over the year was a clinically relevant finding, and any future work on 
a similar theme should include this. It would require a clear definition of a 
“consultation”, as documented “interactions” in primary care come in many guises. 
 
Additionally, doing a larger scale study with similar design could also examine in 
more detail the possible relationship of HbA1c and hypoglycaemia/non-specific 
“hypo clue” consultations. The larger dataset would also allow more 
exploration/stratification particularly in terms of type of diabetes or duration – in the 
current study “insulin-treated” patients are reported as one group, but there will be 
differences in risks and frequencies according to these. Additionally other potential 
risk factors could be considered, eg comorbidities. 
 
Any simple clinical message that has potential widespread utility in improving 
management of patients in primary care – including self-management – is worth 
exploring, even if not straightforward to do so! This study emphasises once again the 
widely-recognised side effect of hypoglycaemia in insulin-treated patients, but also 
suggests there may be certain symptoms, such as falls and unsteadiness, and 
nausea, which when occurring in insulin-treated patients, should serve as extra 
alerts to review carefully for possible unrecognized hypoglycaemia episodes, and to 
alter management accordingly.  
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Chapter 3 
Assessment of Practical Classification Guidelines for Diabetes in  
insulin-treated patients 
 
Summary 
This study examines the accuracy of the UK Practical Classification Guidelines for 
diabetes (using age at diagnosis and time to insulin treatment), which were 
developed by the Royal College of General Practitioners and NHS Diabetes (2). It 
uses a “gold-standard” definition of Type 1 and Type 2 diabetes, based on 
endogenous insulin levels (measured by urinary C-peptide creatinine ratio, UCPCR), 
and time to insulin, and looked at patients who were insulin-treated, and who had 
had diabetes for at least five years. These guidelines are important as classification 
guidelines for diabetes are rare, and the correct diagnosis is vital for patients having 
the right treatment and education.  
 
Compared to the gold-standard definitions of Type 1 and Type 2 diabetes, the UK 
Practical Classification Guidelines correctly classified 86% of insulin-treated patients 
at least 5 years after diagnosis. The group which were most frequently misclassified 
were those who developed diabetes over the age of 35, but by virtue of being put 
immediately on insulin were classed as having Type 1 diabetes by the guidelines. In 
fact 56% of these patients were still producing significant amounts of endogenous 
insulin after 5 years.  
 
Time to insulin and age of diagnosis were found to be stronger predictors of diabetes 
type than BMI, and no improvement to the guidelines was found by altering the 
clinical criteria or cut-offs used – and thus it was concluded that the UK Classification 
Guidelines were useful in their current form. 
 
Limitations 
Only insulin-treated patients with a diabetes duration of >5 years were studied, in 
order to avoid the honeymoon period where some with Type 1 diabetes may still 
have been producing insulin. If considering all patients with diabetes the guidelines 
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would perform even better – ie patients tablet or diet-treated >5y from diagnosis are 
likely to have been correctly diagnosed with Type 2 diabetes.  
 
The tool which would be of most use to healthcare professionals would be one which 
could correctly classify people at diagnosis. However at present there is insufficient 
data to do this too accurately. The UK Classification Guidelines (2) have time to 
insulin as one of their criteria. UCPCR can correctly identify people with severe 
insulin deficiency early on (ie Type 1), but as above cannot rule out a diagnosis of 
Type 1 diabetes in someone who was producing reasonable endogenous levels of 
insulin early on, as they may still be in the honeymoon period.  
 
The gold-standard criteria used a UCPCR cut-off of 0.2nmol/mmol, which has a 
sensitivity and specificity of 100% and >95% to detect absolute insulin deficiency. In 
a large scale study of community-dwelling adults, this is the best – and most 
practical - “gold-standard” available. UCPCR levels have been shown to be 1.48-fold 
higher in women than men, due to the lower rates of creatinine excretion as a result 
of lower muscle mass (3). This could mean that slightly altered cut-offs should be 
used for the gold-standard definition, which was not done in this study. Insulin 
treatment has the potential to suppress endogenous insulin, but this rarely affects 
diabetes classification (4) – and the small possibility of an over-diagnosis of Type 1 
diabetes is a safer direction of error than the opposite. 
 
Due to recruitment locations and difficulty in recruiting Asian patients, the majority of 
recruited patients in this study were white Caucasian, with only 30 Asian patients 
studied. Comment cannot therefore be made on the accuracy of the UK 
Classification Guidelines in high prevalence populations, and further work is needed 
in these groups.   
 
Limited data on BMI at diagnosis was available only for 60% participants; this could 
be improved in future prospective study. 
 
The two main types of diabetes were addressed in this study, but there are 
alternative subgroups such as genetic forms of diabetes (e.g. MODY). These are 
rare but also part of the UK guidelines, and have their own criteria for diagnosis. It is 
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important the clinician takes into account other factors that may indicate these. The 
term latent autoimmune diabetes in adults (LADA) is sometimes proposed for adults 
with islet autoantibodies who eventually (up to 12 years) become severely insulin-
deficient, but do not require insulin for at least the first 6 months. However LADA is 
not included in international guidelines for classification or treatment, and given 
endogenous insulin status determines treatment requirements, it was felt to be 
appropriate to classify according to UCPCR status as per these “gold-standard” 
criteria.  
 
Future work 
The most useful clinical tool would be one that could be used close to diagnosis of 
diabetes, in order to help classify patients accurately. Further large-scale prospective 
study closer to diagnosis, taking into account clinical factors including age and 
gender, BMI at diagnosis, time to insulin, and measures such as C-peptide and 
pancreatic antibodies would be of great value - and to follow results over time – eg 
regular C-peptide follow up in order to confirm the future course of insulin deficiency. 
It would also be very important to do these studies in other ethnic groups, and in a 
paediatric population. 
 
On a smaller scale, it could be interesting to follow up those identified in the current 
study as misclassified, and those diagnosed with Type 2 and still producing insulin 
beyond 5 years, eg to find out if some might be able to withdraw successfully from 
insulin.  
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Chapter 4 
Urinary C-peptide creatinine ratio detects absolute insulin deficiency  
in Type 2 diabetes 
 
Summary 
This study looked at 191 insulin-treated patients with a clinical diagnosis of Type 2 
diabetes, and found 6% had two UCPCR tests suggesting severe insulin deficiency 
(<0.2nmol/mmol). These patients undertook a mixed meal tolerance test, to assess 
C-peptide levels by the “gold-standard” C-peptide test of 90 minute stimulated serum 
C-peptide (sCP). This confirmed that overall 3% insulin-treated patients with a 
clinical diagnosis of Type 2 diabetes had severe insulin deficiency (sCP <0.2nmol/L 
(200pmol/L)).  
 
Only a third of those with absolute insulin deficiency were treated with (arguably) the 
optimal treatment regimen (basal bolus insulin regimen), suggesting their severe 
insulin deficiency had not been recognised by healthcare professionals. This was 
perhaps not surprising given the only notable clinical differences were that those with 
confirmed absolute insulin deficiency had shorter time to insulin than those with 
UCPCR>0.2nmol/mmol (median 2.5 v 6 years, p=0.005), and slightly lower BMIs 
(25.1 v 29.1kg/m2, p=0.04).  
 
Overall this study therefore showed that absolute insulin deficiency may occur in 
long-standing T2D, and cannot be reliably predicted by clinical features or 
autoantibodies. Its recognition should help guide treatment, education and 
management. UCPCR is a practical non-invasive method to aid detection of absolute 
insulin deficiency, with UCPCR>0.2nmol/mmol being a reliable indicator of retained 
endogenous insulin secretion. 
 
Limitations 
This was the first time UCPCR had been used in a reasonably large scale 
community study, and it was possible as a result to iron out some practical 
methodological issues after reviewing the reasonably high rate of low UCPCR results 
upon repeat becoming “positive”, and/or MMTT sCP being “positive” despite two low 
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UCPCR results. The study was done around the time of some postal strikes, and 
thus some samples returned beyond the 5 days that UCPCR testing had been 
validated for. Other points were noting that some patients had been tipping out the 
boric acid preservative from the urine specimen pots. It was also worth considering 
checking for a concurrent urine infection in the presence of a surprising low UCPCR 
result. Variability in meal stimulus may have also played a role, supported by the 
finding that in four patients despite two home UCPCR results suggestive of absolute 
insulin deficiency, a higher UCPCR and measurable sCP (though low) levels were 
seen under controlled MMTT conditions. This suggests the MMTT was more 
stimulating than the home meals of these patients as they were still able to mount an 
insulin response when maximally stimulated. Finally practically, although every 
precaution was taken to process (centrifuge) and freeze samples immediately, there 
is a chance that samples acquired from those MMTTs done by two different 
investigators in patients’ own homes may have encountered some variation in 
consistency. 
 
Future work 
As demonstrated in this thesis, given the potential importance of identifying those 
people with severe insulin deficiency, and having ironed out the above practical 
issues, it would be highly valuable to do another study assessing the prevalence of 
severe insulin deficiency in a population with a clinical diagnosis of “Type 2 diabetes” 
– and as per the discussion around the previous chapter, look further as to whether 
there are any clinical features particularly associated with it. In other studies UCPCR 
has been found to be particularly practical for measuring endogenous insulin levels 
in children, but in adults with insulin-treated diabetes the relative frequency of blood 
tests means that random non-fasting blood C-peptide may prove more practical (as 
well as accurate) for any such future studies.   
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Chapter 5 
Random non-fasting C-peptide: 
bringing robust assessment of endogenous insulin secretion to the clinic 
 
Summary 
Traditionally it was thought that C-peptide degraded rapidly and thus needed to be 
sent on ice to the lab for rapid centrifuging and analysis. As such it has only really 
been measured regularly in the context of research studies – and hence the 
development of a clinical speciality which does not routinely measure the hormone 
which it is trying to respond to. UCPCR was hence a turning point. However this 
study came about because of the realisation that C-peptide is substantially more 
stable in blood than previously thought (5), and thus samples could be sent in at 
room temperature from outpatients or primary care without degrading. If measuring 
random non-fasting C-peptide was accurate, this could potentially revolutionise 
clinical measurement of C-peptide.  
 
This study therefore compared the “gold-standard” measure of C-peptide at 90 
minutes in a MMTT (sCP) with random non-fasting blood C-peptide (rCP) and 
random non-fasting urine C-peptide creatinine ratio (rUCPCR) in 41 participants with 
insulin-treated diabetes. The impact of concurrent glucose when taking the random 
samples was also evaluated. 
 
rCP and sCP levels were similar: median 546pmol/L and 487pmol/L, p=0.92. rCP 
and sCP were also highly correlated, which improved even further when excluding 
samples with concurrent glucose <8mmol/L. For detection of severe insulin 
deficiency (<200pmol/L), rCP was highly sensitive (100%) and specific (93%); for 
looking at a cut-off often taken to define insulin “requirement” (<600pmol/L), rCP was 
less discriminatory (sensitivity 87% and specificity 83%). rUCPCR was also well-
correlated with sCP, and an rUCPCR cut-off of <0.2nmol/mmol gave a sensitivity and 
specificity of 83% and 93% to detect severe insulin deficiency.  
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Random non-fasting C-peptide measures may thus give the potential of assessing 
C-peptide levels at the point patients are seen for clinical care, which will certainly 
increase their utility. 
  
Limitations  
The main limitation of this study was the very modest sample size, and this meant 
that the confidence intervals for the results were wide. The sample size also limited 
our ability to assess the impact of concurrent glucose on rCP testing, which seems to 
have some impact.  
 
Additionally the population in this study may not be wholly representative of the 
patients where C-peptide testing may have most utility (difficult to classify diabetes) 
in that they are older patients (median age 73), nearly all white Caucasian, and were 
selected on the basis of a clinical diagnosis of Type 2 diabetes with or without 
discordant C-peptide.  
 
Future work 
Further validation of the random non-fasting C-peptide measure in a larger and more 
heterogeneous insulin-treated group would allow more confidence in its accuracy in 
comparison to the “gold-standard” 90 minute C-peptide in the MMTT, and in 
particular the impact of concurrent glucose. 
 
Obtaining understanding of the variability of the random non-fasting C-peptide 
measure in the same individual on different occasions over a short time period would 
also be highly valuable for interpretation purposes.  
 
It would be fascinating to see if people who had “undetectable” rCP measures on 
some occasions had measurable rCP levels on other occasions. Overall the 
opportunity to easily prospectively assess C-peptide levels over time is immensely 
exciting.   
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Chapter 6 
A clinically collected random non-fasting C-peptide sample may be used as a 
risk assessment tool for hypoglycaemia frequency and awareness in insulin-
treated patients 
 
Summary 
Further to the previous study, we set up in this study an automated system for 
measuring random non-fasting C-peptide on routine blood samples sent in for HbA1c 
testing from 480 consenting insulin-treated patients (Type 1 and Type 2). We asked 
those participating to complete a questionnaire regarding their experience of 
hypoglycaemia frequency and awareness.  
 
An increased frequency of recognised hypoglycaemia episodes with blood glucose 
<3.5mmol/L was associated with lower C-peptide deciles, p=0.0001, regardless of 
the clinical diagnosis of Type 1 or Type 2. This was despite similar HbA1c levels 
across all C-peptide deciles, p=0.44. 
 
Median C-peptide was lower in those with hypoglycaemia unawareness: 12pmol/L 
(2.9-977) vs 370(12-910), p=0.044. Other than duration of diabetes (31(16-43) vs 
18(13-27) years, p=0.0015), clinical characteristics were similar including age, 
gender, BMI, HbA1c, and type of diabetes. 
 
This clear link between patient-reported hypoglycaemia frequency and awareness, 
and C-peptide level in all insulin-treated patients, regardless of clinical diagnosis, is 
exciting. We propose measuring rCP could be a useful clinical tool in assessment 
and management of insulin-treated patients and their risks of hypoglycaemia. 
 
Limitations  
Although given its wide use in clinical and research settings it seemed appropriate to 
use the standardised hypoglycaemia questionnaire, it is not the most user-friendly, 
and some patients reported difficulty or frustration in completing it. There were 
instances where answers for some individuals were slightly inconsistent between 
questions, but we did not over-interpret, and the hope is that the reasonably large 
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number of participants means any inconsistencies will not affect the overall results. 
For reasons of consistency we chose to use the more “robust” Clarke method for 
assessing hypoglycaemia unawareness, which takes results from several questions. 
This may identify a slightly different (smaller) group of patients who meet the criteria 
for having unawareness than might be detected in an outpatient clinic (where they 
might be screened with the one-off Gold question regarding their awareness).  
 
The random non-fasting C-peptide measures were taken as close to completion of 
the questionnaires as possible, and within one year. The possible lag between the 
two means it is conceivable there may have been the occasional participant whose 
C-peptide levels were rapidly falling and as such there may have been a discrepancy 
between their results. However this is unlikely to have been a major problem: rapidly 
changing C-peptide levels are most likely to occur in those with recently diagnosed 
Type 1 diabetes; during the course of the study new recruits to DARE were 
completing the questionnaire at recruitment, and C-peptide levels were taken at the 
same time. 
 
Random non-fasting C-peptide as previously discussed is well-correlated with the 
gold-standard MMTT measure of C-peptide. Endogenous insulin levels (and thus C-
peptide levels) have the potential to be suppressed by exogenous insulin treatment 
(4, 6), and hence it is possible that those with hypoglycaemia as a result of over-
treatment with exogenous insulin may have lower C-peptide levels on random non-
fasting measurement than they are capable of. Unfortunately we did not have 
concurrent glucose levels available. Taken in a clinical context however, a review of 
anyone with apparent low C-peptide or frequent hypos would be relevant, and thus a 
low C-peptide level could serve as an alert for review. 
 
Future work 
Expansion of this simple study in terms of size, and in terms of following up these 
participants over time would be extremely valuable, and now the precedent of setting 
up automated rCP analysis has been set, should be relatively easy to do. With a 
bigger sample size it may also be possible to explore further whether endogenous 
insulin levels and self-reported hypoglycaemia frequency is indeed a continuous 
relationship, or whether any particular cut-offs of C-peptide are associated with 
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increased rates of hypoglycaemia/ unawareness. If this was seen to be so, if there is 
any difference according to diabetes diagnosis. Very important questions still remain 
regarding the true impact of HbA1c on hypos, and whether perhaps HbA1c targets 
should be different according to endogenous C-peptide level. Further study of this 
style, with a larger sample size, and collecting concurrent HbA1c, glucose and C-
peptide levels along with concurrent hypoglycaemia questionnaire completion could 
help address this further.  
 
The final thing which would be incredibly useful, is to develop a more user-friendly 
(and discriminatory) hypoglycaemia questionnaire, which could easily be validated in 
this population.   
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Chapter 7 
Low c-peptide is associated with high glycaemic variability and hypoglycaemia 
in insulin-treated patients with type 2 diabetes 
 
Summary 
In order to address the developing hypothesis that insulin-treated people with a 
clinical diagnosis of Type 2 diabetes but differing endogenous insulin levels are at 
different risks of hypoglycaemia, this final study recruited pairs of patients who were 
matched by gender and HbA1c, but differed in endogenous levels. They underwent 
continuous glucose monitoring (CGM), and completed the standardised 
hypoglycaemia questionnaire.  
 
Those with a low random non-fasting C-peptide (<200pmol/L) had a much greater 
glucose variability than those with higher rCP levels  (>500pmol/L): standard 
deviation of glucose measurements 4.15 vs 3.01mmol/L, p=0.0005.  
 
The number of episodes of hypoglycaemia on CGM was higher in the low C-peptide 
group: median (interquartile range) 5.3(1.7-7.7) vs 0(0-2.3) episodes/person/week, 
p=0.003. Consistent with this, the participants in the low C-peptide group reported 
more episodes of hypoglycaemia, the majority being asymptomatic. 
 
Limitations 
The sample size was small, although power was increased by matching of 
participants. A larger sample size may have been able to detect differences in other 
measures of glucose variability, such as MAGE or episodes of severe 
hypoglycaemia.  
 
As previously discussed, rCP was used as a practical measure in this study to 
categorise participants into the two groups, this is the most easily available C-
petpide measure in clinical practice as the sample can be taken at the point of 
clinical contact, and we have shown it to be well-correlated with sCP. In this study 
93% of patients remained in the same category when sCP was assessed; those 
which did not strictly stay in the <200pmol/L group still had low sCP levels, of 221 
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and 443 pmol/L. Of note however the latter had an (asymptomatic) blood glucose of 
2mmol/mol when the rCP sample was taken, confirming the recommendation of 
avoiding concurrent hypoglycaemia for accurate assessment of C-peptide levels (7). 
 
Future work 
It would be great to repeat this study with larger numbers, and to also recruit 
matched patients in the “middle” C-peptide range (200-500pmol/L) – in order to 
replicate findings, confirm an “interim” level of hypoglycaemia with the “middle” 
group, and hopefully to be able to demonstrate differences in other glucose 
variability measures. It would also be very interesting to be able to stratify people in 
more detail, eg according to their HbA1c, or to their insulin regimens.  
 
It would also be extremely valuable to assess changes to treatment on the basis of 
endogenous insulin levels, and see if the glycaemic variability and risk of 
hypoglycaemia decreases. 
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FINAL SUMMARY 
 
This thesis has examined some of the challenges in managing older 
people with diabetes. Measurement of C-peptide, initially using the timed 
spot urine test UCPCR, and then the random non-fasting blood test, has 
been used to evaluate patients’ endogenous insulin levels. We have 
demonstrated that patients with a clinical diagnosis of longstanding Type 
2 diabetes can develop severe insulin deficiency, and that patients in 
this category have more marked glycaemic variability and more frequent 
hypoglycaemia than clinically similar patients with preserved 
endogenous insulin levels. Using random non-fasting C-peptide levels 
and questionnaires, we have also demonstrated that patients with low 
endogenous insulin levels are at increased risk of hypoglycaemia 
regardless of their clinical diagnosis of Type 1 or 2 diabetes. We have 
also shown data which suggests that hypoglycaemia is not always 
recognised in older patients with diabetes.  
Further work is needed, but it seems that random non-fasting C-peptide 
could easily be integrated into routine clinical practice in order to help 
evaluate older patients with diabetes who may potentially be at risk of 
hypoglycaemia, in order to help detect those at highest risk. This would 
help in getting the right strategies in place for minimizing hypoglycaemia 
and maximizing quality of life for these individuals, as well as helping 
target the right resources to the right people. 
There is much scope for further work in this area – eg further work to 
help clarify appropriate individual diabetes goals for older patients, which 
may include work on frailty, weight loss, cognition and HbA1c to name 
but a few; and perhaps looking at possible use of C-peptide 
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measurement to review treatment in older patients. I hope to be able to 
take some of this work forward from here. 
 
I would once again like to thank wholeheartedly all the patients who 
have inspired me; those who have participated in this research, and 
shared their experiences and stories with me. I would also like to thank 
my inspirational and generous colleagues and friends in the Clinical 
Research Facility and the Diabetes & Vascular Research Centre. 
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Introduction
Type 2 diabetes is one of the most common chronic 
conditions in older adults, and the number of elderly 
individuals with diabetes is growing worldwide. For 
example, of the 2.6 million people in the UK with diabetes, 
at least half are over 65 years old.2 The prevalence of 
diabetes in the elderly is more than 10% compared with 
4.1% in the general adult population,1 and approaches 
25% in care home residents.2 The management of 
elderly patients presents unique challenges. Episodes of 
hypoglycemia are a major complication of the treatment 
of diabetes with insulin and some oral medications. The 
consequences of hypoglycemia may be much greater in the 
frail older population than in younger adults.
This older population with diabetes represents a 
heterogeneous group, ranging from those who have been 
diagnosed recently (mainly with type 2 diabetes) to those 
with longstanding type 2 diabetes or type 1 diabetes, 
and from fit and active people to frail institutionalized 
individuals. Treatment of elderly patients also varies 
considerably. Once diabetes is established, the principal 
aims of ‘good diabetes care’ comprise blood glucose 
lowering, managing cardiovascular risk and identifying 
and treating long-term complications.3 As glycemic control 
tends to deteriorate with disease progression, stepwise 
intensification of treatment is usual. This often includes 
prescription of sulfonylureas (SUs) and insulin, the agents 
most likely to precipitate hypoglycemia. 
 
The utilization of these agents in order to achieve strict 
glycemic control is facing increasing scrutiny. The Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) study4 
demonstrated increased mortality with intensive treatment 
using strategies based around the use of SUs and insulin. 
Other studies have not shown this increased mortality with 
stricter glycemic control, but they have also failed to show 
any improvement in all-cause mortality.5-7 Meta-analysis of 
five relevant randomized controlled trials4-6, 8, 9 that examined 
the effect of intensive glycemic control on major outcomes 
in type 2 diabetes, has demonstrated that stricter glycemic 
control (an average of 0.9% reduction in HbA1c maintained 
over 5 years from a mean baseline of 7.8%) can lead to a 
17% reduction in events of non-fatal myocardial infarction, 
and a 15% reduction in events of coronary heart disease.7 
In the Action in Diabetes and Vascular disease: preterAx and 
diamicroN MR Controlled Evaluation (ADVANCE) study,5 
severe hypoglycemia was associated with increased risk 
of macrovascular events, microvascular events, and death 
from both cardiovascular and non-cardiovascular causes,10 
although not in a clear exposure-outcome or  
dose-response manner. The link between hypoglycemia 
and other conditions, which is also relevant to quality of life 
in older patients, such as diminishing cognitive function, 
necessitates a better understanding of the precipitants of 
hypoglycemia and its avoidance in older people  
with diabetes. 
Hypoglycemia in the elderly
Suzy V Hope and W David Strain
Institute of Biomedical and Clinical Science and NIHR Exeter Clinical Research Facility, University of Exeter Medical School, 
Barrack Road, Exeter EX2 5AX, UK
Abstract
Hypoglycemia is a common, under-recognized complication of the management of type 2 diabetes. Elderly individuals 
have a higher burden of co-morbidities, cognitive impairment, physical dysfunction and frailty, which makes them more 
vulnerable to complications of hypoglycemia, such as falls, fractures, cognitive impairment and cardiovascular events, than 
younger patients. Furthermore, with ageing comes impairment of autoregulatory responses, which means the symptoms of 
hypoglycemia are often less specific, and are therefore either missed or incorrectly diagnosed as transient ischemic attacks or 
other cerebrovascular events. Older adults with diabetes have a greater risk of hypoglycemia associated with the physiological 
decline of ageing, and the extended duration of diabetes and insulin treatment. The elderly are also more prone to the 
effects of hypoglycemia such as the increased risk of accidents, falls and fractures, hospitalizations, in-hospital mortality, and 
long-term impairment of cognition. Using individualized treatment targets to base treatment strategies around individual 
circumstances may reduce the risk of hypoglycemia. 
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This review examines how hypoglycemia can affect an older 
population, and highlights the need for increased attention 
to avoid hypoglycemia completely in elderly people.
Prevalence
The true prevalence of hypoglycemia in the elderly is 
unknown. Most studies that have tried to address this 
question rely on recall of hypoglycemic episodes by 
participants. Accurate recall of hypoglycemia is notoriously 
difficult in any age group, and none more so than in an 
elderly population. For epidemiological purposes ‘severe’ 
hypoglycemia is usually defined as that requiring external 
assistance for treatment. This is easier to measure in terms 
of prevalence as it is usually more dramatic and accuracy of 
recall is more robust for up to a year in type 1 and type 2 
diabetes.11, 12 Episodes of severe hypoglycemia can also be 
corroborated with documentary evidence from the medical 
emergency services.  
The difficulties in accurate patient recall of episodes of 
hypoglycemia was addressed by a carefully designed 
prospective observational study over 9–12 months in the 
UK.13 Participants were required to return a data-collection 
sheet every time they experienced a severe hypoglycemia 
episode. The annual prevalence of SU-associated severe 
hypoglycemia was 7%, similar to that observed in people 
with type 2 diabetes treated with insulin for <2 years. This 
compared to a prevalence of 25% in patients with type 2 
diabetes who had received insulin treatment for >5 years, 
and 46% in those with long-standing type 1 diabetes 
(>15 years). However, the highest mean age of any of the 
subgroups included in this study was only 62 years and all 
had good glycemic control (HbA1c <8%). In the retrospective 
assessment of an older population over the age of  
70 years, taking oral glucose-lowering agents, which relied 
on participant recall, Bramlage et al14 found that only 1% 
reported episodes of symptomatic hypoglycemia in which 
external assistance had been required. 
Different definitions, varying ability to recognize 
hypoglycemia and varying ability to recall preceding episodes 
all contribute to disparate estimates between studies. Mild 
episodes of hypoglycemia – usually defined as those that can 
be self-treated – are much more difficult to estimate. It has 
been shown that recall of mild episodes is unreliable beyond 
one week in people with type 1 diabetes.15 It may be poorer 
still in the older population with type 2 diabetes in whom 
cognitive function is often diminished. In the year prior to 
inclusion in their study, Bramlage and colleagues found that 
12.8% of the participants aged over 70 years and on oral 
treatment reported any episode of hypoglycemia, compared 
with 10.1% aged 60–69 years, and 9% aged under  
60 years.14 Over one year in the prospective UK 
Hypoglycaemia Study13 with its intensive concurrent 
data collection, 39% of those with SU-treated type 2 
diabetes reported at least one episode of mild (self-treated) 
hypoglycemia, compared with 64% in those with type 2 
diabetes who had been treated with insulin for >5 years, 
and 85% of those with long-standing type 1 diabetes. 
Furthermore, this represented a middle-aged cohort, so 
the prevalence might well differ in an older population, 
and it may be lower if clinicians are more pragmatic with 
glycemic targets and choice of treatment. However, in the 
INdividualised Treatment targets for EldeRly patients with 
type 2 diabetes using Vildagliptin Add-on or Lone therapy 
(INTERVAL) study, where clinicians were encouraged to set 
individualized treatment targets for elderly patients, taking 
account of age, frailty, and co-morbidities, physicians still 
set HbA1c targets in the region of 7.0% (55 mmol/mol),16 
making this premise unlikely. Conversely, more hypoglycemia 
might be anticipated in elderly patients who eat less and are 
not confident about altering the dose of their medications. 
In addition, hypoglycemia may be missed in older patients 
when their non-specific symptoms are attributed to other 
age-related ailments, or the neurological symptoms are 
misinterpreted as transient ischemic attacks (TIAs) or other 
cerebrovascular events.17
Knowledge of symptoms of hypoglycemia in patients of this 
age group is often poor.18, 19 Mild episodes of hypoglycemia 
are under-recognized by patients, relatives or carers, and their 
healthcare providers. Studies have shown poor correlation 
between recall of hypoglycemia by relatives and patients,20-22 
with relatives tending to recall more episodes. Furthermore, 
the recognition of mild hypoglycemia is made more difficult 
as the hypoglycemia symptom profile changes with age, 
as do the glycemic thresholds for symptom generation and 
cognitive impairment.23 Even if hypoglycemia is recognized, 
patients are known to under-report this to their doctors.24
Symptoms, physiology and recognition
The symptoms of hypoglycemia derive from the 
physiological response to the change in glucose.25 Although 
symptoms may differ between people, in the younger 
adult these are usually easy to perceive. The Edinburgh 
Hypoglycaemia score was developed from analyzing the 
most common symptoms reported by people experiencing 
hypoglycemia,26, 27 and comprises autonomic symptoms 
(such as sweating and pounding heart), neuroglycopenic 
symptoms (such as confusion and light-headedness), and 
non-specific symptoms (such as malaise). Considerable 
variability in symptoms occurs between hypoglycemic 
events, even within the same person.28 In older people, the 
symptoms of hypoglycemia are notably less intense during 
hypoglycemia than in younger adults,17, 29 and there is an 
overall reduced subjective awareness of hypoglycemia with 
increasing age.30 In younger people, autonomic symptoms 
of hypoglycemia tend to be more prominent than 
neuroglycopenic symptoms, although the latter also occur. 
These autonomic symptoms of hypoglycemia become less 
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prominent with increasing duration of diabetes and also 
in older patients with diabetes.29, 31 It has been postulated 
that this change in symptoms may be related to a reduced 
end-organ response in older people.29 The attenuation of 
autonomic symptoms, and change in glycemic threshold at 
which they are generated, crucially restricts the ‘protective 
window’ for action between the recognition of symptoms 
and the onset of cognitive dysfunction.23, 32 This may be 
particularly dangerous in an elderly person, who may 
therefore progress to severe neuroglycopenia.
The Edinburgh Hypoglycaemia score can be adapted to 
include the neurological symptoms that are common in 
older people (studied in those aged over 70 years);  
light-headedness and unsteadiness were found to 
be particularly frequent.17 The non-specific nature of 
symptoms and their lower intensity in the elderly person 
with diabetes can make self-recognition of hypoglycemia 
difficult; a non-specific episode of confusion can be 
caused by numerous conditions prevalent in older patients, 
such as infection, early cognitive impairment, cerebral 
hypoperfusion resulting from postural hypotension or 
a TIA. If an episode is not thought to be significant 
enough to ‘worry the doctor’ it may not be recorded as 
a hypoglycemic event or even treated, and even if it is 
mentioned to medical attendants, the chances of it being 
recognized as hypoglycemia are not high, because of 
conflicting differential diagnoses. The treatment of the 
patient’s diabetes may therefore remain unchanged, and 
unrecognized hypoglycemia may continue to occur. As 
with younger patients with diabetes, repeated episodes 
of hypoglycemia can lead to impaired hypoglycemia 
awareness.27, 33 In insulin-treated people with type 2 
diabetes, patients with impaired hypoglycemia awareness 
had a 17-fold higher frequency of severe hypoglycemia 
events than those with normal awareness.33 Furthermore, 
newer methodologies, such as continuous glucose 
monitoring (CGM), have demonstrated that hypoglycemia is 
more common than previously appreciated.34 
As symptoms of hypoglycemia are varied and non-specific 
in the older population,33 the most pertinent pragmatic 
question is how to identify those at greatest risk?
Risk factors – including comorbidities  
and frailty
Elderly people have multiple potential risk factors for 
hypoglycemia. These risk factors are similar to those 
observed in young adults, but in people of advanced age 
these risk factors are cumulative and have a greater impact. 
In type 1 diabetes, duration of insulin therapy, loss of 
endogenous insulin secretion, and a previous history of 
severe hypoglycemia are predictors for an increased risk of 
severe hypoglycemia.17, 35 Other than treatment with insulin 
and SUs,8 the predictors for an increase in incidence of 
hypoglycemia in type 2 diabetes are more varied, consistent 
with the heterogeneity of type 2 diabetes, and advanced 
age increases the potential for serious morbidity. One 
important risk factor is the duration of insulin  
treatment.8, 22, 27, 36, 37 Other observed associations vary 
between studies, and include older age,38 longer duration 
of diabetes per se,22, 27 increased comorbidities (especially 
chronic kidney disease),38, 39 impaired hypoglycemia 
awareness,22, 27, 33 intensive therapy and strict glycemic 
control,27, 40 and behavioral factors, such as irregular 
eating,41 exercise,39, 42 and errors in timing of medication.42
The observed association between increased frequency of 
hypoglycemia with increased duration of diabetes is linked 
with increasing age and increasing loss of endogenous 
insulin secretion.43 Certainly in type 1 diabetes, the 
Diabetes Care and Complications Trial (among others) 
showed that the lower the C-peptide the higher the rate 
of severe hypoglycemia.17, 35, 44 Surprisingly, few studies 
have examined the role of endogenous insulin secretion 
in type 2 diabetes, and results have been conflicting: the 
UK Hypoglycaemia Study Group found an association with 
frequency of hypoglycemia and C-peptide levels,13 whereas 
a Danish study by Akram et al22 did not. 
There is increasing evidence that people with cognitive 
impairment may be at higher risk of experiencing 
hypoglycemia.45-49 Of the 11,140 patients with type 2 
diabetes in the ADVANCE study,45 212 were classed as 
having ‘severe’ cognitive impairment (scoring <24/30 on 
the Mini-Mental State Examination), and this subgroup had 
double the risk of severe hypoglycemia (hazard ratio [HR] 
2.10, 95% CI 1.14–3.87; p=0.018), than those with ‘mild’ 
or no cognitive impairment. Similarly, in 497,900 veterans 
with diabetes aged 65 years or over,46 the adjusted odds 
ratios for experiencing hypoglycemia that required medical 
assistance over the course of 1 year were 1.58 (95% CI 
1.53–1.62) for those with dementia. Over a median  
3.25 years of follow-up, post-hoc analysis of 2,956 patients 
with type 2 diabetes aged over 55 years in the ACCORD 
trial,47 showed that poorer scores on a battery of cognitive 
tests were predictive of a first episode of hypoglycemia 
requiring medical assistance (HR 1.13, 95% CI 1.08–1.18). 
Yaffe at al49 have recently demonstrated that over  
12 years of follow-up, 14.2% of patients with diabetes 
who developed dementia, subsequently experienced an 
episode of severe hypoglycemia, compared with 6.3% of 
those who did not develop dementia (multivariate-adjusted 
HR 3.1, 95% CI 1.5–6.6; p<0.001).
People with diabetes who live in residential homes, where the 
estimated prevalence of diabetes is 20–25%,2, 50 are perhaps 
at particular risk. Reasons for this include advanced age,38 
duration on insulin treatment,8, 22, 27, 36, 37 comorbidities,38, 39 
reduced ability to manage their food consumption,41 
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reduced cognition,45-49 impaired mobility, limited facilities 
to resolve fluctuations in glucose levels, and progressive 
impairment of hypoglycemia awareness.22, 27, 33 Holstein 
et al38 found that 34% of German patients with type 2 
diabetes who required emergency medical services for 
severe hypoglycemia were nursing home residents or were 
being cared for by home nursing services. The residential 
home population has not, however, been systematically 
evaluated.33, 51 Education about diabetes among care home 
staff is often patchy or absent.52
Effects of hypoglycemia on quality of life, 
morbidity and mortality
So why does it matter that older people are exposed to 
hypoglycemia? Hypoglycemia has a major adverse impact 
on quality of life,53-55 which has been under-appreciated 
by healthcare professionals for many years.56 Patients fear 
hypoglycemia more than the long-term consequences 
of diabetes.57 Hypoglycemia has been linked to poor 
outcomes pertinent to an older population: increased risk 
of accidents,58 falls and fractures,58-60 hospitalizations,58 
in-hospital mortality,61 frailty,62 long-term impairment of 
cognition48, 63 and a two-fold increased risk of developing 
dementia.49, 64 It is also associated with electrophysiological 
changes, particularly prolongation of the QT interval, a 
known precipitant of cardiac dysrhythmia, which may 
persist for up to 48 hours after the hypoglycemic event.65, 66
The risk of accidents resulting in hospital visits among people 
with type 2 diabetes on medications excluding insulin, 
was assessed retrospectively in a large US health insurance 
database.58 Hypoglycemia was associated with significantly 
increased hazards for any accident (HR 1.39, 95%  
CI 1.21–1.59; p<0.001), accidental falls (HR 1.36, 95% CI 
1.13–1.65; p<0.001) and motor vehicle accidents (HR 1.82, 
95% CI 1.18–2.80; p=0.007). Diabetes per se is associated 
with an increased risk of osteoporosis67 and a large retrospective 
observational study in the USA60 of more than 360,000 patients 
with type 2 diabetes aged over 65 years, found 4.7% who had 
a documented hypoglycemic episode over the course of 1 year 
(resulting in an outpatient medical claim) had a 70% higher 
chance of having a fall-related fracture (odds ratio 1.7, 95%  
CI 1.58–1.83); the odds still remained high even after 
correcting for potential confounders, such as presence of 
diabetic peripheral neuropathy.
 
These far-reaching and still under-estimated consequences 
of hypoglycemia have many financial as well as human 
costs, which are difficult to quantify. Hospital admissions 
resulting from hypoglycemia in type 2 diabetes are longer 
than those with type 1 diabetes, reflecting older age, more 
comorbidities and polypharmacy.68
It has been repeatedly observed that dementia is more 
common in those affected by diabetes,69-72 although 
the precise mechanism(s) are still not established. 
Acute hypoglycemia impairs many aspects of cognition: 
immediate verbal and visual memory, working memory, 
delayed memory, visual-motor skills, visual-spatial skills, and 
global cognitive dysfunction.71, 73, 74 It has been suggested 
that this transient impairment is associated with long-term 
cognitive defects. Severe hypoglycemia could result in 
neuronal cell death, which might conceivably accelerate 
the development of dementia.75 One might postulate 
that an episode of severe hypoglycemia may be more 
likely to have a long-term effect on cognition in an older 
and more vulnerable brain, or that repeated episodes of 
hypoglycemia (even if apparently less severe) may have a 
deleterious effect. 
One large scale epidemiological study that suggested severe 
hypoglycemia may lead to dementia, was a longitudinal 
cohort study in the USA by Whitmer and colleagues.64 They 
found a graded increase in risk of dementia with increasing 
numbers of previous hypoglycemic events requiring 
hospitalization – even after adjustment for age, education, 
comorbidities, duration of diabetes, diabetes treatment, 
years on insulin, and 7-year mean HbA1c. This was based 
on the electronic hospital records of 16,667 patients with 
a diagnosis of type 2 diabetes (mean age 65 years): 8.8% 
(1,465) had documented at least one episode of severe 
hypoglycemia (requiring hospitalization) between 1980 
and 2002, and 11% (1,822) had a diagnosis of dementia 
by follow-up. The fully adjusted HR for dementia having 
had one episode of hypoglycemia requiring hospitalization 
was 1.26 (95% CI 1.1–1.49), having had two episodes was 
1.8 (95% CI 1.37–2.36), and for three or more episodes 
was 1.94 (95% CI 1.42-2.64). Similar HRs were found 
when considering emergency department admissions for 
hypoglycemia. This appeared to amount to a 2.3% increase 
in absolute risk of dementia per year of follow-up for 
patients with a history of severe hypoglycemia. 
In a broadly similar study design based on the Taiwanese 
National Health Insurance Research Database, Lin and 
Sheu76 found that of over 15,000 people with type 2 
diabetes, mean age of 64.2 years and no documentation 
of a dementia diagnosis at recruitment, 7.2% developed 
dementia over 7 years of follow-up. From coding (hospital 
or ambulatory episodes), approximately 2% of the cohort 
were found to have an episode of hypoglycemia recorded 
over a 3-year period. An episode of hypoglycemia predicted 
an almost 3-fold increase in the risk of dementia (29.9 
people developing dementia per 1,000 person-years [95% 
CI 22.1–39.2] versus 11.1 per 1,000 person-years [95% 
CI 10.3–11.8]), giving a crude risk ratio of 2.76 (95% CI 
2.06–3.70; p<0.001). After adjustment for age and sex the 
risk ratio for developing dementia after hypoglycemia was 
1.60 (95% CI 1.19–2.14; p=0.002), and this was a graded 
increase in risk according to the number of episodes of 
hypoglycemia experienced.
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Both of these studies64, 76 can be criticized for potential 
selection bias, lack of correction for certain potentially 
significant confounders, and inability to accurately assess 
for cognitive function.77 By only recording the most severe 
hypoglycemic events (those requiring medical assistance), 
when most episodes of hypoglycemia are self-treated in 
the community, those patients identified may be those 
least able to look after their own diabetes and potentially 
may be those most at risk of being cognitively impaired 
(eg, with subclinical cerebrovascular disease) at the time of 
their severe hypoglycemia episode, which could neither be 
measured nor corrected for. Other potentially significant 
comorbid conditions such as a history of alcoholism, 
epilepsy, psychiatric illness or head injury could also not 
be corrected for.77 Additionally, patients who experience 
hypoglycemia needing hospitalization are often considered 
to be an atypical group of patients; they are often severely 
ill (eg, with sepsis), which may provide other causes 
precipitating subsequent cognitive decline.77 The authors 
considered that because the sub-analysis of data from 
emergency department attendances was as robust as 
that from hospital episodes, this made this scenario less 
likely – plus the up-to 15 year lag from hospital episode 
of hypoglycemia to diagnosis of dementia was likely to 
dispel the effect of any other comorbid conditions from 
the hospital admission.78 While it is acknowledged by 
the authors78 that no observational study can completely 
eliminate all confounders, the strength of the data raises 
legitimate concerns that hypoglycemia may precipitate the 
onset of dementia. This calls for some circumspection when 
treating frail elderly to strict glycemic targets – and calls for 
the need for prospective studies in this area.
The Edinburgh Type 2 Diabetes Study avoided some of the 
methodological concerns of the above study64 and also 
supported the suggestion of an association between severe 
hypoglycemia and subsequent development of dementia.48 
In this study, a cross-sectional methodology was used, with 
1,066 participants aged 60–75 who had type 2 diabetes, 
being asked to complete a validated questionnaire to assess 
their frequency of severe hypoglycemia in the previous 
year, and over their lifetime. Cognitive function was 
assessed both at the time of the study (using  
age-sensitive psychological tests to derive a ‘late-life 
cognitive ability factor’), and projected prior cognitive ability 
(using vocabulary tests that are stable during ageing). In 
those reporting at least one severe hypoglycemic event 
(113 patients, 10.6%), a slightly lower mean vocabulary 
score was observed, but was not statistically significant 
(p=0.13), ie, there was seemingly no major difference in 
premorbid cognitive ability. However, a clear difference 
was found in their ‘late-life general cognitive ability 
factor’ (p<0.001), and this difference persisted even after 
adjustment for various potential confounders such as 
duration of diabetes, smoking, HbA1c and vascular disease. 
Additionally, although those having experienced severe 
hypoglycemia scored higher on the Hospital Anxiety and 
Depression Scale, the cognitive associations remained 
significant after being corrected for this. The temporal 
relationship between hypoglycemia and cognitive decline 
cannot be determined accurately with this cross-sectional 
design,48 and it is interesting to note that 76% of the 
patients reporting at least one episode of hypoglycemia 
had experienced an episode in the year preceding 
recruitment. However, on analysis no significant difference 
was observed in the overall strength of the association 
with cognition when hypoglycemia in the year preceding 
recruitment was used versus lifetime history. 
The Fremantle Diabetes Study in Australia79 found an 
association between previous severe hypoglycemia and 
subsequent cognitive impairment and dementia, when 
the cognition of 302 individuals was assessed and their 
previous exposure to severe hypoglycemia estimated 
retrospectively. However, a small prospective arm was 
included in an attempt to address the question of 
temporal decline. The study was probably underpowered 
to answer this question, and the authors did not find an 
association between severe hypoglycemia and evidence of 
premature dementia in 205 individuals over 70 years old 
without cognitive impairment who were followed over a 
comparatively short period of 4 years. 
A recently published prospective study by Yaffe et al49 
provides more convincing evidence and lends weight to the 
causality of dementia in relation to hypoglycemia exposure. 
The authors found a two-fold increased risk of developing 
dementia in people who had experienced an episode of 
severe hypoglycemia requiring hospitalization. A total of 
783 older adults (mean age 74 years) with diabetes but no 
evidence of cognitive impairment at recruitment (determined 
by a baseline Modified Mini-State Examination), were 
followed for 12 years. During this time, 7.8% (61 patients) 
had a severe hypoglycemic event requiring hospitalization, 
and 18.9% (148 patients) developed dementia (determined 
by a dementia-related hospital event or prescription 
of a dementia medication, and confirmed by cognitive 
assessment). Of those who had experienced a hypoglycemic 
event, 34.4% developed dementia, compared with 17.6% 
who did not (p<0.001), with a multivariate-adjusted HR 
of 2.1 (95% CI 1.0–4.4). A bidirectional association was 
observed; those who developed dementia had a greater 
risk of subsequently experiencing hypoglycemia (14.2%) 
compared with those who did not develop dementia (6.3%, 
multivariate-adjusted HR 3.1, 95% CI 1.5–6.6; p<0.001). 
Overall, an increasing body of evidence ould support 
a putative association between hypoglycemia and 
dementia – in bidirectional fashion – and given the 
increasing prevalence and burden both of dementia and 
of diabetes in the older population, this is an area that 
deserves much more attention. Causes of dementia are 
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still poorly understood; if reducing hypoglycemic events in 
the older population can help to reduce the likelihood of 
the development of dementia, physicians should tangibly 
address this possibility.   
HbA1c targets
Strict glycemic control and intensive therapy are associated 
with an increased incidence of severe hypoglycemia.5, 6, 80 
A meta-analysis of randomized controlled trials81 – which 
included over 28,600 patients with type 2 diabetes – found 
the relative risk of severe hypoglycemia was increased by 
30% in the groups undergoing strict glycemic control. 
The frequency of mild hypoglycemia is also likely to be 
increased, as are acute daily glucose fluctuations, which 
are increasingly recognized as being associated with poor 
outcomes, such as effects on cognition.63 A retrospective 
cohort study using data from nearly 28,000 patients over 
the age of 50 years and with type 2 diabetes sourced 
from the UK General Practice Research Database, found 
a U-shaped association between HbA1c and all-cause 
mortality and cardiac events,82 with the lowest risk at an 
HbA1c of 7.5%.
Targets for glycemic control in elderly patients have become 
more controversial and pragmatic.83 Guidelines are starting 
to reflect a need for more individualized treatment, but 
the evidence base is very limited. To date only one clinical 
study has even attempted to utilize individualized treatment 
targets,16 and no study has used clinically meaningful 
outcomes for elderly patients, such as falls, progression of 
frailty and quality of life. Disappointingly, in the INTERVAL 
study, despite being asked to individualize glycemic 
targets around patients’ age, frailty and co-morbidities, 
the participating physicians only considered baseline 
HbA1c and gender, and they set a HbA1c target of 7.0%. 
Individualizing the treatment target was associated with 
lower than anticipated side effects, including hypoglycemia, 
and good tolerability of the strategy. Indeed, 27% of 
the population achieved their targets with nothing more 
than lifestyle change and increased contact with the care-
providers. The American Diabetes Association (ADA) and 
the European Association for the Study of Diabetes have 
issued a joint position statement suggesting a more patient-
centered approach for the treatment of type 2 diabetes.84 
For older adults, they have relaxed the HbA1c target to 
<7.5% or even 8% if stricter targets are more difficult to 
achieve. In 2012, the ADA and American Geriatrics Society 
also issued a consensus report on diabetes in older adults,85 
which suggested more pragmatic glycemic targets for older 
adults than those previously published (Table 1). 
Table 1. The ADA/American Geriatrics Society consensus 
guidelines for setting HbA1c targets based on patient baseline 
characteristic85
Patient type Examples of patient features HbA1c target
“Healthy” Few coexisting chronic  <58.5 mmol/mol 
 illnesses; cognitive &  (7.5%) 
 functional status intact 
“Complex” or Multiple coexisting chronic <64 mmol/mol 
“intermediate” illnesses;  >2 activities of daily (8%) 
 living impairments; mild-to- 
 moderate cognitive impairment
“Very complex” Long-term condition/end-stage  <69 mmol/mol 
or “in poor  chronic illnesses; moderate-to- (8.5%) 
health” severe cognitive impairment; 
  >2 activities of daily living  
 dependencies
However, more relaxed HbA1c targets do not eradicate 
hypoglycemia. Munshi et al86 used CGM to estimate the 
frequency of hypoglycemia in an older population  
(>69 years) with a ‘more relaxed’ glycemic target of HbA1c 
of >8%, and found that 65% experienced at least one 
episode of hypoglycemia (glucose <70mg/dl; 3.9 mmol/l) 
during the 72 hours of monitoring. They concluded that 
relaxing glycemic control to >8% was not necessarily 
sufficient to prevent hypoglycemia in this population. 
They did not compare the frequency of hypoglycemia 
events in this population with the frequency of events in 
patients with stricter glycemic targets; the frequency of 
hypoglycemia in patients with strict glycemic targets would 
be expected to be even higher. 
In practice, inadequate recognition of hypoglycemia may 
not alert patients or clinicians to the need to re-evaluate 
individual treatment targets. With the increased recognition 
of the adverse effects of hypoglycemia and glucose 
variability, an increasing number of older people on insulin, 
and continued strict glycemic targets, hypoglycemia will 
become increasingly important. A stronger evidence base 
for individualized treatment is needed.
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INTRODUCTION
Correctly classifying patients with diabetes 
with type 1 or type 2 is fundamental 
to ensuring they receive correct 
management.1–3 In clinical practice this 
can be challenging, with 7–15% patients 
misclassified in England, and large 
variations in practice.4–7
Historical lack of clear clinical 
guidelines for diabetes classification is 
likely to have contributed to this variation. 
International guidelines from the World 
Health Organization8 and the American 
Diabetes Association9 base classification on 
underlying aetiology, with type 1 described 
as a destruction of beta cells leading to 
absolute insulin deficiency. However, these 
guidelines do not provide clear criteria or 
classification pathways for clinical use.8,9 A 
pragmatic classification algorithm (Figure 1) 
was thus developed in 2010 by key diabetes 
stakeholders in the UK, and published by 
the Royal College of General Practitioners 
(RCGP) and (the previously existing) NHS 
Diabetes in their Coding, Classification and 
Diagnosis of Diabetes document.4 This uses 
age at diagnosis and time to commencing 
insulin treatment from diagnosis as its 
diagnostic criteria. The efficacy of this 
algorithm has not yet been tested on a large 
cohort of patients with diabetes. 
The fundamental difference between 
type 1 and type 2 diabetes is the rapid 
development of absolute insulin deficiency 
in type 1, forming the basis of their different 
treatment and management. Patients 
with type 1 require accurate insulin dose 
replacement;10,11 patients with type 2 
continue to produce substantial amounts 
of their own insulin, responding to non-
insulin therapy, or if insulin is needed 
good control can be achieved with non-
physiological insulin regimens.12,13 
Measuring endogenous insulin secretion 
(using C-peptide, a component of the 
insulin pro-hormone secreted in equimolar 
amounts to insulin) in longstanding 
diabetes may be a useful ‘gold standard’ 
marker of endogenous insulin production, 
confirming a diagnosis of type 1 versus 
type 2 diabetes. Development of the spot 
urine test urinary C-peptide creatinine 
ratio (UCPCR)14–17 has enabled practical 
testing in a community setting. UCPCR is 
well-correlated with mixed meal tolerance 
test measures,16,17 and a UCPCR cut-off 
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of 0.2 nmol/mmol gives a sensitivity and 
specificity of 100% and >95% for detecting 
severe insulin deficiency16,17 as defined 
by the gold-standard mixed meal test 
90-minute C-peptide level of 200 pmol/L.18
Therefore, this study aimed to determine 
the reliability of the 2010 UK Practical 
Classification Guidelines4 to correctly 
classify diabetes in a large cohort of insulin-
treated participants against ‘gold-standard’ 
classification based on measurement 
of C-peptide, in those with diabetes of 
≥5 years’ duration. Although UCPCR can 
be used at any stage in diabetes to confirm 
endogenous insulin levels, in the current 
study ≥5 years’ duration was chosen to 
avoid misclassifying people with early type 1 
who may have been still producing their 
own insulin. 
METHOD
Participants
Adults with insulin-treated diabetes 
centred in/around three UK centres (Exeter, 
Northampton and Leicester) were sent 
letters before attending routine diabetes 
appointments or retinal screening (in 
primary care, both urban and rural, and 
secondary care). Those expressing an 
interest in participating either by returning 
an expression of interest form in advance, or 
when arriving for their routine appointment, 
were formally consented on the same day, 
and provided the research team with data 
on:
• age at diagnosis; 
• weight at diagnosis; 
• current age;
• weight and height;
• treatment; 
• time to insulin from diagnosis; and
• ethnicity.
Body mass index (BMI) at diagnosis and 
recruitment were calculated where possible; 
weight at diagnosis for those diagnosed as 
children converted to the adult equivalent 
using the UK Child Growth Reference 
Standards.19 Participants were also given a 
boric acid-containing urine specimen pot 
and padded stamped addressed envelope. 
They were asked to collect a urine sample 
for UCPCR14 2 hours after their largest 
meal of a day, and post the next morning 
(within 24 hours) for analysis in the Exeter 
biochemistry laboratory. UCPCR is stable in 
boric acid at room temperature for at least 
3 days.14 There was no financial incentive for 
participating.
Classification of diabetes 
Participants were classified as having type 1 
or type 2 diabetes using the UK guidelines,4 
(Figure 1). The authors developed ‘gold-
standard’ criteria: type 1 diabetes: 
continuous insulin treatment within the first 
3 years of diagnosis and absolute insulin 
deficiency (UCPCR <0.2 nmol/ mmol 
≥5 years post-diagnosis);16 type 2 
diabetes: UCPCR >0.2 nmol/mmol, or 
UCPCR <0.2 nmol/mmol but not treated 
with insulin for first 3 years after diagnosis. 
Statistical analysis 
Proportions of patients correctly classified 
by the UK guidelines according to the 
‘gold standard’ C-peptide-based definition 
were calculated, and differences in clinical 
characteristics between those correctly and 
incorrectly categorised were explored using 
the Mann-Whitney test. 
Diagnostic performance of continuous 
variables (age at diagnosis, time to insulin, 
How this fits in
Correct classification as type 1 or type 2 
diabetes is fundamental to appropriate 
diabetes management. The UK Practical 
Classification Guidelines for Diabetes 
published by the Royal College of General 
Practitioners and (the previously existing)
NHS Diabetes are pragmatically based on 
age at diagnosis and time from diagnosis 
to commencing insulin treatment. 
This the first study testing the UK 
classification guidelines in a large cohort 
of insulin-treated patients against a gold 
standard classification of diabetes subtype 
based on presence or absence of retained 
endogenous insulin secretion (measured 
using C-peptide) >5 years post-diagnosis.
The UK classification criteria correctly 
classified 86% of patients, with age at 
diagnosis and time to insulin being the 
best clinical predictors of long-term 
endogenous insulin production.
Diabetes
Type 1
Diagnosis <35 yearsa AND continual insulin
treatment within 6 months of diagnosis
OR
Diagnosis ≥35 yearsa AND continual insulin
treatment from diagnosis
aIn high-risk ethnicities a cut-off of 30 years should be used.
Type 2
Diagnosis <35 yearsa AND not on continual
insulin treatment within 6 months of diagnosis
OR
Diagnosis ≥35 yearsa AND not on continual
insulin treatment from diagnosis
Figure 1. UK Practical Classification Guidelines for 
Diabetes (extract showing algorithm of classification 
guidelines for type 1 and type 2 diabetes).4
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BMI at diagnosis and recruitment) was 
assessed using receiver operating 
characteristic (ROC) curves. Optimal cut-
offs for these variables (with maximum 
specificity and sensitivity for discrimination) 
were calculated, and this study explored 
whether use of these optimal cut-offs led 
to improvements in classification over 
and above the RCGP algorithm using net 
reclassification improvement.20 
Detailed subgroup analysis could not be 
carried out on the Asian patients due to 
small numbers. Analysis was carried out 
on Stata (version 13.1) and R (version 3.1.2). 
RESULTS
In total, 601 white European and 30 
Asian patients who had had diabetes 
for ≥5 years responded. Table 1 shows 
the characteristics of participants per 
classification 
UK guidelines versus gold standard
The UK clinical classification criteria were 
compared with the gold standard C-peptide 
based criteria for defining type 1 and 
type 2 diabetes in the cohort of 601 white 
European patients. In total, 514 (86%, 95% 
confidence interval [CI] = 83 to 88) patients 
overall were correctly classified by the UK 
guidelines when compared with the gold 
standard criteria. 
Figure 2 shows 163 out of 193 patients 
(84%, 95% CI = 79 to 89) were correctly 
classified with type 1 diabetes, and 351 out 
of 408 (86%, 95% CI = 82 to 89) with type 2 
diabetes. The extent of the agreement 
between the classifications of diabetes type 
using the UK guidelines compared with the 
gold standard is evident in Figure 3. 
In the Asian group, the criteria (taking note 
of the age cut-off of 30 years for high-risk 
ethnicities) performed less well, classifying 
only 21 out of 30 (70%) correctly (P = 0.02 
Type 1 by
UK guidelines
Diagnosed <35 years
AND on continual
insulin treatment within
6/12 of diagnosis
n = 154 (25.6%)
Type 2 by
‘gold standard’
UCPCR >0.2nmol/mmol
OR UCPCR ≤0.2 and not
treated with insulin
for first 3 years
after diagnosis
n = 408 (67.9%)
134
agree
87%
20
disagree
13%
Type 1 by
UK guidelines
Diagnosed ≥35 years
AND continual
insulin treatment 
from diagnosis
n = 66 (11%)
Type 1 by
‘gold standard’
UCPCR ≤0.2nmol/mmol
AND continual
insulin treatment within
3 years of diagnosis
n = 193 (32.1%)
29
agree
43.9%
37
disagree
56.1%
Total
601
patients
Type 2 by
UK guidelines
Diagnosed <35 years
AND not on continual
insulin treatment within
6/12 of diagnosis
n = 26 (4.3%)
20
agree
76.9%
6
disagree
23.1%
Type 2
UK guidelines
Diagnosed ≥35 years
AND not on continual
insulin treatment 
from diagnosis
n = 355 (59.1%)
331
agree
93.2%
24
disagree
6.8%
Table 1. Participant characteristics
  Gold standard UK guidelines Gold standard UK guidelines 
 Overall type 1 diabetes type 1 diabetes type 2 diabetes type 2 diabetes
Age at recruitment,  64 54 53 68 68 
median years  (53–73) (41–64) (41–64) (60–74) (61–75) 
(IQR)
Sex, % male 58.2 48.7 52.7 62.8 61.4
BMI at 28.7 26.5 26.8 29.7 30 
recruitment,  (25.3–33.3) (23.1–29.3) (23.8–29.7) (26.6–34.5) (26.6–34.1) 
median (IQR)
Age at diagnosis, 45 24 25 50 50 
median years  (30–56) (12–36) (13–39) (42–59) (43–58) 
(IQR)
BMI at 27 21.8 22.9 28.4 28.3 
diagnosis,  (23.9–32.0) (19.8–26.3) (20.0–27.6) (25.4–32.9) (25.2–33.6) 
median (IQR)
Latest HbA1c,  8.0 8.1 8.0 7.9 7.9 
% (IQR) (7.3–8.8) (7.4–8.9) (7.3–8.9) (7.2–8.8) (7.3–8.8)
Insulin, 0.64 0.61 0.61 0.65 0.64 
IU/kg/24 hours (0.44–0.90) (0.50–0.84) (0.49–0.88) (0.42–0.93) (0.43–0.92) 
(IQR)
UCPCR, 0.6 0.019 0.019 1.19 1.1 
nmmol/mmol,  (0.03–1.60) (0.019–0.03) (0.019–0.22) (0.59–2.25) (0.4–2.1) 
median (IQR)     
BMI = body mass index. IQR = interquartile range. UCPCR = urinary C-peptide creatinine ratio.
Figure 2. Classification of type of diabetes according 
to UK guidelines’ clinical criteria compared to ‘gold 
standard’ C-peptide-based criteria.
e317  British Journal of General Practice, May 2016 
for comparison with white Europeans) (data 
not shown). Three out of four (75%) were 
correctly classified with type 1 diabetes, and 
18 out of 26 (69%) with type 2 diabetes.
Misclassifications
Of patients misclassified by the UK 
guidelines’ clinical criteria in comparison 
with the gold standard (n = 87), most 
(n = 57, 66%, Figure 2) were misclassified as 
having type 1 diabetes and were producing 
substantial endogenous insulin ≥5 years 
post diagnosis (data not shown). Thirty out 
of 87 patients (34%) were misclassified 
as having type 2 diabetes (Figure 2); these 
individuals were severely insulin deficient 
and had started insulin treatment within 
3 years of diagnosis. 
The majority of misclassifications 
(eight out of nine) in the Asian group were 
also cases in which the UK guidelines’ 
criteria suggested type 1 diabetes (using 
the UK guidelines’ age cut-off of 30 years 
for high-risk ethnicities) but the patients 
were still producing their own insulin 
(data not shown). Most patients who were 
misclassified as having type 1 diabetes 
were diagnosed aged ≥35 years, and were 
given insulin immediately. According to UK 
guidelines, 66 patients had type 1 diabetes 
by these criteria, however 37 of these (56%) 
had a UCPCR of >0.2 nmol/mmol and 
so, by gold standard criteria, had type 2 
diabetes (Figure 2). 
Those misclassified as having 
type 1 diabetes were older than those 
correctly classified (median age 44 years 
[interquartile range {IQR} 30–59 years] 
versus 20 years [IQR 11–30 years], P <0.001) 
and had a higher BMI at diagnosis (26.4 kg/
m2 [IQR 23–30.3 kg/m2] versus 21.8 kg/m2 
[IQR 18.9–25.4kg/m2], P = 0.002) (data not 
shown). 
In contrast, those who were insulin 
deficient but were incorrectly classified by 
UK guidelines as having type 2 diabetes 
commenced insulin treatment more 
quickly than those correctly classified as 
having type 2 diabetes (time to insulin from 
diagnosis 12 months [IQR 2–18 months]) 
versus 84 months [IQR 42–138 months], 
P <0.001), had lower BMI (22.5 kg/m2 
[IQR 21.1–26.3 kg/ m2] versus 28.1 kg/
m2 [IQR 25.4–33.3 kg/m2], P <0.001), 
and were younger at diagnosis (44 years 
[IQR 35–56 years] versus 51 years 
[IQR 43–59 years], P= 0.014).
Optimal clinical criteria 
ROC curves were used to examine the 
discriminative ability of key clinical 
criteria: time to insulin, age at diagnosis, 
BMI at diagnosis, and BMI at recruitment 
(Figure 4). They were also used to identify 
the best cut-offs for classification based on 
the ‘gold standard’ criteria. An area under 
the curve (AUC) equal to 1 represents the 
perfect discrimination between types of 
diabetes, and an AUC of >0.8 is generally 
deemed clinically useful.
The most discriminatory individual 
characteristic was months from 
diagnosis to insulin treatment (AUC 0.904, 
95% CI = 0.88 to 0.93), with the optimal cut-
off at 12 months. In total, 91.5% patients 
were correctly classified as having type 1 
diabetes and 82.1% were correctly classified 
as having type 2 diabetes (data not shown). 
Age at diagnosis was also a useful 
discriminator between type 1 and type 2 
diabetes (AUC 0.871, 95% CI = 0.84 to 0.90), 
with the optimal cut-off being ≤39 years 
for type 1 diabetes. This correctly classified 
81.9% of patients with type 1 and 84.3% of 
those with type 2 diabetes (data not shown).
BMI at diagnosis gave an AUC of 0.824 
(95% CI = 0.77 to 0.87; data were available 
in 359 of 601 [59.7%] patients only), with the 
optimal cut-off being ≤23.1 kg/m2. However, 
although this correctly classified 89.4% of 
400
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Figure 3. Proportion of patients classified as having 
type 1 or type 2 diabetes according to the UK 
guidelines. aAccording to C-peptide-derived gold 
standard definition. AD = age at diagnosis. TTI = time 
to insulin from diagnosis. 
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Figure 4. Receiver operating characteristic curve for 
discriminating between type 1 and type 2 diabetes 
(Based on the gold standard definition).
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those with type 2 diabetes, it only classified 
65.7% of patients with type 1 correctly .
BMI at recruitment was even less 
discriminatory, with an AUC of 0.72 
(95% CI = 0.67 to 0.76) and an optimal cut-
off of 28.0 kg/m2; this correctly classified 
66.8% of people with type 2 diabetes, and 
61.8% of people with type 1 diabetes.
Modifying the guidelines’ clinical criteria 
The UK guidelines use age at diagnosis and 
time to insulin as the classification criteria 
to differentiate between type 1 and type 2 
diabetes. On the basis of the ROC curve 
data, the optimal cut-offs for time to insulin 
(12 months), age at diagnosis (39 years), BMI 
at diagnosis (23.1 kg/m2), and recruitment 
(28.0 kg/m2) were incorporated into modified 
criteria in various combinations to see 
whether they improved diagnostic accuracy. 
Aiming for a sensitivity and specificity of 
>80% (equivalent to an ROC AUC of >0.8), 
none were superior to the UK guidelines as 
improvements in sensitivity led to greater 
decreases in specificity and vice versa. 
The best-performing alternative was the 
combination of an age cut-off of 39 years 
and time to insulin of 12 months; this 
improved the correct classification of those 
with type 2 diabetes to 94%, but reduced 
to 78.3% those correctly classified with 
type 1 diabetes. In general, adding BMI at 
diagnosis or time of recruitment improved 
the proportion of those with type 2 diabetes 
that were correctly classified, but markedly 
reduced the proportion correctly classified 
with type 1 diabetes.
DISCUSSION
Summary
The study results show that the UK guidelines 
are an accurate method of predicting long-
term endogenous insulin production and 
perform well in correctly classifying patients 
with insulin-treated diabetes based on the 
development of absolute insulin deficiency 
using endogenous insulin levels and time 
to insulin from diagnosis. This supports the 
guidelines’ use as a beneficial, pragmatic 
way of classifying patients. When all 
patients with diabetes are considered, the 
authors hypothesise that the performance 
of the UK guidelines will be even better 
because the vast majority of patients who 
are not treated with insulin will be correctly 
classified as having type 2 diabetes.
Patients diagnosed at an older age 
(≥35 years) in whom insulin treatment 
commenced at diagnosis are at the highest 
risk of being misclassified when using the 
UK guidelines.
In clinical practice, emphasis is often 
placed on BMI to help differentiate between 
type 1 and type 2 diabetes but the study 
findings presented here indicate that, 
among patients treated with insulin, time 
to insulin and age at diagnosis are better 
predictors of diabetes subtype than BMI. 
Median BMI at diagnosis of those with type 1 
diabetes by the gold standard criteria was 
lower than in those with type 2 diabetes: 
21.8 kg/m2 versus 28.1 kg/m2 (P <0.001 but 
the interquartile ranges overlapped (19.8–
26.3 kg/m2 and 25.4–32.9 kg/m2). By the 
time of recruitment (that is, ≥5 years from 
diagnosis), the difference in BMI between 
those with type 1 and type 2 diabetes 
was smaller (26.5 kg/m2 [23.1–29.3 kg/
m2] versus 29.7 kg/m2 [26.6–34.5 kg/m2]) 
although still significant (P <0.001), and the 
ROC AUC was low, highlighting the reduced 
discriminative ability of this as a clinical 
marker to differentiate between type 1 and 
2 diabetes once the patient was receiving 
insulin.
Strengths and limitations 
This study comprised patients who had 
had diabetes for ≥5 years. If considering all 
patients with diabetes, the misclassification 
rate of 14% is likely to be much lower: 
patients who are treated with tablets or 
diet who were diagnosed ≥5 years ago are 
likely to have been correctly diagnosed with 
type 2 diabetes. In patients with a diabetes 
duration of <5 years, some patients with 
type 1 diabetes may be still producing insulin 
(the ‘honeymoon’ period) and not yet treated 
with insulin, although it is rare for patients 
with type 1 diabetes to be without insulin 
for prolonged periods. Due to recruitment 
locations and difficulty in recruiting Asian 
patients,21 the majority of the recruited 
patients were white European; only 30 Asian 
patients participated. Take-up rates in the 
white European population were high, and 
participants drawn from urban and rural 
populations, and thus the authors consider 
the results in this group are likely to be fairly 
representative for insulin-treated patients 
≥5 years from diagnosis. In comparison, the 
authors cannot comment on the reliability 
of the UK guideline criteria for populations 
in which the prevalence of diabetes is high; 
further work is needed in these groups. 
Limited data on BMI were available 
at diagnosis, due to a combination of 
participants not knowing their weight at 
diagnosis and/or missing details in GP 
records in patients having been diagnosed 
with diabetes ≥5 years ago. Improved 
recording of such details in those newly 
diagnosed with diabetes over the last few 
years means the authors consider this 
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information is likely to be more available in 
any future studies. 
The gold standard criteria used a 
UCPCR cut-off of 0.2 nmol/mmol, which 
has a sensitivity and specificity of 100% 
and >95% respectively to detect absolute 
insulin deficiency.16,17 It is the best gold 
standard available in this context, being 
practical for use in large numbers of adults 
living in the community. Insulin treatment 
has the potential to suppress endogenous 
insulin,22–24 but the findings presented 
here show that this rarely affects diabetes 
classification.24 In addition, it should be noted 
that the small possibility of an overdiagnosis 
of type 1 diabetes is a safer direction of error 
than the opposite.
Comparison with existing literature
Previous reports on the misclassification 
of diabetes4,6,25,26 were mainly based on 
contraindications in coding rather than 
on gold standard definitions of insulin 
deficiency.18,27,28 These reports have 
attempted to assess accuracy of recorded 
diagnosis on the basis of electronically 
recorded data. Although this may detect 
patients who are miscoded, for example as 
having type 1 diabetes but are not on insulin 
10 years postdiagnosis, it is less likely to 
detect patients who are misdiagnosed, 
for example in receiving insulin despite 
high endogenous insulin levels several 
years after diagnosis. The UK Practical 
Classification Guidelines for Diabetes4 use 
very simple clinically available information 
to classify patients from scratch, and the 
authors have assessed their accuracy 
using a gold-standard diagnosis based 
on endogenous insulin levels and time to 
insulin.
A recently published systematic review 
identified diagnostic accuracy studies in the 
literature, which compared clinical criteria 
with C-peptide cut-offs.7 Age at diagnosis, 
time to insulin, and BMI are the clinical 
characteristics most frequently used to 
classify type 1 and type 2 diabetes, but 
few studies have addressed clearly which 
are most strongly associated with long-
term C-peptide secretion.7 Where strength 
of association has been measured, time 
to insulin and age at diagnosis appear 
stronger than BMI. Again as found in the 
current study, combining time to insulin 
and age at diagnosis improved diagnostic 
accuracy, with BMI adding little.7 
Implications for research and practice
Correct classification of type 1 and type 2 
diabetes is important so the appropriate 
treatment and management guidelines are 
followed;3,29 this will relate to treatment, 
education (for example, about dose 
adjustment for normal eating for those with 
type 1), and the monitoring of complications, 
all of which are based on the presence or 
absence of endogenous insulin.
The clinical problem facing GPs and other 
health professionals is that classification 
can be tricky at the time of diagnosis and all 
guidelines — including the UK classification 
guidelines assessed in this study — rely 
on information that is only available 
further down the line (for example, time 
to insulin). The gold standard classification 
using UCPCR ≥5 years from diagnosis, 
by definition, cannot completely solve this 
conundrum: UCPCR of >0.2 nmol/mol 
within 5 years of diagnosis may represent 
someone with type 1 diabetes who is still in 
the ‘honeymoon’ phase, or someone with 
type 2 diabetes; a UCPCR of <0.2 nmol/
mmol within 5 years of diagnosis can 
diagnose type 1 diabetes however. 
Studies designed to improve classification 
at diagnosis, for example by using islet 
antibodies, are needed to address this 
problem. 
This study has shown that the UK 
guidelines based on time to insulin and age 
at diagnosis are accurate and pragmatic 
for classifying patients with type 1 or type 2 
diabetes. Time to insulin is subject to many 
influences — physician or patient factors, 
or guidelines for treatment in a particular 
area or patient population — but the high 
rate of correlation of diagnosis with the 
gold standard suggests overall timing 
of insulin initiation may be reasonably 
consistent. Clinically, where the type of 
diabetes is unclear, giving insulin from 
diagnosis is a rational decision to avoid 
the potential consequences of untreated 
type 1 diabetes, such as ketoacidosis. This 
study however demonstrates high rates 
of misclassification as type 1 diabetes in 
those diagnosed >35 years of age, and thus 
revisiting the diagnosis in these patients 
may be worthwhile. The authors suggest 
that, if there is diagnostic uncertainty, the 
diagnosis be reviewed, specialist advice 
sought, and further investigations (for 
example, C-peptide and islet autoantibodies) 
be considered.
It could be interesting to follow up 
those patients identified as misclassified, 
and those diagnosed with type 2 and 
still producing insulin beyond 5 years to 
ascertain whether some of them may be 
able to withdraw successfully from insulin.
The authors have concentrated on the 
two main types of diabetes, but recognise 
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that there are alternative subgroups such 
as genetic forms of diabetes. Although 
rare, these are also covered by the UK 
guidelines and have their own criteria for 
diagnosis.30
It is important that clinicians take into 
account other factors that may indicate 
these. The term ‘latent autoimmune 
diabetes in adults’ (LADA) is sometimes 
proposed for adults with islet autoantibodies 
who eventually (>12 years) become severely 
insulin deficient, but do not require insulin 
for at least the first 6 months.31–34 However, 
LADA is not included in international 
guidelines for classification/treatment.
 Finally, nothing was found to indicate 
that modification of the criteria used or 
the cut-offs proposed would improve 
their diagnostic performance. This study, 
like others such as that of Shields et al,7 
suggest that age of diagnosis is a better 
clinical predictor of type 1 diabetes than 
BMI, which is often used clinically to 
determine diabetes subtype when it is not 
clinically obvious; this supports the fact 
that more emphasis should be placed on 
age of diagnosis in uncertain cases. This 
is perhaps particularly relevant in a time 
when the BMI of the average population is 
increasing.35,36 
This study demonstrates that the UK 
Practical Classification Guidelines for 
Diabetes are an accurate means for 
differentiating between type 1 and type 2 
diabetes in most instances, with time to 
insulin and age at diagnosis being the most 
discriminatory clinical characteristics. As 
patients aged ≥35 years who were treated 
with insulin from diagnosis had the highest 
rate of misclassification (56% classed 
incorrectly as having type 1 diabetes), 
further investigation should be considered 
in this subgroup.
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Abstract
Aims To determine the prevalence and clinical characteristics of absolute insulin deficiency in long-standing Type 2
diabetes, using a strategy based on home urinary C-peptide creatinine ratio measurement.
Methods We assessed the urinary C-peptide creatinine ratios, from urine samples taken at home 2 h after the largest
meal of the day, in 191 insulin-treated subjects with Type 2 diabetes (diagnosis age ≥45 years, no insulin in the first
year). If the initial urinary C-peptide creatinine ratio was ≤0.2 nmol/mmol (representing absolute insulin deficiency), the
assessment was repeated. A standardized mixed-meal tolerance test with 90-min stimulated serum C-peptide
measurement was performed in nine subjects with a urinary C-peptide creatinine ratio ≤ 0.2 nmol/mmol (and in nine
controls with a urinary C-peptide creatinine ratio >0.2 nmol/mmol) to confirm absolute insulin deficiency.
Results A total of 2.7% of participants had absolute insulin deficiency confirmed by a mixed-meal tolerance test. They
were identified initially using urinary C-peptide creatinine ratio: 11/191 subjects (5.8%) had two consistent urinary
C-peptide creatinine ratios ≤ 0.2 nmol/mmol; 9 of these 11 subjects completed a mixed-meal tolerance test and had a
median stimulated serum C-peptide of 0.18 nmol/l. Five of these 9 had stimulated serum C-peptide <0.2 nmol/l and 9/9
subjects with urinary C-peptide creatinine ratio >0.2 had endogenous insulin secretion confirmed by the mixed-meal
tolerance test. Compared with subjects with a urinary C-peptide creatinine ratio >0.2 nmol/mmol, those with confirmed
absolute insulin deficiency had a shorter time to insulin treatment (median 2.5 vs. 6 years, P=0.005) and lower BMI
(25.1 vs. 29.1 kg/m2, P=0.04). Two out of the five patients with absolute insulin deficiency were glutamic acid
decarboxylase autoantibody-positive.
Conclusions Absolute insulin deficiency may occur in long-standing Type 2 diabetes, and cannot be reliably predicted
by clinical features or autoantibodies. Absolute insulin deficiency in Type 2 diabetes may increase the risk of
hypoglycaemia and ketoacidosis, as in Type 1 diabetes. Its recognition should help guide treatment, education and
management. The urinary C-peptide creatinine ratio is a practical non-invasive method to aid detection of absolute
insulin deficiency, with a urinary C-peptide creatinine ratio > 0.2 nmol/mmol being a reliable indicator of retained
endogenous insulin secretion.
Diabet. Med. 30, 1342–1348 (2013)
Introduction
Most older patients with diabetes have Type 2 diabetes,
which is typically a disease where endogenous insulin
persists. Progressive b-cell dysfunction occurs in Type 2
diabetes [1–4], but it is unclear if this leads to absolute
insulin deficiency. By contrast, in Type 1 diabetes absolute
insulin deficiency is usual outside the initial ‘honeymoon
period’, the period soon after diagnosis when some residual
b-cell function may persist [5].
Some patients may present clinically later in life as having
Type 2 diabetes, but have the autoimmune destructive
process as seen in Type 1 diabetes. These patients can be
recognised by pancreatic autoantibodies, known as latent
autoimmune diabetes of adulthood (LADA) [6]. People with
LADA may develop absolute insulin deficiency [7–10]. In
practice, however, autoantibody levels are rarely measured in
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patients presenting with adult-onset diabetes: a clinical
diagnosis of Type 2 diabetes is usually made and seldom
revisited, and so later subsequent development of absolute
insulin deficiency is rarely suspected or tested for.
Absolute insulin deficiency in patients with Type 2
diabetes is likely to carry similar risks to those associated
with Type 1 diabetes, such as fluctuant blood glucose levels,
high hypoglycaemia risk and diabetic ketoacidosis [11]. The
patient with Type 2 diabetes, however, is unlikely to be
offered a similar level of education to deal adequately with
these, such as the Dose Adjustment for Normal Eating
(DAFNE) programme [12]. Frail older people, in particular,
may be ill-equipped to cope with such complications, with
less functional reserve both physically and cognitively, and in
terms of their social support. The development of absolute
insulin deficiency in Type 2 diabetes will alter treatment: oral
hypoglycaemic agents (especially sulphonylureas) will not be
effective, the newer agents, e.g. glucagon-like peptide (GLP)-
1 receptor analogues and dipeptidyl peptidase (DPP)4
inhibitors, are not suitable, and the most appropriate insulin
regimen may be basal-bolus rather than background long-
acting insulin. With an estimated 870 000 people with
insulin-treated Type 2 diabetes in the UK, the development
of absolute insulin deficiency in even a small proportion
could have significant impact on both individuals and
society.
Endogenous insulin levels are rarely measured in routine
clinical practice, even in secondary care, owing to practical
limitations, including the need for rapid laboratory analysis
of blood tests. The majority of patients with Type 2 diabetes
are cared for in primary care where this is even less practical.
Recently, a simple urine test, the urinary C-peptide creatinine
ratio (UCPCR) [13], has been shown both in Type 1 diabetes
and Type 2 diabetes, to be excellently correlated with the
‘gold standard’ measure of endogenous insulin secretion, the
formal mixed-meal tolerance test (MMTT), and a sensitive
and specific test for absolute insulin deficiency [5,14]. The
UCPCR test has the advantages of being widely available,
and stable at room temperature for 3 days, so offering the
potential for widespread non-invasive testing which may be
particularly useful for a more frail, older population. The
aim of the present study was to use the UCPCR to test for
absolute insulin deficiency in older people with insulin-
treated Type 2 diabetes.
Methods
Subjects
A total of 191 insulin-treated subjects with Type 2 diabetes
(clinical diagnosis of Type 2 diabetes, diagnosis at ≥ 45 years
of age, insulin treatment not started within 1 year of
diagnosis) were recruited from primary care at the time of
their routine retinal screening appointment, and written
consent was obtained for participation in the study. Baseline
data collected included duration of diabetes, current treat-
ment, BMI and most recent HbA1c concentration.
Urine collection and analysis
Participants were asked to provide an initial urine sample,
collected at home, 2 h after their largest meal of the day. The
urine sample was collected in a standard mid-stream urine
boric acid-containing specimen pot, and returned by post to
the routine pathology laboratories for UCPCR analysis.
UCPCR ≤ 0.2 nmol/mmol is equivalent to a stimulated
serum C-peptide (sSCP) of 0.2 nmol/l in an MMTT [15,16],
representing an absence of clinically significant insulin
secretion [11]. This level is associated with unstable glyca-
emia, increased risk of hypoglycaemia and microvascular
complications (as well as absolute insulin requirement) in
Type 1 diabetes [11,16].
All patients identified as insulin-deficient were asked to
provide a repeat sample to confirm their initial result, as
were a random group of those with a UCPCR >0.2 nmol/
mmol.
Mixed-meal tolerance test
In those patients with consistent UCPCR results ≤0.2 nmol/
mmol, we performed a formal MMTT with their insulin
excluded, to confirm the absolute insulin deficiency [5].
A comparison group of age-matched participants with
UCPCR >0.2 nmol/mmol also underwent the standardized
MMTT [17]. In brief, subjects fasted from midnight, and
omitted their morning medications including insulin. Fasting
serum and urine samples were taken before participants
consumed 6 ml/kg Ensure Plus HP (Abbott Laboratories,
Abbott Park, IL, USA). A blood sample for sSCP was taken
90 min later, and a urine sample for UCPCR at 2 h. As
above, a sSCP concentration of <0.2 mmol/l was used to
represent absolute insulin deficiency [5,18].
Sample analysis
Urine and serum samples were analysed for C-peptide using
an electrochemiluminescence immunoassay (intra-assay coef-
ficient of variation <3.3%; interassay coefficient of variation
<4.5%) on a Roche Diagnostics E170 analyser (Roche,
Mannheim, Germany) by the biochemistry department at the
Royal Devon and Exeter NHS Foundation Trust. Urine
creatinine was analysed on the Roche P800 platform using
creatinine Jaffe reagent (standardized against isotope dilution
mass spectrometry) to obtain a urinary C-peptide creatinine
ratio. Blood samples for all patients completing the MMTT
were analysed for glutamic acid decarboxylase (GAD)65 and
islet antigen 2 (IA2) autoantibodies, using the Biokit auto-
mated Elisa System (BEST 2000; Biokit, Barcelona, Spain)
following the manufacturer’s instructions. The cut-offs used
were those based on the 99th centile for 500 individuals
ª 2013 The Authors.
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without diabetes; for GAD65 the reference-positive value
was >64 units/ml, for IA2 the reference-positive value was
>15 units/ml.
Data analysis
The data were not normally distributed, and so are presented
as medians and interquartile ranges (IQRs). Results
were analysed primarily by comparing the clinical charac-
teristics of those with confirmed absolute insulin deficiency
on MMTT and those with endogenous insulin secretion,
using Mann–Whitney U- and chi-squared tests (using
Predictive Analytic Software: PASW 17.0). The full group
of 167 participants with an initial home UCPCR >0.2 nmol/
mmol was used to represent those with significant insulin
secretion, given the consistency of repeat UCPCR and
MMTT results in subgroups drawn from these (see Results
and Fig. 1).
Ethics approval was obtained from the Southwest
Research Ethics Committee.
Results
A total of 191 participants, with a median (IQR) age 73.5
(67–78) years and of whom 37% were women, provided an
initial urine sample for UCPCR measurement. They had a
median (IQR) age at diagnosis of 58 (50–65) years, duration
of diabetes of 13.5 (9–19) years, and BMI at recruitment of
29 (25.9–33.54) kg/m2. Their median (IQR) time to insulin
treatment from diagnosis was 6 (3.5–11) years.
Figure 1 shows the flow of patients through the study. Of
the 191 participants screened, 24 (12.5%) had UCPCR ≤
0.2 nmol/mmol. Of these, 21 provided a repeat sample, and
11/188 (6% of the whole cohort) had two consistent UCPCR
results of ≤ 0.2 nmol/mmol.
Table 1 shows the MMTT results of the two groups
selected on the basis of their UCPCR. These two groups were
similar in age, duration of diabetes, time to insulin from
diagnosis, and BMI. As expected the sSCP concentration was
lower in those with a low UCPCR than in those with a high
UCPCR (median 0.18 vs. 2.0 nmol/l, respectively, P = 0.002).
Five of the nine participants with a low UCPCR had a sSCP of
<0.2 nmol/l, representing absolute insulin deficiency [18], in
contrast to none with a high UCPCR had a sSCP <0.2 nmol/l.
This suggests a minimum prevalence of absolute insulin
deficiency in insulin-treated Type 2 diabetes of 3% [5/186,
excluding the five subjects who were unable to provide repeat
urine samples or participate in the MMTT (Fig. 1)].
Notably, the UCPCR results obtained in both groups were
substantially higher after the MMTT than after the home
Insulin-treated subjects with Type 2 
diabetes, diagnosed ≥45 and started 
insulin treatment >12 months from 
diagnosis
UCPCR ≤0.2 nmol/mmol
n = 24
N = 191
UCPCR >0.2nmol/mmol
n = 167
n = 21
(three uncontactable)
n = 21
(to match ≤0.2 subgroup)
UCPCR >0.2nmol/mmol 
n = 10 
UCPCR ≤0.2nmol/mmol  
n = 11
UCPCR >0.2nmol/mmol
n = 21
UCPCR ≤0.2nmol/mmol 
n = 0
n = 9
(two unable to do MMTT)
n = 9
(matched to UCPCR <0.2)
sSCP ≤0.2nmol/L 
n = 5
sSCP >0.2nmol/L
n = 9
Home UCPCR
Repeat Home UCPCR
MMTT
FIGURE 1 Flow of participants through the study. UCPCR, urinary C-peptide creatinine ratio; MMTT, mixed-meal tolerance test; sSCP, stimulated
serum C-peptide.
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meal. For those four patients with two home UCPCRs ≤
0.2 nmol/mmol but an sSCP >0.2 nmol/l, the post-MMTT
UCPCR results were also >0.2 nmol/mmol. This suggests the
MMTT provided more b-cell stimulation than did the meals
consumed at home.
The five patients with confirmed absolute deficiency on
MMTT had a lower BMI (BMI 25.1 vs. 29.1 kg/m2,
P=0.04), and commenced insulin treatment more rapidly
after diagnosis (2.5 vs. 6 years, P=0.005), although there was
substantial overlap for both these measures between those
with (n=5) and without (n=167) absolute insulin deficiency.
There was no difference in age of diagnosis, duration of
diabetes, glycaemic control or insulin dose (Table 2).
Two of the five participants with absolute insulin defi-
ciency were GAD-positive (titre in both >2000 units/ml); one
of these was also IA2 positive (titre 74.9 units/ml). In
addition, one patient who had two low UCPCR measure-
ments from home but an sSCP of 0.37 nmol/l was GAD-
positive (titre >2000 units/ml). None of the nine participants
from the comparison MMTT group, i.e. with home UCPCR
demonstrating residual endogenous insulin secretion and
confirmed on MMTT, were positive for GAD or IA2
antibodies.
Notably, only two of the five participants with absolute
insulin deficiency were on a basal-bolus regimen, and two
were treated with oral agents in combination with insulin.
Discussion
A total of 2.7% of insulin-treated patients with a clinical
diagnosis of Type 2 diabetes in the present study were found
to have absolute insulin deficiency. Patients who may have
had absolute insulin deficiency were detected using the
simple non-invasive testing method, the UCPCR, and a
MMTT was used to confirm findings. These patients cannot
be solely identified on the basis of clinical characteristics, or
by testing of GAD antibodies.
Prevalence and aetiology of absolute insulin deficiency in
Type 2 diabetes
Our prevalence of absolute insulin deficiency of 2.7% (5/
186) is similar to the 2.3% (3/133) found at 10 years from
diagnosis in an observational study by Niskanen et al. [7].
This looked at adult patients over the age of 45 years with
new-onset non-insulin-dependent diabetes, and measured
sSCP and GAD titres at 0, 5 and 10 years. By including only
insulin-treated patients in our study, one might have
expected a more insulin-deficient group and hence a com-
paratively higher proportion of patients with absolute insulin
deficiency than in the study by Niskanen et al. The aim for
tighter glycaemic control (and hence earlier initiation of
insulin) in the post-Diabetes Control and Complications
Trial/United Kingdom Prospective Diabetes Study era may
provide an explanation for why this was not seen. Addition-
ally, the 2.7% prevalence in our study population is a
minimum: there were five additional participants with an
initial UCPCR suggestive of absolute insulin deficiency
who were either uncontactable or unable to undergo a
MMTT (Fig. 1). If all these participants had confirmed
sSCP <0.2 nmol/l, the prevalence would have risen to 5.2%
(10/191).
Table 1 Urinary C-peptide creatinine ratios and stimulated serum
C-peptide values in nine subjects with two home UCPCRs of
≤0.2 nmol/mmol, compared with nine matched subjects with two
home UCPCRs of >0.2 nmol/mmol
UCPCR ≤0.2
nmol/mmol
UCPCR >0.2
nmol/mmol P
UCPCR (home),
nmol/mmol
<0.02
(<0.02–0.2)
1.7
(0.8–7.1)
<0.001
UCPCR (MMTT)
nmol/mmol
0.07
(<0.02–0.7)
2.6
(1.9–5.6)
0.001
fSCP, nmol/l 0.13
(0.08–0.35)
0.59
(0.45–0.88)
0.003
sSCP, nmol/l 0.18
(0.08–0.64)
2.0
(1.53–2.52)
0.002
Data are shown as median values (interquartile range).
UCPCR, urinary C-peptide creatinine ratio; MMTT, mixed-
meal tolerance test; fSCP, fasting serum C-peptide; sSCP,
stimulated serum C-peptide.
Table 2 Clinical characteristics of those with absolute insulin
deficiency as confirmed by a mixed-meal tolerance test, vs those with
endogenous insulin secretion (urinary C-peptide creatinine ratio
>0.2 nmol/mmol)
Absolute
insulin
deficiency
Endogenous
insulin
secretion P
n 5 167
Age at diagnosis,
years
63 (54–72) 58 (50–66) 0.28
Duration of
diabetes, years
12 (9.5–19.5) 13 (9–17) 0.87
BMI, kg/m2 25.1 (22.8–28.8) 29.1 (26.3–33.6) 0.04
HbA1c,
mmol/mol
72 (57–85) 62 (55–69) 0.24
HbA1c,% 8.7 (7.4–9.9) 7.8 (7.2–8.5)
Time to
insulin from
diagnosis,
years
2.5 (1.5–3) 6 (3–10.75) 0.005
Insulin/kg/24 h,
units/kg/24 h
0.72 (0.54–0.88) 0.51 (0.31–0.84) 0.26
No. of subjects
on oral hypo-
glycaemic
agent, in
addition to
insulin (%)*
2/5 (40) 115/167 (69) 0.17
No. of subjects
on basal-bolus
regime (%)*†
2/5 (40) 19/167 (11) 0.05
Data shown as medians (interquartile range).
*Chi-squared tests; all others Mann–Whitney U-test. †Basal-
bolus regime: four or five injections of insulin a day.
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In subjects with high titres of GAD antibodies and
reasonably long diabetes duration (10–12 years), prospective
longitudinal studies have shown that many (but not all)
develop absolute insulin deficiency [7,9]. When combined
with the clinical features of adult-onset diabetes not
immediately requiring insulin treatment, the presence of
pancreatic autoantibodies is known as LADA [7,9,10].
Two of the five participants with absolute insulin defi-
ciency in our study fit these criteria, having high GAD titres
(>2000 units/ml, reference value >64 units/ml); however,
with three participants with a confirmed absolute insulin
deficiency not exhibiting GAD antibodies, it suggests that the
presence of these antibodies is not a sensitive test for
detecting the development of absolute insulin deficiency in
those with long-standing diabetes.
Our study has hence identified three people with apparent
non-autoimmune Type 2 diabetes and confirmed absolute
insulin deficiency. Of the three patients developing absolute
insulin deficiency in the study by Niskanen et al. [7], one was
GAD-antibody-negative. This was the only other case we
found in the literature of absolute insulin deficiency con-
firmed using sSCP in non-autoimmune Type 2 diabetes [7].
It is possible that the cross-sectional measurement of pancre-
atic autoantibodies in our study may have missed some
patients who were antibody-positive at an earlier stage, but
lost this positivity over time; however, numerous studies have
found that high GAD titres persist [7,9,19,20]. The cross-
sectional design of the present study meant we were able to
look a wide range of durations of diabetes, longer than those
looked at before in Type 2 diabetes, and this may help explain
why we have detected absolute insulin deficiency where
others have not. No previous studies we have found were
designed to look for absolute insulin deficiency in Type 2
diabetes; the majority have looked at the significance of GAD
antibodies on the deterioration in b-cell function over time.
Urinary C-peptide creatinine ratio testing
The urinary C-peptide creatinine ratio was used in this study
as a practical test in a large number of individuals, and was
able to detect patients at risk of absolute insulin deficiency.
The gold standard MMTT was used to confirm findings.
Those with evidence of endogenous insulin secretion on an
initial UCPCR test had consistent results, both on repeat
UCPCR and on MMTT. As would be expected by regression
to the mean when selecting a low cut-off, those with an
initial low UCPCR suggesting absolute insulin deficiency had
a tendency to higher results upon repeat testing, taking some
above the designated 0.2 nmol/mmol threshold. In addition,
some practical issues were identified which may have led to
erroneously low UCPCR results on initial testing: these
included patients tipping out the boric acid preservative from
the sample pots, and postal delays. Additionally, in those
with low endogenous insulin levels, variation in meal
stimulus may have contributed to a low UCPCR on one
occasion vs. a UCPCR over the 0.2 nmol/mmol threshold on
another occasion. This is supported by the finding that, in
four patients, despite two home UCPCR results suggestive of
absolute insulin deficiency, a higher UCPCR and measurable
(though low) sSCP levels were seen under controlled MMTT
conditions. This suggests the MMTT was more stimulating
than the home meals of these patients and they were still able
to mount an insulin response when maximally stimulated.
Nevertheless, insulin secretion with their normal diet may be
more clinically relevant.
The screening method did identify individuals with genu-
ine absolute insulin deficiency. With clear instructions on
how optimally to take a sample for UCPCR testing, and
advice to repeat a low UCPCR in the first instance, it is a very
easy and practical test which has the advantage of being
widely available, avoiding the need for venepuncture, and
being able be carried out at home and posted in. Since the
completion of the present study, it has been shown that the
previously widely perceived practical limitations in measure-
ment of C-peptide in blood may be to some extent overcome
by using ethylenediaminetetraacetic acid (EDTA) sample
tubes: these can improve the stability of C-peptide concen-
trations to > 24 h at room temperature (average 19.5C)
[21]. This would also make measurement of C-peptide in
blood a viable test in the outpatient/primary care setting.
In the increasingly complex climate of diabetes manage-
ment options, confirmation (or not) of insulin deficiency
should help guide treatment, education and management
decisions, which will be valuable in optimizing care for any
patient, but perhaps particularly for the more frail, older
patient. We would suggest that a measure of C-peptide, such
as UCPCR, may have an important role when clinical
features, such as marked variation in blood glucose values,
suggest absolute insulin deficiency.
Clinical characteristics
In our study, those with confirmed absolute insulin deficiency
had started insulin sooner after diagnosis than those with
retained endogenous insulin (2.5 vs. 6 years), and had lower
BMIs (25 vs. 29 kg/m2). In terms of other easily available
and measurable baseline patient characteristics, there was
little else to distinguish them.
Although two of the five patients with confirmed absolute
insulin deficiency were on basal-bolus regimens, the three
others, and several of those with low endogenous insulin
levels, were on unusual regimens more suited to patients with
endogenous insulin secretion. Two of the five were still on
oral hypoglycaemic agents, and none had had any training,
such as the DAFNE course [12], to help them understand and
manage their diabetes better.
Theoretically despite a clinical diagnosis of Type 2
diabetes, patients with absolute insulin deficiency may be at
risk of the complications seen in Type 1 diabetes. This was
reflected in all of the patients with absolute insulin deficiency
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– and those with low endogenous insulin levels - reporting
difficulty in managing their blood glucose levels owing to
seemingly unpredictable fluctuations in blood glucose levels,
and one patient having had an episode of ketoacidosis.
Implications for clinical practice
Identification of absolute insulin deficiency in patients with a
clinical diagnosis of Type 2 diabetes may enable optimization
of their treatment such as basal-bolus regimens, management
and education such as DAFNE courses [12], and recognition
of potential complications such as higher risks of hypoglyca-
emia or ketoacidosis. All these have not been traditional
considerations in many patients with Type 2 diabetes, and
recognition should help improve the quality of life of these
individuals.
The UCPCR is a practical and useful test to detect
absolute insulin deficiency in Type 2 diabetes and should be
used in individuals with Type 2 diabetes developing
ketoacidosis, severe hypoglycaemia or having a large fluc-
tuation in blood glucose values, to help inform optimum
diagnosis and/or management. A UCPCR suggestive of
endogenous insulin production is reliable, and in this clinical
context may suggest other explanations for the clinical
features (such as compliance). A low UCPCR suggestive of
insulin deficiency should be repeated in the first instance, but
may help guide management and education as described
above.
Conclusion
In conclusion, we have shown that absolute insulin deficiency
is present in 3% of insulin-treated subjects with Type 2
diabetes and may be detected using UCPCR. Clinical features
such as GAD antibodies, starting insulin sooner after
diagnosis, and having a lower BMI are pointers to help
recognize those at risk, but are not diagnostic. Those with
absolute insulin deficiency are at risk of more fluctuant blood
glucose levels, hypoglycaemia and ketoacidosis, which may
adversely affect quality of life as well as potentially have
more severe consequences, especially in the older population.
Recognition of absolute insulin deficiency is thus important
as it will aid the optimum management of these individuals,
and the UCPCR is a useful test that can be used in general
practice or in outpatients to confirm a clinical suspicion of
insulin deficiency.
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Abstract
Background Measuring endogenous insulin secretion using C–peptide can assist diabetes management, but standard
stimulation tests are impractical for clinical use. Random non-fasting C–peptide assessment would allow testing when a
patient is seen in clinic.
Methods We compared C–peptide at 90 min in the mixed meal tolerance test (sCP) with random non-fasting blood
C–peptide (rCP) and random non-fasting urine C–peptide creatinine ratio (rUCPCR) in 41 participants with insulin-
treated diabetes [median age 72 (interquartile range 68–78); diabetes duration 21 (14–31) years]. We assessed
sensitivity and specificity for previously reported optimal mixed meal test thresholds for severe insulin deficiency
(sCP < 200 pmol//l) and Type 1 diabetes/inability to withdraw insulin (< 600 pmol//l), and assessed the impact of
concurrent glucose.
Results rCP and sCP levels were similar (median 546 and 487 pmol//l, P = 0.92). rCP was highly correlated with sCP,
r = 0.91, P < 0.0001, improving to r = 0.96 when excluding samples with concurrent glucose < 8 mmol//l. An rCP cut-
off of 200 pmol//l gave 100% sensitivity and 93% specificity for detecting severe insulin deficiency, with area under the
receiver operating characteristic curve of 0.99. rCP < 600 pmol//l gave 87% sensitivity and 83% specificity to detect
sCP < 600 pmol//l. Specificity improved to 100% when excluding samples with concurrent glucose < 8 mmol//l.
rUCPCR (0.52 nmol/mmol) was also well-correlated with sCP, r = 0.82, P < 0.0001. A rUCPCR cut-off of
< 0.2 nmol/ mmol gave sensitivity and specificity of 83% and 93% to detect severe insulin deficiency, with area
under the receiver operating characteristic curve of 0.98.
Conclusions Random non-fasting C–peptide measures are strongly correlated with mixed meal C–peptide, and have
high sensitivity and specificity for identifying clinically relevant thresholds. These tests allow assessment of C–peptide at
the point patients are seen for clinical care.
Diabet. Med. 00, 000–000 (2016)
Introduction
Assessment of endogenous insulin secretion using C–pep-
tide is useful in clinical practice to assist in the classifica-
tion and treatment of diabetes [1]. Assessment of a
stimulated blood C–peptide level following a standardized
stimulus such as a mixed meal (mixed meal tolerance test,
MMTT) provides a gold standard measure of endogenous
insulin secretion, but is impractical for clinical use [2].
Other C–peptide measures such as fasting blood C–peptide
[3], or a post-home meal urinary C–peptide creatinine ratio
(UCPCR) [4–6], give a reasonable approximation to the
gold standard, and high sensitivity and specificity in
classifying diabetes [7–10]. However, for routine clinical
care, the most practical test would be a spot ‘random’
non-fasting sample, sent when a patient is seen in an
outpatient or primary care clinic.
Random non-fasting blood C–peptide (rCP) has been
shown to have superior performance to both post-glucagon
and fasting blood C–peptide assessment in differentiating
clinically well-defined Type 1 and Type 2 diabetes [7,8], and
to have clinical utility in detecting Maturity Onset Diabetes
of the Young (MODY) [11,12]. However, rCP has never
been formally validated against a gold-standard MMTT C–Correspondence to: Angus G. Jones. E-mail: Angus.Jones@exeter.ac.uk
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peptide assessment. Although UCPCR changes little from 2
to 4 h post meal in those with Type 2 diabetes (McDonald
T. J., unpublished), utility of a random non-fasting UCPCR
sample has never been assessed.
We aimed to compare non-fasting random blood C–
peptide and UCPCR with ‘gold standard’ blood C–peptide
assessment at 90 min in the MMTT.
Methods
Participants
Forty-one participants with insulin-treated diabetes were
recruited to the GREAT study (https://clinicaltrials.gov,
NCT02506296). To ensure a range of C–peptide values,
participants were selected on the basis of prior C–peptide
assessment to include participants with and without severe
insulin deficiency (under/over 200 pmol//l post-MMTT blood
C–peptide or equivalent [1]). All participants had a clinical
diagnosis of Type 2 diabetes, and an estimated glomerular
filtration rate (eGFR) > 30 ml/min/1.73 m2. Ethical approval
was obtained from the NRES Committee South West, and all
participants gave written informed consent.
Mixed meal tolerance test
Participants fasted from 10 p.m., then attended the following
day prior to 11 a.m., having not taken their morning medi-
cation prior to arrival. Baseline bloods for glucose and C–
peptide were taken, morning insulin given [13] and 160 ml of
Fortisip Compact (Nutricia, Trowbridge, UK) drunk within
10 min (content per 100 ml: carbohydrate 29.7 g, protein
9.6 g, fat 9.3 g). Bloods for C–peptide and glucose analysis
were repeated every 30 min, up to and including 180 min
post-mixed meal. Samples were immediately centrifuged after
collection and stored at –80°C, for later batched analysis.
Non-fasting tests
On a separate occasion (within 8 days of the MMTT), blood
was taken between 9 a.m. and 5 p.m., within 5 h of a meal,
and without restriction on snacks or other intake. Whole-
blood samples collected in potassium–EDTA (C–peptide)
and fluoride oxalate (concurrent glucose) tubes were sent at
room temperature to be processed routinely at the Royal
Devon & Exeter Hospital Blood Sciences department.
Participants were also asked to provide a spot urine sample.
This was frozen at –80°C before later batch analysis.
Sample analysis
C–peptide was analysed using the automated Roche Diag-
nostics (Manheim, Germany) E170 immuno-analyser (limit
of detection: 3.3 pmol//l; inter- and intra-assay coefficients of
variation: < 4.5% and < 3.3%, respectively). Urinary crea-
tinine was analysed on the Roche P800 platform to obtain
UCPCR (nmol/mmol).
Analysis
We compared the median rCP with the median blood C–
peptide at 90 min in the MMTT (sCP) using Wilcoxon’s
signed rank test, and correlation coefficient between both
rCP and random non-fasting UCPCR (rUCPCR) with sCP
using Spearman’s rank correlation.
We then assessed the utility of rCP and rUCPCR in
correctly classifying participants in relation to previously
described clinically relevant MMTT C–peptide thresholds
using receiver operating characteristic (ROC) curves, with
corresponding specificities and sensitivities:
1. MMTT sCP < 200 pmol//l: absolute insulin deficiency
[1,14];
2. MMTT sCP < 600 pmol//l: Type 1 diabetes/inability to
withdraw insulin [1].
Finally, we assessed the influence of concurrent glucose
repeating the above analyses excluding hypoglycaemia (con-
current glucose < 4 mmol//l), and a previously suggested cut-
off of < 8 mmol//l [1,8,15].
Results
Participant characteristics
Twenty-eight of the 41 participants (68%) were men.
Participants had a median age of 73 years [interquartile
range (IQR), 68–78], diabetes duration 21 (14–31) years,
BMI 26.8 (25–29.9) kg/m2 and HbA1c 68 (58–75) mmol/
mol [8.4% (7.5–9.0%)].
Twelve of the 41 participants (29%) had severe insulin
deficiency (sCP < 200 pmol//l). C–peptide was detectable
What’s new?
• Measuring endogenous insulin secretion using C–pep-
tide can assist diabetes management, but standard
stimulation tests are impractical for clinical use.
• This study assessed whether a random non-fasting C–
peptide can be used to assess endogenous insulin
secretion.
• Random blood C–peptide and urine C–peptide crea-
tinine ratio (UCPCR) were both highly correlated with
mixed meal tolerance test C–peptide and were sensitive
and specific measures for clinically useful mixed meal
test thresholds.
• A random non-fasting C–peptide taken when a patient
is seen in clinic can be used to assess endogenous insulin
secretion in clinical practice.
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(> 2.9 pmol//l) at all time-points, fasting and stimulated, in
40 of 41 participants.
C–peptide was stable 1–3 h after meal stimulation
There was little change in the C–peptide from 60 min to 3 h
post MMTT: median C–peptide ranged from 487 to
622 pmol//l across these five time points (Fig. 1a). Mean
individual coefficient of variation over the 1–3–h post-
MMTT period was 14.3%.
Random non-fasting blood C-peptide level is strongly
correlated with the gold standard 90–min mixed meal test
C–peptide
The median rCP of 546 pmol//l (IQR 76–943) was similar to
sCP at 90 min, 487 pmol//l (75–985), P = 0.92 (Fig. 1a).
rCP was strongly correlated with sCP: Spearman’s rho
correlation coefficient = 0.913, P < 0.0001 (Fig. 1b). When
only participants who had a concurrent lab glucose value of
≥ 8 mmol//l were included (66% participants), the correla-
tion coefficient increased to 0.96.
As expected, the results showed more variation in the
higher C–peptide range (Fig. S1).
Random non-fasting bood C-peptide is a highly sensitive and
specific test for severe insulin deficiency
rCP was a highly sensitive and specific test for severe insulin
deficiency (sCP < 200 pmol//l), with an area under the ROC
curve (AUC ROC) of 0.99 [95% confidence interval (95%
CI): 0.91–1; Table 1]. An rCP cut-off of < 200 pmol//l gave
a sensitivity of 100% (74–100) and specificity of 93% (77–
99) for severe insulin deficiency, with 95% (83–99) of
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FIGURE 1 (a) Blood C–peptide levels on random sampling and in the mixed meal test. rCP, random non-fasting; time points reflect minutes post
mixed meal ingestion, 0 m: fasting sample. (b) Random non-fasting C–peptide vs. 90–min C–peptide in the mixed meal tolerance test. Level of blood
glucose measured concurrently with rCP shown by blue diamonds > 8 mmol/l; green circles > 4–8 mmol/l; red triangles: < 4 mmol/l.
Table 1 Ability of random non-fasting blood C–peptide (rCP) and UCPCR (rUCPCR) to define absolute insulin deficiency [90-min mixed meal
tolerance test C–peptide (sCP) < 200 pmol/l] and Type 1 diabetes/insulin dependence (sCP < 600 pmol/l) using equivalent thresholds, with and
without exclusion based on concurrent glucose (blood C–peptide only)
Mixed meal test
C–peptide threshold
Concurrent glucose
cut-off (mmol/l) n AUC
AUC 95%
CI
Specificity
95% CI (%)
Sensitivity
95% CI (%)
Correctly classified
95% CI (%)
Random non-fasting blood C–peptide
< 200 pmol/l All 41 0.99 0.91–1.0 93 (77–99) 100 (74–100) 95 (83–99)
≥ 4 39 1.0 0.91–1.0 96 (82–100) 100 (72–100) 97 (87–100)
≥ 8 27 0.99 0.87–1.0 94 (73–100) 100 (66–100) 96 (80–100)
< 600 pmol/l All 41 0.94 0.84–0.99 83 (59–96) 87 (66–97) 85 (71–94)
≥ 4 39 0.94 0.79–0.98 83 (59–96) 86 (64–97) 85 (69–94)
≥ 8 27 0.99 0.87–1.0 100 (74–100) 87 (60–98) 93 (76–99)
Random non-fasting UCPCR
< 200 pmol/l All 40 0.98 0.87–1.0 93 (76–99) 83 (52–98) 90 (76–97)
< 600 pmol/l All 40 0.90 0.76–0.97 83 (59–96) 82 (60–95) 83 (67–93)
Sensitivity, specificity and % correct classification are given for numerically equivalent thresholds (rCP: 200 and 600 pmol/l; UCPCR: 0.2
and 0.6 nmol/mol) because these were close to optimal on ROC analysis. 95% CI, 95% confidence intervals.
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participants correctly classified. This did not alter signifi-
cantly with concurrent glucose (Table 1).
rCP was also able to identify participants with sCP
< 600 pmol//l (Type 1 diabetes/inability to withdraw insu-
lin): AUC ROC 0.94 (95% CI: 0.84–0.99). An rCP value
< 600 pmol//l gave a sensitivity of 87% (66–97) and speci-
ficity of 83% (59–96) to detect sCP< 600 pmol//l – with
85% (71–94) correctly classified. Excluding concurrent
glucose values < 8 mmol//l improved specificity to 100%
(74–100) without altering sensitivity (Table 1).
rUCPCR is also strongly correlated with the gold standard
blood C–peptide measure and a sensitive and specific test for
severe insulin deficiency
rUCPCR [median 0.52 nmol/mmol (IQR 0.095–1.57 nmol/
mmol)], was well-correlated with sCP, r = 0.82, P < 0.0001
(n = 40). rUCPCR was also a sensitive and specific test for
detecting the clinically relevant thresholds of sCP < 200 and
< 600 pmol//l: ROC AUC 0.98 (0.87–1.0) and 0.90 (0.76–
0.97), respectively (Table 1). For identifying severe insulin
deficiency (sCP < 200 pmol//l), an rUCPCR cut-off of
< 0.2 nmol/mmol gave a sensitivity and specificity of 83%
(52–98) and 93% (76–99), with 90% (76–97) participants
being correctly classified. An rUCPCR cut-off of < 0.6 nmol/
mmol had a sensitivity and specificity of 82% (60–95) and
83% (56–96) for detecting sCP< 600 pmol//l.
Discussion
Our results show that random non-fasting blood C-peptide
and UCPCR measurements taken when a patient attends
clinic are highly correlated with the gold standard mixed
meal test assessment of endogenous insulin secretion,
and are sensitive and specific tests for clinically relevant
thresholds. These tests, combined with the demonstration
of stability at room temperature of blood C–peptide
for > 24 h (in EDTA) [16] and UCPCR for > 72 h (in
boric acid) [17], offer a practical way of assessing
endogenous insulin excretion when contact is made for
clinical care.
Our findings are consistent with previous research demon-
strating that a random non-fasting blood C–peptide offers
similar performance to C–peptide in a formal glucagon
stimulation test when classifying clinically well-defined
Type 1 and Type 2 diabetes [8], is superior to fasting C–
peptide when identifying autoimmune diabetes [7] and has
high clinical utility for detecting patients with undiagnosed
monogenic diabetes [11]. This is the first study to formally
evaluate use of a random non-fasting C–peptide sample
against a gold standard in a mixed meal test. The use of a
random non-fasting UCPCR has not been previously
assessed.
Limitations of our study include that our modest sample
size limits our ability to assess the impact of concurrent
glucose on random non-fasting C–peptide testing. In addi-
tion, our population may not be representative of the patients
in whom C–peptide testing has most utility (difficult to
classify diabetes) in that they are older patients who have
been selected on the basis of a clinical diagnosis of Type 2
diabetes with or without discordant C–peptide.
Our results suggest that a random non-fasting blood C–
peptide or UCPCR could be used to assess endogenous
insulin secretion in clinical practice. This would have major
practical advantages in that the test can be conducted when
a patient is seen for clinical care. Although our sample size
is too small to robustly assess the impact of concurrent
glucose, our results suggest this has only modest impact.
Although a high value in the presence of any glucose is
likely to be robust it may be prudent to treat random non-
fasting C–peptide values below a clinical threshold where
concurrent glucose is < 8 mmol//l with caution, and con-
sider a repeat sample.
Conclusion
Random non-fasting blood and urine C–peptide measures
seem to be strongly correlated with the gold standard C–
peptide test and have high sensitivity and specificity in
identifying clinically relevant C–peptide thresholds. A larger
study would confirm findings, but these tests could allow
assessment of C–peptide at the point patients are seen for
clinical care.
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